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Abstract 
The number of adults living with congenital heart disease has increased greatly 
over recent years. This has broadly been attributed to advances in the surgical 
management of children and adolescents born with wide ranging abnormalities 
of cardiac anatomy. As a result, adult congenital cardiology has become a 
specialty in its own right and specialist care is centralised in tertiary referral 
centres. 
Despite these improvements, patients rarely achieve a ‘cure’ and remain 
exposed to various clinical uncertainties and often premature mortality. Despite 
this, little is known regarding the current outlook for adults with congenital 
heart disease and the factors which influence outcomes. Furthermore, no 
substantive efforts have previously been made to describe ACHD mortality on a 
population basis in Scotland. These uncertainties and unanswered questions pose 
real problems to patients and clinicians alike. Providing guidance on seemingly 
simple matters such as participating in the workforce, the merits of a pension, 
or the risks involved with starting a family often defies consensus and is opinion 
based. Clearly in a modern age of evidence-based practice and shared decision 
making we must strive to do more. 
Scotland has one of the most complete and comprehensive indexes of clinical 
records in the world. With the ability to link patient data over time and between 
different records, an individual patient’s entire ‘in hospital’ history is logged and 
available in an anonymised format to facilitate academic study and service 
optimisation. 
This thesis has sought to utilise the unique opportunity afforded by this Scottish 
Morbidity Database to define the present state, and recent trends of mortality 
amongst adults with congenital heart disease in a truly non-selective, population 
wide cohort. Context is provided via a comprehensive analysis of the current, 
international literature followed by analysis of the survival and causes of death 
encountered for ACHD patients between 1986 and 2017.  
A total of 16,210 individuals were identified throughout the data period, of 
whom 4162 died. Anonymised data from the Scottish Morbidity Database was 
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examined to establish; age, sex, underlying congenital heart disease, deprivation 
status (as established by Scottish Index of Multiple Deprivation), and the 
presence of co-morbidity (diabetes, atrial fibrillation, ischaemic heart disease, 
cerebrovascular disease, hypertension and cancer).  
Survival was seen to improve in more contemporary analyses. This improved 
survival was seen for both sexes, all degrees of socioeconomic deprivation and 
across the spectrum of ACHD complexity. Improved temporal survival persists 
upon adjustment for age, sex, co-morbidity and congenital lesion. 
Survival of men with ACHD is relatively poorer than for women with ACHD and 
this is predominantly accounted for by non-cardiovascular death.  
Individuals with ACHD were found to suffer disproportionate deprivation as 
compared to that of the general population. Women with ACHD experienced 
more deprivation than men with ACHD. Higher deprivation was associated with 
higher mortality and again, this persists in robustly adjusted analyses. 
The reported causes of death for adults with congenital heart disease changed 
over time. At the begging of the data period the majority of deaths were by 
cardiovascular causes. In more recent analyses, non-cardiovascular death 
dominates. The rate of reduction in cardiovascular deaths outstrips that of the 
general population.    
These analyses provide much needed insight into the survival prospects of the 
Scottish ACHD population and confirm the utility of the Scottish Morbidity 
Database as a resource. Improving survival coupled with a shift towards non-
cardiovascular mortality highlights the importance of an holistic and integrated 
approach in the modern care of the ACHD patient. An important spotlight is 
shone on the socioeconomic disparity encountered by this cohort and provides a 
basis for further analyses to redress this as a matter of priority.  
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1.1 Preamble 
Congenital heart lesions are the most common birth defect (1) with a reported 
incidence among live births of 7 - 11 per 1000. When inclusive of the bicuspid 
aortic valve (BAV) and the often less clinically significant small, muscular 
ventricular septal defect (VSD) and silent patent ductus arteriosus (PDA), 
incidence rates as high as 75 per 1000 live births have been supported by robust 
epidemiology data (2). Better imaging, screening protocols and technical 
advances have improved preterm and postnatal diagnosis (3–5). Meta-analysis 
data suggests a rising incidence at birth over time, most recently estimated from 
4.55 per 1000 live births in 1970 to 9.41 per 1000 in 2017 (5).The role of better 
imaging and screening protocols is suggested by an association of higher 
incidence amongst more advanced economies and health care systems (4,5). 
However, improved antenatal screening has been linked to a higher frequency of 
pregnancy termination when major congenital heart defects are detected (5), 
although it is likely that significant geographical variation exists. Relatively 
higher rates of preterm abortion have been reported amongst Scandinavian 
nations and lower rates among Asian countries and former Soviet states (6,7). It 
is likely that technological capabilities for screening, national laws and cultural 
practices impact this particular factor (5). 
Overall it is probable that the true birth incidence of congenital heart disease 
(CHD) is relatively stable. What is certain is that the prevalence of congenital 
heart disease has increased greatly over recent years and decades (8,9) and this 
is a result of improved survival. 
Historically, surgical treatment for congenital heart disease began in 1939 when 
the first patent ductus arteriosus (PDA) was surgically ligated at Boston 
Children’s Hospital by Robert Gross (10). In 1945 Helen Taussig and Alfred 
Blalock famously published the first reported systemic arterial (subclavian 
artery) to pulmonary arterial shunt (11). The Blalock-Taussig (BT) shunt was 
performed on a young girl named Eileen Saxon who was known to have Tetralogy 
of Fallot (TOF). These operations were however exclusively external to the 
heart. Prior to the necessary technological advances required to perform 
cardiopulmonary bypass, a few ‘life saving’ intracardiac operations were 
attempted via hypothermia and caval inflow occlusion. This allowed the 
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operator a few minutes to carry out basic procedures and its utility was thus 
limited. Cardiac trauma was one application but relief from congenital disease 
was also attempted, with success in some cases. Both pulmonary valvotomy for 
congenital stenosis and closure of atrial septal defects under inflow stasis have 
been reported (12,13).   
John Gibbon reported the first successful atrial septal defect (ASD) closure under 
cardiopulmonary bypass with his revolutionary ‘heart-lung machine’ in 1953 (14). 
In doing so the possibilities of intracardiac surgery were vastly expanded, and of 
course this legacy is not exclusive to congenital heart disease. Early mortality 
with cardiopulmonary bypass was however prohibitively high and with multiple 
engineering solutions offering varying hopes of success, other more 
‘physiological’ techniques were trialled. Once such technique known as 
‘controlled cross circulation’ offered comparatively favourable outcomes in this 
early phase. This technique involved using a live ‘donor’, usually the mother or 
father of the patient as the oxygenator. In this technique the femoral vein and 
artery of the donor were cannulated, and arterial blood extracted via an 
extracorporeal pump to supply the centrally cannulated patient’s arterial 
circulation. Venous blood was then returned via the pump to the donor’s femoral 
vein. This was of course a controversial technique, not least because it put an 
otherwise healthy individual at risk from potential complications as a donor. It 
did however provide potential hope from otherwise untreatable conditions. In a 
case series of 45 defects repaired under cross circulation at the University of 
Minnesota, a positive long-term outcome (greater than 30 years survival) was 
achieved in 49%. All donors survived with only one significant complication (15). 
In the early 1950s this was revolutionary and significantly better than the 
outcomes offered by rudimentary bypass machines.  
With time and investment, technological advances in artificial oxygenation and 
the ability to anticoagulate the patient with heparin and reverse this with 
protamine saw mechanical cardiopulmonary bypass become safe and effective. 
Intracardiac surgery for simple congenital heart lesions was relatively common 
place by the 1970s. The technical surgical approach to the repair of many of the 
simpler lesions (ASD, PDA and VSD) has changed little since those early years of 
experimental intracardiac surgery.  
21 
 
The surgical management of more complex and cyanotic lesions has equally 
experienced significant advances. Francois Fontan reported the first successful 
‘right heart bypass’ for tricuspid atresia in 1971 (16). Although much modified 
over the years, the physiological principles of the Fontan operation remain the 
mainstay for the treatment of cyanotic congenital heart disease where 
biventricular repair is not possible. A more recent advancement of similar 
magnitude is the arterial switch procedure for transposition of the great arteries 
(TGA). First performed by Jatene in 1975, initial outcomes were poor (17). 
Significant advances in the technique of anastomosing the coronary arteries and 
the adaptation and simplification by Lecompte (18) ensured that this would 
become the standard of care for the management of TGA. As with all procedural 
advances, implementation of this new practice varied from health system to 
health system and according to personnel and surgical capabilities but in general 
the arterial switch was fully established by the late 1980s – early 1990s in 
developed countries. This relatively recent advance is of particular note as the 
surgical predecessor to the arterial switch, the atrial switch (Mustard or Senning 
procedure) is still frequently encountered in surviving patients of the prior era. 
As a result, two patient cohorts born with the same condition and of a similar 
age experience vastly different physiology, complications and survival prospects 
(19,20). 
Alongside the progress in open surgical practices, major advances in other fields 
of cardiology have improved outcomes for patients. A transcatheter approach 
has become the preferred method of intervention for many congenital heart 
defects. The first transcatheter closure of an ASD was achieved by King and Mills 
in 1975 (21). Numerous updated and improved technologies have been pioneered 
since the ‘King and Mills umbrella’, and over the last two decades minimally 
invasive ASD closure has become common place and the first line method when 
technically feasible. A similar evolution of transcatheter interventions has been 
witnessed in the treatment of VSDs, PDAs and certain types of aortic coarctation 
(22,23).  
In the year 2000 Bonhoeffer successfully implanted the first transcatheter valve 
into the pulmonary position (24). Although a recent advent, percutaneous 
pulmonary valve implantation has become a safe and effective first line therapy 
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for re-do pulmonary valve replacement across the world. Transcatheter 
pulmonary valve implantation into the native right ventricular outflow tract is 
now becoming increasingly routine in some centres and marks another advance 
in ACHD intervention (25).  
Following the successful implantation of a biological valve in the pulmonary 
position, Cribier successfully used a similar technology in the aortic position as a 
‘last resort’ treatment for acquired aortic stenosis (26). Subsequently, 
transcatheter valve replacements have also been described in the tricuspid (27) 
and mitral (28) positions. 
Cardiac transplantation remains as a therapeutic option in certain scenarios. 
After the first human-human cardiac transplant was performed by Dr Christiaan 
Barnard in 1967 (29) the operation rapidly gained popularity. However, the early 
mortality rate was significant and by 1970 it had fallen out of favour. Organ 
rejection was recognised as the cause for the majority of early failures and the 
eventual improvements in survival are more closely mirrored by the pioneering 
developments in the fields of immunology and immunosuppression than surgical 
practice per se (30,31). 
In CHD, de novo or reconstructed anatomy and physiology is often complex and 
sometimes unique. As a result, cardiac transplantation in this population is more 
complex still. In addition to the obvious issues of implanting a heart where 
complex anatomical variations exist, patients with CHD have often had multiple 
previous procedures; compromising thoracic access as well as vascular options 
for cardiopulmonary bypass. Additionally, the presence of pre-formed human 
leukocyte antigen (HLA) antibodies from prior blood transfusions or the use of 
surgical homografts significantly complicates tissue typing. As a result of the 
increased complexity of cardiac transplantation in CHD, operative mortality is 
higher than for other patient groups. If this initial period is survived however, 
contemporary long-term outcomes in experienced centres are favourable (32).  
In 1984 the first successful paediatric transplant was carried out on a 4-year-old 
with a single ventricle as a primary operation. The more usual scenario in 
modern practice is to obtain primary repair or palliation in the first instance 
with a small cohort exploring the option of transplantation later in life due to 
23 
 
late complications of the repaired phenotype or failing haemodynamics in the 
natural history of the disease. 
Due to the myriad and often lifelong haemodynamic abnormalities observed in 
certain CHD (be it de novo or surgically altered), it is frequently not just the 
cardiovascular system which is affected. As a result, it is more frequent to 
pursue multi-organ transplantation in this patient population than others. 
Pulmonary hypertension may mandate the need for heart-lung transplant in the 
case of long standing or severe shunt lesions. Likewise, iatrogenic pulmonary 
hypertension may develop due to surgically created systemic arterial to 
pulmonary arterial shunts. Conditions where chronic systemic venous 
hypertension predominates, such as with Fontan physiology, may induce liver 
cirrhosis and in such cases the possibility of heart-liver transplant may be 
explored. Finally, it remains an unfortunate fact that for some patients with 
complex congenital heart disease or congenital heart disease with complicating 
features, transplantation is not a realistic option. 
Described above is a synopsis of the rapid progression in the management of 
congenital heart disease. This can be summarized into three eras; 
• The pre-surgical era (prior to 1940). No surviving patients with significant CHD can be 
expected under current follow-up. 
• The extra-cardiac operative era (1940 – 1970). Few patients with significant CHD surviving to 
current follow-up. Often patients with milder phenotypes and later intracardiac operations. 
• The intra-cardiac era (1970 – present). A greater than 90% survival to adulthood is predicted 
in modern cohorts (33). 
 
It is clear that the major advances as outlined above have been instrumental in 
the improved initial survival of individuals, particularly those with more complex 
CHD. This has been demonstrated by Khairy et al (34) who reported a rising 
median age at death among those with severe CHD from 2 years to 23 years of 
age between 1987 and 2005. As a result, a new era of sustained improvement is 
now the collective goal of the CHD community. It is no longer the aim to simply 
provide a life-saving structural solution to a haemodynamic lesion. Lifelong care 
planning must consider complex issues such as; providing an attractive substrate 
for further intervention in time; the interaction of therapeutic options such as 
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cardiac devices with imaging modalities such as cardiac MRI and even the 
difficult choice taken not to intervene to preserve the future option of advanced 
therapies such as cardiac transplantation. All of these decisions must be taken 
into context with the concerns and health expectations of the patient. From 
previously being content with survival, the expectation of patients is now to lead 
a life far more comparable to the general population.  
It is essential that we understand the impact of the shifting paradigms of the 
current era of congenital heart disease management and the effect that these 
are having on patient survival at a population level.   
1.2 Cardiac development and lesion aetiology 
Congenital heart disease comprises a vast array of structural abnormalities of 
the heart and great vessels which are present from birth. Despite the relatively 
simple function of the heart, which essentially serves as a series of pumps and 
valves, the embryological processes involved in normal cardiac development are 
complex with multiple time critical steps required for complete structural 
maturation. An in-depth review of the embryological processes is beyond the 
scope of this thesis, however a basic understanding of the developmental 
processes allows an understanding of the aetiology and physiology of commonly 
encountered defects. 
The cardiac structures begin to form at around 18-19 days post fertilisation and 
originate from the mesoderm, one of the three germ layers which will ultimately 
comprise all organ tissue (35). Initially two strands known as cardiogenic cords 
are produced. These develop a lumen at around day 20, becoming endocardial 
tubes. These then migrate and fuse to form a single heart tube. This in turn 
develops 5 distinct regions which will later define mature cardiac structures; the 
truncus arteriosus (later becoming the aorta and pulmonary trunk), the bulbus 
cordis (later to become the right ventricle), the primitive ventricle (which 
matures into the left ventricle), the primitive atrium (which will become the 
anterior atrial mass), and the sinus venosus (which will form the posterior right 
atrium, cavae and coronary sinus). At this stage all blood enters via the sinus 
venosus and is propelled via the primitive atrium, the primitive ventricle, the 
bulbus cordis and into the truncus arteriosus in sequence.  
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At around day 28 the primitive heart folds and ‘loops’ to form an ‘S’ shape, 
aligning chambers to approximate the mature heart. A complex process of 
chamber fusion and subsequent septation of the atrial and conotruncal masses 
ensues. Further maturation with valve development and integration of a blood 
supply via the coronary vessels comprises the mature foetal heart (36). 
Developmental errors can give rise to defects at any one or several phases of 
cardiac development. Some of these are easy to comprehend even if the 
underlying processes are complex. For instance, failure in the septation of the 
atrial mass will result in an ASD. The processes involved and resulting spectrum 
of ASDs are myriad, however all result from a failure to septate the 
embryological shared atrial mass and will result in a pathological shunting of 
blood from the relatively high pressure left atrium to the relatively low pressure 
right atrium in the fully matured heart. Similarly, a failure to septate the 
conotruncal mass, or the bulbis cordis from the primitive ventricular mass will 
result in a common arterial trunk or VSD respectively.  
As the primitive tube-like heart loops to oppose the embryological ventricular 
structures, errors of ventricular laterality may occur. In conventional 
development, a rightward, or dextro loop (D loop) gives rise to the usual 
arrangement where the morphological right ventricle lies to the anatomical right 
of the morphological left ventricle. Leftward or levo looping (L loop) confers the 
opposite arrangement where the morphological right ventricle lies to the 
anatomical left of the morphological left ventricle. As a single defect this will 
give rise to the condition, congenitally corrected transposition of the great 
arteries (ccTGA). The physiological implication is a morphological right ventricle 
and associated tricuspid valve in the systemic position. 
Maturation of the inflow and outflow of the embryological structures occur 
broadly in unison. Myriad disorders can occur during these processes and in some 
respects may be considered on a spectrum. Ventricular inlet and outlet 
structures form as a tube and are thus in continuity. It is only with a complex 
process of leftward migration and differentiation that the conotruncal structures 
are appropriately septated and aligned with their appropriate ventricular 
chambers. A ‘complete’ failure to do so will result in a double outlet right 
ventricle (as it is the bulbis cordis which provides continuity with the truncus 
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arteriosus). Other errors in the process or spectrum of malformation of 
ventricular outflow comprises diseases such as TOF (where there is overriding of 
the aorta to the right ventricle), transposition of the great arteries (or 
ventriculo-arterial discordance) and aortic coarctation. Similar abnormalities of 
ventricular inflow development may result in complete double inlet left 
ventricle (as the primitive atrial tissue is in continuity with the primitive left 
ventricular mass) at the extreme end of the spectrum, with varying degrees of 
atrioventricular canal with atrioventricular valve override also possible. 
Often more than one, or even multiple congenital lesions can co-exist, defying 
simple or eponymous nomenclature. In such circumstances an understanding of 
cardiac development, chamber continuity, laterality and connections is essential 
to allow a structured segmental approach to classification. 
1.3 Classification and coding of congenital heart disease 
An adult with congenital heart disease is any individual over 16 years of age who 
was born with any form of congenital heart disease i.e. a structural abnormality 
of the heart or great vessels which is present from birth. There is variation as to 
the age at which an individual is classified as an adult within the literature. The 
cut-off is usually between 15 and 18 years (37,38).   
The spectrum of congenital heart disease is vast and requires some degree of 
classification and grouping to be manageable, of clinical relevance and allow 
categorisation for clinical and epidemiological study. There are many ways by 
which CHD can be divided-up, each with benefits and limitation. Additionally, 
the intended utility of classification systems extends beyond clinical usefulness.  
Informing the National Records of Scotland and providing a basis for 
remuneration of services at a trust level is also a function of certain coding 
systems.   
1.3.1 ICD 10 
Standardising the classification of pathologies has challenged physicians and 
statisticians for centuries. Perhaps the earliest, comprehensive attempt at 
classification can be credited to the French physician Francois Boissier de 
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Larcoix who published his Nosologia methodica in 1768, utilising methodology 
developed in the field of botany which he applied to medical pathology (39). A 
century later another French physician, Jacques Bertillon announced the 
introduction of the Bertillon Classification of Cause of Death at the congress of 
the International Statistical Institute in Chicago (40). This early edition can claim 
direct lineage to what is now the International Statistical Classification of 
Diseases and Related Health Problems (ICD). Bertillon classified the cause of 
death to reflect the organ system or anatomical locus of the pathology, and this 
remains the cornerstone of contemporary iterations. 
Undergoing periodic review, it wasn’t until the 6th revision (ICD 6) in 1949 that 
the system began to reflect morbidity as well as mortality, assuming the ICD 
moniker. It was also at this point that the World Health Organisation (WHO) 
assumed responsibility for the publication and upkeep of the classification 
system, and as such its applicability should be standardised within the health 
authority of the United Nations System. 
The current format (ICD 10) was endorsed by the World Health Assembly in 1990 
and was first adopted by WHO member states in 1994, with the UK being among 
the first to make the change. ICD 10 represented a significant expansion of the 
previous iteration to over 14,000 unique codes. Individual codes represent 
diseases, signs and symptoms, injuries and causes of death and are grouped by 
an alpha-numerical system into similar pathologies and by anatomical locus. 
Bacterial infections for instance will be prefixed with ‘A’ followed by up to 3 
numerical characters to define the organism and affected tissue. The codes used 
to define congenital heart lesions are summarised in Table 1-1. 
ICD coding is the most common means by which health care systems record 
activity within institutions. In the USA and Canada this is primarily mediated 
through health insurance databases and serves the primary purpose of financial 
remuneration. In Scotland, ICD data is translated at a trust level before being 
stored and managed at a national level by the Information Services Division of 
the NHS. This will be discussed in more detail in section 4. 
There are some clear strengths to the ICD coding system and as such, advantages 
to its use as a classification tool. The foremost of these is the international 
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applicability of this system. As a WHO endorsed methodology, ICD coding is 
almost universally recognised. Furthermore, the binary nature of the coding 
system makes categorical analysis of epidemiological data particularly straight 
forward. This has been exploited by previous large scale CHD studies (34,41). 
There are several drawbacks to the ICD coding system, some generic and some 
specific to CHD. Coding is not typically performed by clinicians and is performed 
retrospectively by case note review. Therefore, there is a degree of subjectivity 
regarding the translation from clinical notes to ICD codes. This may also be 
influenced by the training and experience of the clerical staff which may vary 
within a health care system and will certainly vary from country to country. 
Specific to CHD, the clinical problem affecting an individual does not always 
equate to their ‘diagnosis’. In adult CHD in particular, it is the surgically created 
anatomy which often defines the clinical picture, and this cannot be accounted 
for by ICD coding alone. The most obvious example would be for patients with 
Fontan physiology. The Fontan physiology is surgically created and as such is not 
included in ICD coding which will reflect the birth diagnosis (e.g. tricuspid 
atresia or hypoplastic left heart syndrome) instead. Fortunately, in the UK a 
separate coding system is used to record surgical and interventional procedures 
and is coded alongside ICD diagnoses at point of care. This is known as the Office 
of Population Censuses and Surveys Classification of Surgical Operations and 
Procedures (OPCS). 
The (ICD) provides an extensive breakdown of congenital cardiac lesions. It 
attempts to group them according to the structures affected and assign them a 
code. For example; lesions of the atrioventricular septum are grouped under the 
code Q21 with the addition of a third numerical character to increase the 
specificity of the lesion in question.   
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Table 1-1- ICD 10 codes for congenital heart disease 
Code Description 
Q20.0 Common arterial trunk 
Q20.1 Double outlet right ventricle 
Q20.2 Double outlet left ventricle 
Q20.3 Discordant ventriculoarterial connections 
Q20.4 Double inlet ventricle 
Q20.5 Discordant atrioventricular connections 
Q20.6 Isomerism of atrial appendages 
Q20.8 Other congenital malformations of cardiac chambers and connections 
Q20.9 Congenital malformation of cardiac chambers and connections, unspecified 
Q21.0 Ventricular septal defect 
Q21.1 Atrial septal defect 
Q21.2 Atrioventricular septal defect 
Q21.3 Tetralogy of Fallot 
Q21.4 Aortopulmonary septal defect 
Q21.8 Other congenital malformations of cardiac septa 
Q21.9 Congenital malformations of cardiac septum, unspecified 
Q22.0 Pulmonary valve atresia 
Q22.1 Congenital pulmonary valve stenosis 
Q22.2 Congenita pulmonary valve insufficiency 
Q22.3 Other congenital malformations of pulmonary valve 
Q22.4 Congenital tricuspid stenosis 
Q22.5 Ebstein’s anomaly 
Q22.6 Hypoplastic right heart syndrome 
Q22.8 Other congenital malformations of tricuspid valve 
Q22.9 Congenital malformations of tricuspid valve, unspecified 
Q23.0 Congenital stenosis of aortic valve 
Q23.1 Congenital insufficiency of aortic valve 
Q23.2 Congenital mitral stenosis 
Q23.4 Hypoplastic left heart syndrome 
Q23.8 Other congenital malformations of aortic and mitral valves 
Q23.9 Congenital malformations of aortic and mitral valves, unspecified 
Q24.0 Dextrocardia 
Q24.1 Laevocardia 
Q24.2 Cor triatriatum 
Q24.3 Pulmonary infundibular stenosis 
Q24.4 Congenital subaortic stenosis 
Q24.5 Malformation of coronary vessels 
Q24.8 Other specified congenital malformations of heart 
Q24.9 Congenital malformation of heart, unspecified 
Q25.0 Patent ductus arteriosus 
Q25.1 Coarctation of aorta 
Q25.2 Atresia of aorta 
Q25.3 Stenosis of aorta 
Q25.4 Other congenital malformations of aorta 
Q25.5 Atresia of pulmonary artery 
Q25.6 Stenosis of pulmonary artery 
Q25.7 Other congenital malformations of pulmonary artery 
Q25.8 Other congenital malformations of great arteries 
Q25.9 Congenital malformation of great arteries unspecified 
Q26.0 Congenital stenosis of vena cava 
Q26.2 Total anomalous pulmonary venous connection 
Q26.3 Partial anomalous pulmonary venous connection 
Q26.4 Anomalous pulmonary venous connection unspecified 
 
The clinical coding of diagnoses is fallible in some respects. It is clear from 
reviewing the available ICD 10 codes that applying specificity to a code is of 
paramount importance. For example, a patient who has a congenital 
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abnormality of their tricuspid valve might be assigned the ICD 10 code Q22.4, 
Q22.5, Q22.8 or Q22.9 however without more detailed clinical information this 
important distinction cannot be made.  
Since clinical coding is performed by non-clinical staff via case note review, a 
lack of detail in medical record keeping or a failure to appreciate the clinical 
coding process will inevitably translate into a lack of accuracy in coding output. 
Also, many of the congenital lesions listed are rarely encountered on an 
individual basis and so clinical coding staff may lack the esoteric knowledge to 
adequately apply the specificity required. To refer back to the example of 
congenital tricuspid valve disease, suppose this is further specified to be 
tricuspid atresia; a congenital lesion at the most severe end of the spectrum. 
This should be coded as Q22.4, representing ‘congenital tricuspid valve 
stenosis’. It is easy to see how this could be missed due to the use of the 
specialist terminology ‘atresia’ which is not explicitly included in the code 
description. It is reasonable to see how this may end up being coded as Q22.8, 
representing ‘other congenital malformation of tricuspid valve’ which does not 
adequately represent the complexity of the condition and as a stand-alone 
indicator would seriously limit any interpretation of mortality data. 
ICD coding is further complicated as versions change over time. The current 
iteration replaced ICD 9 in 1995. This previous version used a different, purely 
numerical method of coding and subtle differences in the available codes can 
make direct conversion between the two systems challenging. For example; in 
ICD 10 the aortopulmonary septal defect (aortopulmonary window) is given the 
code Q21.4. In ICD 9 however this lesion is included under the code 745.0 for 
common truncus, a lesion which has its own, separate code in ICD 10. WHO 
member states are currently reviewing and planning implementation for the 
latest revision, ICD 11. This promises increased complexity with expanded coding 
potential and increased functionality with the ability to link to other WHO 
endorsed classification systems. This will first be available for adoption in the UK 
in 2022.  
ICD coding does not take into consideration operative procedures. As the 
majority of congenital heart diseases, particularly those of moderate and great 
complexity, remain reliant on early surgical intervention, this is a significant 
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limitation. In clinical practice a patient’s ‘diagnoses’ are equally, or sometimes 
more dependent on the repaired anatomy as compared to the lesion that was 
present at birth. A patient born with tricuspid atresia who later has a Fontan 
operation is predominantly thought of as a Fontan patient thereafter. Although 
the original diagnosis of tricuspid atresia remains of some clinical relevance it is 
the Fontan discriminator which bears far more clinical significance. As this is a 
procedure not a diagnosis, ICD coding does not account for it. In such 
circumstances the OPCS coding system is used. This is currently in its fourth 
iteration (OPCS-4), although frequent amendments within each version are 
carried out. The OPCS system is coded in a similar way to ICD and is subject to 
similar vulnerabilities.   
1.3.2 Bethesda classification  
Due to the vast array of congenital cardiac lesions, efforts have been made to 
rationalise the list and separate it into cohorts depending on complexity.  
The most commonly used system is that devised at the 2001 Bethesda 
conference (42) which groups all congenital lesions into those of simple, 
moderate and great complexity (Table 1-2). This system was not designed for 
use to remunerate health care providers in the same way as ICD coding. Neither 
was it meant to infer disease ‘severity’ or prognosis. Instead it was intended to 
stratify patients as to the frequency and level of specialty required for their 
ongoing care. That being said, it has become commonplace for this, or a 
variation on this system to be used in the CHD literature when studying 
outcomes, including mortality (43,44). 
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Table 1-2: Summary of lesion complexity according to 'Bethesda' classification 
  
Unlike ICD coding, this system can take into consideration the surgically altered 
anatomy of the individual, refining its correlation to clinical practice. An 
additional benefit is that it allows grouping of often rare conditions into one of 
three comparably large cohorts. This permits a degree of generalisability for 
conditions which would otherwise be too uncommon to study. This also has 
implications to protect anonymisation which may otherwise be jeopardised by 
small patient cohorts.  
The primary drawback to the use of this classification system is the considerable 
heterogeneity which remains within each cohort of complexity. For instance, 
transposition of the great arteries corrected by the arterial switch operation is 
considered of great complexity along with univentricular hearts and Fontan 
physiology. Although individuals with TGA arterial switch can encounter complex 
problems in adulthood, a significant cohort have a relatively uncomplicated 
adulthood and are considered to have low morbidity and good survival prospects, 
not dissimilar to the general population (19,20,45). The American Heart 
Association (AHA), American College of Cardiology joint 2018 ACHD guideline has 
sought to address this issue by significantly expanding this classification system 
Complexity Lesion
ASD (secundum septum)
Isolated congenital aortic valve disease
Isolated congenital pulmonary stenosis
Anomalous pulmonary venous drainage
Atrioventricular septal defect
Tetralogy of Fallot
Ebstein's anomaly
Valvular lesions (unless isolated pulmonary stenosis or aortic valve disease)
Aortic coarctation
Sub and supravalvular aortic stenosis
Transposition of the great ateries (irrespective of repair)
Congenitally corrected transposition of the great arteries
Fontan
Eisenmenger syndrome
Truncus arteriosus
Univentricular heart
Hypoplatic left heart syndrome
Tricuspid atresia 
Pulmonary atresia
Aortopulmonary window
Simple
Moderate
Severe
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to incorporate the patient’s physiological status (46). This ‘ACHD anatomic and 
physiological’ (ACHD-AP) classification incorporates metrics such as functional 
capacity, New York Heart Association (NYHA) class, degree of hypoxaemia and 
the presence of end organ dysfunction. As such, this classification system holds 
much promise in clinical practice and for the study of recruited cohorts but 
holds no utility in the presented studies hence forth. 
 
1.3.3 Lesion physiology 
At its most basic, the essence to understanding congenital heart disease stems 
from the understanding of cardiac anatomy, chamber connections and the 
physiology of blood flow. As I have alluded to within this chapter, surgical 
intervention for congenital heart disease remains common and of crucial 
importance. The proposed or even ‘correct’ intervention is not necessarily 
determined by the underlying cardiac lesion but the unrepaired and the 
intended post-surgical physiology of blood flow and chamber continuity. As such 
the same or similar operations may be used for more than one and often many 
native diagnoses. In such circumstances it is the physiological grouping of lesions 
which is most clinically useful. This method of classifying lesions has been used 
to teach congenital heart disease to prospective practitioners for decades and is 
a cornerstone of textbook methodology (47,48). 
Recent years have seen attempts to formalise and standardise the physiological 
grouping of CHD in the literature. One such system of classification proposed by 
Thiene et al. (49) is summarized in Table 1-3. 
34 
 
Table 1-3: Classification of congenital heart disease by common physiology 
 
Using the examples outlined in Table 1-3 it is easy to understand the benefits of 
utilising a physiological classification system, the foremost of which being the 
practical implications for management options. For CHD with increased 
pulmonary blood flow a common goal of therapy will be to protect the 
pulmonary vasculature from irreversible damage and subsequent right heart 
failure. CHD with reduced pulmonary blood flow shares the common strategy of 
augmenting pulmonary blood flow when required and mitigating cyanosis. 
Obstructive lesions require assessment of severity and intervention to relieve the 
obstruction where appropriate. CHD incompatible with postnatal physiology 
requires persistence of the arterial duct, procedures to encourage non-septation 
and/or early reparative intervention. And CHD silent until adulthood requires 
effective identification, referral procedures and decision making for intervention 
timing. The main drawback to this methodology is that its utility is spent in the 
post-operative phase, limiting usefulness particularly for more severe lesions. 
Notable examples of surgically altered physiology for more complex lesions 
include operations for complete transposition of the great arteries where 
CHD with increased pulmonary blood flow (septal defects with left to right shunt)
Isolated atrial septal defect
Isolated ventricular septal defect
Partial anomalous pulmonary venous drainage
Atrioventricular septal defect
CHD with decreased pulmonary blood flow (septal defects with pulmonary 
obstruction and right to left shunt)
Pulmonary valve stenosis with ASD
Tetralogy of Fallot
Tricuspid atresia
CHD with obstruction to blood progression and no shunt
Coarctation of the aorta
Aortic and subaortic stenosis
Pulmonary stenosis
CHD incompatible with postnatal circulations (arterial duct dependance)
Pulmonary atresia
Transposition of the great arteries
Total anomalous pulmonary venous drainage
CHD silent until adulthood
Bicuspid aortic valve
Non cyanotic anomalous coronary arteries
Congenitally corrected transposition of the great arteries
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physiological normality of blood flow is achieved either by ‘switching’ the inflow 
of blood to the atria (atrial switch procedure) or by ‘switching’ the outflow of 
the ventricles (arterial switch procedure). The former procedure involves 
baffling the atrial blood into the contralateral ventricular mass to achieve 
physiological flow. This has the drawback of maintaining the morphological right 
ventricle in the systemic position and carries a significant long term burden of 
heart failure, systemic tricuspid valve regurgitation atrial arrythmias. The 
arterial switch procedure has the marked benefit of restoring the left ventricle 
into the systemic position. The procedure does however involve re-anastamosis 
of the coronary arteries to the aorta which can have short and long term 
sequalae. Perhaps the most notable surgically modified physiology which limits 
this system as a tool in adults is following the Fontan operation or a modification 
thereof. This operation (or more commonly, series of operations) has utility for 
several native congenital heart lesions. In-particular, instances where there is 
marked mixing of oxygenated and deoxygenated blood at atrial and/or 
ventricular level, and repair to physiological normality is not possible, ‘Fontan 
physiology’ may be preferred. This is achieved by a series of two or three 
operations with the ultimate goal of bypassing the systemic venous return away 
from the heart entirely with direct anastomosis to the pulmonary arteries. This 
results in the heart acting as a single functional atrial and ventricular mass 
which deals solely with the systemic circulation. This has the benefit of 
mitigating cyanosis and protecting the pulmonary circulation from what may 
otherwise be systemic pressures. This does however result in a delicately 
balanced physiological state with no subpulmonary ventricle, and myriad 
cardiovascular and non-cardiovascular complications can occur in the short and 
medium term and ultimately will occur in the long term.  
Additional to the complications posed by the surgical alteration of physiology, 
the natural history of certain lesions may mean that physiology changes over 
time. A notable example of this is amongst the lesions in Table 1-3 with 
increased pulmonary blood flow due to left to right shunting. In this 
circumstance, where the pulmonary vascular bed is exposed to increased flow 
over the long term, pulmonary pressures may rise dramatically. Over time, in 
some instances this may result in an equalisation and then reversal of the 
gradient of pulmonary to systemic pressure, reversing the shunt and rendering 
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the patient cyanotic and significantly increasing the potential for morbidity and 
mortality.  
To the best of my knowledge, and likely due to the significant limitations stated 
above, this method of categorising lesions by common physiology has not been 
used in the study of outcomes in ACHD. 
1.4 Prognosis in ACHD 
1.4.1 Morbidity in ACHD 
Improvements in paediatric care and early intervention has led to an increasing 
prevalence of CHD in the adult sector (42). Additionally, adults with CHD are 
living longer that previously (50,51). Morbidity in ACHD has therefore increased 
in two main ways; there are now adults with critical CHD who previously did not 
survive to adulthood; and, adults with CHD are living longer and acquiring more 
comorbidity (52). The result has been a dramatic increase in the number of 
hospital admissions amongst ACHD patients. From the mid 1990s until 2005, 
ACHD related admissions in the US doubled (53). Admissions have since been 
shown to increase until at least 2010 and be accounted for by ACHD of all 
degrees of complexity (52).  
The prevalence of comorbidity in adults with ACHD has also increased 
dramatically in recent years. One large US population study reported that from 
2003 – 2012, the percentage of ACHD patients with diabetes increased from 
13.1% – 21.7%, systemic hypertension from 37.3% - 54.4% and chronic kidney 
disease from 2.8% - 12.1% (52). A similar increase in rates of smoking and obesity 
were also found. Despite the growing body of population data regarding 
increased morbidity in the ACHD population, many questions remain 
unanswered. In particular, no study has examined how multimorbidity has 
affected cause of death over time. 
Section 4.2.2 will outline how we intend to utilise this wealth of ACHD data from 
hospital admissions using the Scottish Morbidity Database to address mortality 
and cause of death in the Scottish ACHD population. 
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1.4.2 Survival  
Advances in the care of individuals with CHD have led to a shift away from infant 
and towards adult mortality (54). Despite surgical advances, few, if any, 
congenital heart lesions can be considered to be ‘cured’ by intervention.  
A study by Diller et al (43) reported age and sex standardised mortality ratios for 
congenital lesions between 1991 and 2014 and found that survival amongst 
individuals with lesions of simple complexity (ASD, VSD and PDA) was similar to 
that of the general population. In all other lesions, a significantly higher 
mortality was observed. Individuals with a Fontan circulation or Eisenmenger 
syndrome had the highest age and sex standardised mortality ratios of 23.40 
(95% CI 15.97 -34.29) and 12.79 (95% CI 9.67-16.91) respectively.  Survival 
amongst individuals with CHD of moderate complexity (as defined by the 
Bethesda classification (Table 1-2)) was worse than for simple lesions, however 
the absolute difference in point estimates was relatively small (standardised 
mortality rations 1.3, 95% CI 1.1-1.5 and 2.2, 95% CI 1.8-2.3 respectively). 
Prognosis amongst those with lesions of great complexity on the other hand was 
far poorer with a combined standardised mortality ratio of 10.9 (95% CI 9.3-
12.8).  
1.4.2.1 Survival and year of birth 
There is clear consensus in the literature that survival with congenital heart 
disease has improved over time (33,51,55,56). Although the absolute survival 
varies from cohort to cohort and is dependent on several factors such as the 
definition of CHD; whether this includes silent patent arterial ducts and small 
membranous VSDs for instance; and whether active screening recruitment was 
undertaken or if cohorts were observational; universally, temporal trends show 
improved survival.  
A large Belgian study of over 7000 individuals with CHD compared rates of 
survival to adulthood according to birth era. For individuals born in 1970-1974, 
81% survived to age 18, compared with 88.6% for those born in 1990-1992 (33). 
Similar trends have been demonstrated in more contemporary cohorts. Marelli 
et al. (3) confirmed that the adult prevalence of CHD continued to rise steeply 
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between 2000 – 2010, increasing by 20%. A corresponding increase in age at 
death corroborates these findings. Figure 1.1 demonstrates the changing 
distribution of age at death in a Canadian CHD population (51). This data clearly 
illustrates the shift from frequent infantile mortality in the late 1980s to adult 
mortality by 2005, which is more comparable to that of the general population. 
 
Figure 1-1: Age at death compared to the general population.  
Age at death during two time periods for individuals with congenital heart 
disease and the general population of Quebec, Canada. Reproduced using data 
from Khairy et al. (51) 
 
 
1.4.2.2 Sex differences in Survival with ACHD 
Sex differences in the distribution, presentation, management and outcome of 
cardiovascular disease in general are well recognised (57–60). The important 
attention provided to the excess mortality observed for women with 
cardiovascular disease over recent years is likely to have played an important 
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part in closing the gap in outcomes (61).  Unfortunately, no such consensus 
exists for CHD. This issue will be discussed further in section 6.1 but results to 
date have been contradictory. Of the three large studies to compare all-cause 
mortality according to sex; one found men to be at higher risk (62), one found 
women to be at higher risk (41), and one found no significant difference (63).  In 
terms of specific clinical outcomes there is some consensus of higher rates of 
pulmonary hypertension among women, and higher rates of aortic syndromes and 
infective endocarditis amongst men (41,63). 
As well as being conflicting in outcomes, attempts to delineate the influence of 
sex on mortality in CHD have been limited by an inability to adjust for patient 
characteristics such as pre-existing comorbidity and socioeconomic factors.  
1.4.2.3 Socioeconomic factors associated with survival in ACHD 
There are few published data concerning socioeconomic deprivation in CHD. A 
small number of studies have evaluated the effect of socioeconomic status on 
birth incidence of CHD with a recent systematic review with meta-analysis 
suggesting no correlation (64).  
A recent US observational study has suggested a correlation between lower 
socioeconomic status and a higher risk of the composite outcome of unexpected 
hospital admissions and mortality amongst children with the most severe forms 
of congenital heart disease (hypoplastic left heart and single ventricle 
physiologies) (65). In this case, maternal higher education and private health 
insurance were the metrics used to determine socioeconomic status. The authors 
correlated this to Hispanic race and suggested an interaction between 
socioeconomic status and race/ethnicity in the US and as a potential explanation 
for the previously noted higher mortality in non-white children with CHD (66).  
To the best of the author’s knowledge, no published data is available concerning 
socioeconomic status and survival amongst adults with CHD. One potential 
barrier to the study of socioeconomic status and outcomes in ACHD is the lack of 
a universally accepted measure. Furthermore, postulated interactions between 
ethnicity and socioeconomic status should not be taken at face value and are not 
necessarily transferable from one health care system to another. As a result, the 
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afore referenced interaction between Hispanic ethnicity, socioeconomic status 
and certain health outcomes in the US is of very little relevance to the 
congenital heart disease population of Scotland.  
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1.4.3 ACHD prognosis in clinical practice 
Understanding the survival and circumstances of death amongst adults with CHD 
is desirable on two fronts: firstly, to inform service development and strategy 
for service provision on a national and regional level; and secondly, to inform 
patients on an individual basis, promoting informed decision making regarding 
both clinical and non-clinical factors. Regarding the former, Scotland utilises the 
gold standard ‘hub and spoke’ model for ACHD care where the majority of care 
for the majority of patients takes place in regional referral centres with 
occasional care in the single, national centre located at the Golden Jubilee 
Hospital in Clydebank.  It is therefore essential that the right patients get the 
right care in the right place. Currently, no population data is available regarding 
the mortality of Scottish adults with congenital heart disease and therefore 
decision making with regards to all aspects of care; from frequency and locale of 
review, to timing and method of intervention, is based on clinical judgement 
and extrapolation from often significantly heterogenous data pools. 
Furthermore, in June 2018 the Population Health Directorate for Health and 
Social Care Scotland published a list of six priorities which represent an 
agreement between the Scottish government and local councils regarding how 
best to focus efforts, and by extension resources, to best improve the health of 
the Scottish population (67). Priority five asserts that we should have a 
‘sustainable economy with equality of outcomes for all’. Paramount to this 
statement must be an ability to measure and respond to outcomes, such as 
mortality, across Scotland as a whole, and more specifically amongst different 
demographic and socioeconomic groups.  To the best of my knowledge there has 
been no successful efforts to evaluate the equity of outcomes for adults with 
congenital heart disease in Scotland and no bespoke tool exists to this end.  
Understanding survival and mortality in ACHD is arguably just as important for 
the front-line clinician on a day to day basis. From a clinical perspective it is 
easy to imagine that understanding which patients are most ‘at risk’ might be 
useful as it helps to prioritise patient care. What are perhaps less obvious are 
the myriad real-life practical questions and problems faced by adult survivors 
with CHD.  It is not uncommon to face questions such as “if I have a child am I 
likely to see them graduate?” or “should I pay into my work pension scheme?”. 
And in fact, questions of this ilk should be encouraged. However, as things 
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currently stand, the response is often based on insufficient and/or outdated data 
based on a population remote and quite distinct from that of Scotland. Of 
course, robust epidemiological data alone does not provide the whole picture 
regarding mortality in ACHD. Even within a single diagnosis e.g. ASD or TOF, 
significant heterogeneity exists. There are multiple variables, both inherent to 
the natural history of the lesion and the interventional strategy which must be 
taken into consideration when informing the patient. Taking the relatively 
straightforward example of ASD, factors which may be expected to influence 
outcome include; 
• The position of the defect within the atrial septum (secundum, coronary sinus, superior or 
inferior sinus venosus) 
• Associated lesions e.g. anomalous pulmonary venous drainage, persistent left superior 
vena cava or an ‘unroofed’ coronary sinus 
• Age at detection 
• Biventricular function 
• History of atrial arrhythmia 
• Pulmonary vascular resistance at the time of detection 
• Surgical or percutaneous method of closure 
• Complete versus incomplete closure 
• The need for additional procedures e.g. tricuspid valve intervention or surgical ablation 
(Maze procedure) 
As things currently stand, assessment of how these variables influence prognosis 
is largely down to experience and clinical judgement. Although some evidence 
exists regarding outcomes of surgical compared with percutaneous ASD closure 
(68), this is limited to short term measures and survival outcome data are 
lacking. It is a similar picture across the spectrum of CHD lesions. Clearly this 
situation must be improved if we are to robustly advise our patients on 
important matters as previously stated.  
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2 Literature Review 
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2.1 Introduction 
Despite the advances in the early surgical management of congenital heart 
lesions as outlined in the above chapter, long term survival remains largely 
uncertain. Although representing the most common group of in-born structural 
pathologies, congenital heart disease in the adult cardiology clinic and in patient 
cardiology wards is still uncommon. This relative sparsity of patients makes 
answering important questions regarding survival and mortality even more 
difficult. Furthermore, the rapidly evolving landscape of structural intervention 
for this group of patients and continued improvements in survival to adulthood 
makes studying mortality in this population analogous to a moving target. 
Much of the literature regarding long-term follow up in congenital heart disease 
are concerning outcomes of interventions as case series or surgical cohorts. 
Establishing prognosis for ‘all comers’ at a population level is significantly more 
challenging. In this chapter I aim to review the literature with a view to 
characterising the survival of adults with congenital heart disease; where 
possible describing causes of death and temporal trends for all CHD and 
according to lesions.  
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2.2 Methods 
2.2.1 Search strategy 
I systematically searched the Embase and Ovid MEDLINE databases from 
inception to April 2018 to identify articles pertaining to mortality among adult 
survivors of CHD as a whole or for any one of ten pre-defined lesions; ASD, VSD, 
PDA, aortic coarctation, Ebstein’s anomaly, atrioventricular septal defect 
(AVSD), systemic right ventricle, TGA with arterial switch and Fontan 
circulations. Eligibility for inclusion was established against these criteria: 
1. Must refer to ‘all-comer’ survival. If survival was only provided 
according to exposure to a certain procedure or intervention these were 
excluded.  
2. Must contain survival data during adulthood. Where paediatric data is 
included, adult survival must be reported independently or be 
extricable from paediatric survival data 
3. Published in English language 
4. As a minimum, long term outcome must be reported in one of three 
ways 
1. Mean or median age at death 
2. Survival according to person years of follow-up – or be calculable 
by the provided information 
3. Percentage survival at predefined age points 
 
A title and abstract word search was carried out across the Ovid MEDLINE and 
Embase databases. Three search queries, representing the domains of patient 
population, study design, and outcome were utilised and search terms include; 
Patient population: 
“congenital heart”, “atrial septal defect*”, patent duct*”, “PDA”, 
“ventricular septal defect”, “VSD”,”coarctation”, “supra-valvular 
stenosis”, “atrioventricular septal”, “AVSD”, “coronary sinus defect”, 
“tetralogy of Fallot”, “Fallot’s tetralogy”, “TGA”, “transposition of 
the great arteries”, “DTGA”, “d-TGA”, “LTGA”, “l-TGA”, “ccTGA”, 
“congenitally corrected”, “Fontan”, “total cavo-pulmonary”, “TCPC”, 
and “adult” 
Study design 
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“population”, “epidemiology”, “registry”, “population-based”, “cross 
section*”, “cross-section”, or “cohort” 
Outcome 
“long term”, “long-term”, “late”, “circumstance*”, “temporal”, 
“extent”, and “prognosis”, “outcome”, “survival”, “death” or 
“mortality” 
I screened all titles and abstracts for relevance and those deemed appropriate 
were accepted for full article review. 
2.2.2 Data duplication 
Much of the data contained within the returned searches is derived from local, 
national and multinational databases and registries. As such the potential for 
duplication of patient information across two or more articles is significant. At 
times this was obvious; for example multiple studies derived from the Dutch 
national CONCOR registry, with significantly overlapping data periods were 
reviewed. When competing data sets were encountered the more contemporary 
paper was selected. When the data period was the same, or sufficiently similar 
as to bear no clinical significance, the article with the greater combined patient 
follow-up was selected.  
In several instances it was more difficult to assess for overlapping patient 
cohorts, for example where multinational registries have small numbers of 
patients from a large number of countries/centres which are represented in 
overlapping articles. Instances such as this were assessed on a case-by-case 
basis. Where both studies were included, results were assessed by means of 
sensitivity analysis to limit potential bias. At times, overlapping studies from the 
same centre or registry were encountered where one contained ‘all ACHD’ and 
another contained data concerning a single lesion (e.g. ASD only). In such cases 
the ‘all ACHD’ article would be favoured. However, when the ‘ASD only’ paper 
contained a large patient cohort (greater than the ASD cohort in the ‘all ACHD’ 
study), this data may also be included and the ASD data form the “all ACHD” 
article disregarded in the analysis. This was in an attempt to maximise the 
review cohort.  
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2.2.3 Defining groupings 
2.2.3.1 Congenital lesions 
When defining lesions within a study, little variability was encountered. By and 
large there is not much controversy regarding lesion definition however there 
are a few examples where clarifying heterogeneity within a diagnostic group is 
likely of significance to outcome. The ‘Fontan’ cohort is one such example. 
Clinically the Fontan patient most commonly refers to all who undergo complete 
‘right heart bypass’ surgical palliation. In procedural terms however, the Fontan 
operation is more accurately a specific method of right ventricular bypass using 
the right atrium as a conduit (otherwise referred to as the atriopulmonary 
Fontan) and several other forms or right heart bypass exist. Only cohorts 
inclusive of all methods of complete right heart bypass were considered. 
Similarly, the ASD group includes all except ostium primum forms of atrial septal 
defect. It is therefore inclusive of secundum type as well as sinus venosus and 
coronary sinus defects. A notable exception is where ICD coding was used for 
identification of ASDs. In such cases these are inextricable from PFOs due to the 
same ICD code being used for both. Ostium primum defects are physiologically 
better thought of as partial atrioventricular septal defects. The obligatory 
involvement of atrioventricular valve morphology and other deep cardiac 
structures renders them suitably distinct from other forms of ASD as to 
reasonably assume distinct mortality outcomes. Finally, a lesion group of 
systemic right ventricles was formed. This consists of two groups of patients; 
those with congenitally corrected transposition of the great arteries and those 
with complete transposition of the great arteries who have undergone an ‘atrial 
switch’ procedure (Mustard or Senning palliation). More complex lesions 
involving a systemic right ventricle such as hypoplastic left heart syndrome 
following surgical palliation or unoperated double outlet right ventricle were not 
included in this group as the governing physiology and impact on mortality are 
not comparable. This method of defining the systemic right ventricle has 
precedence within the literature (43,69). 
2.2.3.2 Cardiovascular and non-cardiovascular death 
Causes of death were grouped as either being cardiovascular or non-
cardiovascular in nature. I regarded cardiovascular death to be death due to; 
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heart failure, ischaemic heart disease, sudden cardiac or arrhythmic death, 
pulmonary thromboembolism, stroke, death attributed to cardiovascular 
intervention, or peripheral vascular disease including aneurysmal haemorrhage. 
Non-cardiovascular death included all remaining causes as long as a cause was 
clearly defined. Where the cause of death was unclear it was removed from the 
denominator. As such calculations regarding cause of death may not always be 
equal to 100 percent of the deaths within the total study cohort. Deaths due to 
infective endocarditis were considered to be non-cardiovascular in nature. 
Cause of death is also reported according to lesion complexity. This 
approximates the Bethesda groupings as described in section 1.3.2. 
2.2.4 Statistics 
Descriptive statistics are quoted as either mean +/- standard deviation (SD) or 
median and interquartile range (IQR) depending on the availability from the 
source article. Where both were available the mean +/- SD was favoured. This 
was in order to allow combining of data. For example, when age at death is 
given for sinus venosus ASD and secundum ASD separately using the mean, they 
were multiplied out by the number of deaths in each group and a total ‘ASD 
group’ mean age at death with SD were calculated.  
Mortality rate is quoted in terms of number of deaths per 1000 years of 
cumulative follow up. Where this was not provided in the source material it was 
calculated using the mean number of years followed up per person, the cohort 
size, and the total number of deaths encountered. Where the average follow up 
period per person was given as a median only, the mean was calculated using 
the method described by Hozo et all (70) where the median approximates the 
sample mean when the sample size is large but can otherwise be calculated by 
the method shown below (Equation 1). 
?̅? ≈
𝑎 + 2𝑚 + 𝑏
4
  𝑎 = 𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒, 𝑏 = 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒, 𝑚 = 𝑚𝑒𝑑𝑖𝑎𝑛 
Equation 1, estimating the sample mean from the median and range (70)  
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2.3 Results 
2.3.1 Search results and article eligibility 
Initial search by the manner described above yielded 509 articles. Following 
exclusion of duplicates, 323 articles were screened for eligibility by abstract and 
title according to the predetermined inclusion criteria and to exclude any non-
English language and non-human subject publications. Ultimately, 56 full texts 
were reviewed in detail, 34 of which were excluded: 11 referred to the wrong 
patient population, frequently paediatric populations or subsets of patients who 
have undergone certain interventions or fulfil certain biochemical criteria; 9 
reported the wrong outcomes, either no survival data was given or composite 
outcomes only were provided with no breakdown of mortality; 8 articles were 
deemed to have a high probability of significant patient population overlap; 6 
articles were editorials or review articles. Figure 2-1 summarises article 
screening and inclusion. 
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Figure 2-1: PRISMA diagram of article eligibility 
 
2.3.2 Survival 
A total of 22 articles provided data regarding survival. 7 articles included data 
for all CHD subsets (43,44,71–75); 6 articles for ASD (43,73,75–78); 4 for Fontan 
patients (43,79–81); 6 for TOF (41,43,82–85); 5 for systemic RV (43,69,73,75,86); 
5 for CoA (43,73,75,87); 5 for VSD (37,43,73,75,88); 3 for PDA (37,43,73); 3 for 
Ebstein’s anomaly; 3 for AVSD (43,73,89); and 1 for TGA arterial switch (43). 
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All but two articles originated from Europe or North America: 14 Europe; 6 North 
America; 2 Australasia. A variety of data sources were encountered across the 
studies. Most frequently (n=12) cases were identified from single centre 
databases or clinic list review. Regional or nationally developed databases were 
utilised on 4 occasions, national registries on 3 occasions and a multinational 
registry on one occasion. Only one study utilised a centrally controlled coding 
system to identify individuals with ACHD, and this was on a regional basis (72). 
No data retrieval method was therefore able to identify unselected ACHD 
patients, independent of enrolment in a registry or database, on a national 
level. Data regarding cause of death was derived either from direct inspection of 
medical notes and certificates in 12 cases, or from national death registries in 10 
cases. 
The study characteristics and populations are summarised below (Table 2-1). 
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Table 2-1 - Summary of included articles 
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2.3.2.1 All CHD subtypes 
Survival data as well as demographics and study period for all CHD and for each 
CHD lesion are summarised in Table 2-2. 
Of the 7 articles for which survival data across all CHD subtypes was reported, 6 
were European cohorts and one was Canadian. The era of study ranged from 
1983 (51) to 2014 (73). The median year of study for each article ranged from 
1990 (51) to 2013 (37) with one article presenting survival across two distinct 
data periods, from 1987 – 1993 and 1999 – 2005 (51). 
The number of individuals included within the studies ranged from 646 (74) to 
71686 (51) with a combined total across all studies of 95886 persons. The 
proportion of female patients ranged from 49.9% (43) to 55.1% (44) with a 
combined proportion of 52.7% across all studies (44,261 of 83,916 persons; not 
reported in two articles (71,75)). 
Age at time of study ranged from 22.5 (IQR 18-39) (73) to 35.0 (SD 12) years 
(74). The total number of years of follow up ranged from 3,876 (74) to 982,363 
(51) with a total combined person follow up across all articles of 1,143,117 
person years. Mortality rates ranged from 5.87 (71) to 9.03 (74) deaths per 1000 
person years. The combined mortality rate across all studies was 8.59 per 1000 
person years. Age at death ranged from 40 years (74) to 59 years (73) across the 
total study cohorts and from 40 years (74) to 75 years (34) across the studied 
data periods. 
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Table 2-2 - Demographics and survival according to lesion studied  
(NR=not reported, NC=not able to calculate). 
 
Subtype Article
Year      
(mid point) N
Female 
% Age Dead (%)
Mortality rate 
(per 1000 
person years) Age at death
All CHD Khairy et al 1990 NR NR NR NR NC 60 (3-76)
Khairy et al 2000 NR NR NR NR NC 75 (60-83)
Trojnarska et al 2000 1304 55.1 29.4 +/-10.6 29 (2.2) 6.3 NC
Engelfriet et al 2001 3375 NR 28 +/- 3.0 101 (3.0) 5.9 NC
Diller et al 2002 6969 49.9 29.9 +/- 15.4 524 (7.7) 7.4 47 34-65
Oliver et al 2002 3311 51 22.5 (18-39) 336 (10.1) 8.9 59 (36-75)
Zomer et al 2006 8595 NR NR 231 (2.7) 8.7 48 +/-11.8
Popelova et al 2008 646 53.4 35 +/-12 35 (5.4) 9 40 +/-14
ASD Nyobe et al 1995 2277 61 45.4 +/-0.4 315 (13.8) 7.6 NC
Kotowycz et al 1997 718 70.5 45.8 27 (3.8) NC 56 +/-13.7
Oliver et al 2002 472 65.9 39.4 (23-55) 57 (12.0) 12.1 NC
Diller et al 2003 1092 61.3 39.8 +/-18.3 66 (6.2) NC 72 (62-79)
Kuijpers et al 2008 2207 67 44.8 +/-17 102 (4.6) 7.5 83
VSD Oliver et al 2002 356 53 19.1 (17-23) 5 (1.4) 1.4 NC
Diller et al 2002 713 50.6 26.1 +/-12.5 19 (5.9) NC 48 (39-60)
Zomer et al 2006 1358 NR NR 17 (1.3) NC 51
Gabriels et al 2009 266 NR NR NR NC 51 +/-9.5
Videbaek et al 2013 598 55 45.9 (42-49) 41 (6.9) 1.5 NC
PDA Oliver et al 2002 90 79 28.1 (19-44) 10 (11.0) 8.4 NC
Diller et al 2002 117 77.8 32.8 +/-16.4 2 (1.7) NC 74 (63-88)
Videbaek et al 2013 281 68 48.1 (44-52) 19 (6.8) 1.4 NC
TOF Harrison et al 1993 242 45.5 33.9 10 (4.1) 1.9 40.4
Buys et al 2002 92 30 26.1 +/-7.7 2 (2.7) 3 NC
Oliver et al 2002 327 46 20.3 (18-27) 18 (5.5) 5.3 NC
Diller et al 2002 869 45.9 26.8 +/-13.1 54 (6.3) NC 50 (35-66)
Zomer et al 2006 868 NR NR 28 (3.2) NC 51
Mouws et al 2008 225 43.1 41 +/-12 27 (12.0) 3.4 NC
Bokma et al 2009 794 45 27 20-38 46 (5.8) 6.5 NC
Coarctation Oliver et al 2002 353 42 20.2 (18-29) 21 (5.9) 6.3 NC
Diller et al 2002 860 41.3 28.9 +/-14.3 39 (4.6) NC 48 (37-65)
Choudhary et al 2003 151 42 35 +/-15 7 (4.6) 1.8 59 (29-72)
Zomer et al 2006 868 NR NR 13 (1.5) NC 59
Ebstein's Oliver et al 2002 76 72 32.4 (20-47) 9 (12.0) 15 NC
Diller et al 2002 153 54.3 34.5 +/-16.2 19 (12.6) NC 52 (37-73)
Zomer et al 2006 138 NR NR 8 (5.8) NC 47
AVSD Oliver et al 2002 148 61 20.0 (17-29) 8 (5.4) 6.9 NC
Diller et al 2002 255 57.6 29.1 +/-14.8 15 (5.9) NC 52 (48-63)
Zomer et al 2006 129 NR NR 8 (6.2) NC 37
Systemic RV Oliver et al 2002 42 40 29.4 (20-48) 12 (29.0) 57.1 NC
Diller et al 2002 279 46 27.6 +/-12.4 34 (12.5) NC 37 (28-42)
Chaix et al 2003 140 37.1 25.1 +/-6.7 7 (5.0) 5.1 32
Zomer et al 2006 112 NR NR 8 (7.1) NC 47
Fontan Dennis et al 1996 683 NR 26 +/-8 62 (9.1) 10.6 NC
Diller et al 2002 180 53.3 21.4 +/-7.4 34 (19.2) NC 28 (23-36)
Elder et al 2006 123 43.9 28.5 +/-7.7 13 (10.6) 4.7 32
Burchill et al 2008 106 51 30 +/-10 7 (6.7) 6 NC
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Figure 2-2: Age at entry and age at death for each article included and according to lesion
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2.3.2.2 ASD 
Of the 6 articles for which survival data regarding ASD was included, three were 
subsets from larger cohorts involving multiple CHD subtypes (43,73,75) and three 
were dedicated to ASD alone (76–78). The number of patients in each study 
ranged from 472 (73)to 2,277 (78) with a total of 8,236 across all studies. The 
proportion of women ranged from 61.0% (78) to 70.5% (76) and was cumulatively 
64.3% (4351 of 6766; data not reported for one article (75)). Age at study ranged 
from 39.4 (73) to 45.8 years (76).  
Cumulative patient follow up could be calculated for 3 articles and ranged from 
4,723 (73) to 41,214 years (78). Amongst these articles mortality rate ranged 
from 7.5 (77) to 12.1 (73) deaths per 1000 person years and yielded a combined 
mortality rate of 7.9 per 1000 person years (474 deaths in 59,521 years of follow 
up). 
Age at death ranged from 55.6 (SD 13.7) years (76) to 83.4 (SD not given or 
calculable) years (77). Age at death according to study period is shown in Figure 
2-3. 
2.3.2.3 VSD 
Of the 5 articles contributing survival data for VSD; 4 were subsets from larger 
studies (37,43,73,75) and one was a dedicated VSD cohort (88). The number of 
VSD patients in each study ranged from 266 (88) to 1,358 (37) with a total 
combined cohort of 3,291 patients. The proportion of women ranged from 50.6% 
(43) to 55.0% (37) with a combined proportion across the three studies for which 
it could be extrapolated of 52.7% (879 of 1,667). 
Cumulative person follow up could be calculated for two studies yielding a 
combined 30,946 years (37,73). Mortality rate ranged from 1.39 (73) to 1.50 (37) 
per 1000 person years giving a combined mortality rate of 1.49 per 1000 person 
years. 
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Age at death could be calculated for 3 articles and ranged from 48 (IQR 39-60) 
(43) to 51.3 (SD 9.5) (88) years. Age at death according to era of study is shown 
in Figure 2-3 
2.3.2.4 PDA 
Data regarding survival in PDA was available from three articles, all of which 
were subsets of larger cohorts (37,43,73). The number of PDA patients in each 
study ranged from 90 (73) to 281 (37) with a combined total of 488. The 
proportion of women ranged from 68.0% (37) to 79.0% (73) and a combined 73.0% 
(356 of 488) across the three studies. 
Combined follow up could by calculated for two studies (37,73) yielding a total 
combined follow up of 14,686 years. Mortality rate ranged from 1.41 (37) to 8.35 
(73) deaths per 1000 person years. 
Age at death was only provided by one study (43) and was 74.0 years (IQR 63-
88). 
2.3.2.5 Aortic coarctation 
Survival data concerning aortic coarctation was included from 4 studies; 3 were 
subsets of larger studies (43,73,75), where one was a dedicated coarctation 
cohort (87). 
The total number of coarctation patients across the four studies was 2,232 
(range; 151 (87) to 868 (75)). The proportion of female patients ranged from 
41.3% (43) to 42.0% (73) giving a combined 41.5% (566 of 1364). 
Cumulative person follow up could be calculated for two studies (73,87) yielding 
a total of 7,244 person years. A combined 28 deaths were observed in these two 
studies, yielding a combined mortality rate of 3.9 deaths per 1000 person years 
(range; 1.78 (87) to 6.3 per 1000 person years (73)). 
Age at death could be extrapolated for three studies and ranged from 48.0 (IQR 
37-65) (43) to 59.0 (IQR 29-72) (87). 
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2.3.2.6 Ebstein’s anomaly 
Three articles provided survival data on Ebstein’s anomaly, all of which were 
subsets of larger cohorts (43,73,75). A combined 367 patients with Ebstein’s 
anomaly across the three studies were included (range; 76 (73) to 153 (43)). The 
proportion of women ranged from 54.3% (43) to 72.0% (73) comprising 60.3% (138 
of 229) overall.  
Cumulative follow up and mortality rate could only be calculated for one study 
(73) and yielded 9 deaths in 600 person years, equivalent to 15.0 deaths per 
1000 person years. 
Age at death ranged from 46.8 (SD not given or calculable) (75) to 52.0 (IQR 37-
73) (43) years.  
2.3.2.7 AVSD 
Three articles provided survival data on AVSD, all of which were subsets of larger 
cohorts (43,73,75). A combined 532 patients across the three studies were 
included (range; 129 (75) to 255 (43)). The proportion of female patients ranged 
from 57.6% (43) to 61% (73) giving a combined proportion of 58.8% (237 of 403). 
A mortality rate of 6.93 deaths per 1000 person years could be calculated from 
one study (73). Age at death ranged from 37.3 (SD not given or calculable) (75) 
to 52 (IQR 48-63) (43) years. 
2.3.2.8 Tetralogy of Fallot 
Of the six studies contributing survival data concerning TOF, 2 were subsets of 
larger cohorts (43,73) and four included TOF patients only (82–85). A total of 
2,549 patients were included across all six studies (range; 92 (83) to 869 (43)). 
The proportion of female patients ranged from 30.4% (83) to 46.0% (73). A 
combined proportion of 44.8% (1141 of 2549) were women. 
Cumulative patient follow up could be calculated for 5 of the 6 articles and 
yielded a total cumulative follow up of 24,393 years (range; 677 (83) to 7875 
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(85) years). The cumulative mortality rate across these studies was 4.2 per 1000 
person years (range 1.87 (84) to 6.46 (82) per 1000 person years).  
Age at death was provide by two studies and ranged from 40.4 (unable to 
calculate SD) (84) to 50.0 (IQR 53-66) years. 
2.3.2.9 Arterial Switch 
One study included survival data regarding patients with TGA post arterial switch 
operation (43). A total of 171 patients were included (30.5% female). Only 3 
deaths were reported. 
2.3.2.10 Systemic right ventricle 
Of the 5 studies contributing survival data regarding systemic right ventricles, 3 
were subsets of larger cohorts (43,73,75) and 2 were of systemic RV patients 
only (69,86). A total of 702 individuals across the 5 studies were included (range; 
42 (73) to 279 (43)). The proportion of women ranged from 34.9% (69) to 46.0% 
(43) with a combined 41.2% (243 of 590) across the four studies for which sex 
was reported. 
A total combined follow up of 3,066 person years was observed across the three 
studies for which it could be calculated (69,73,86). The mortality rate across 
these studies was 18.3 deaths per 1000 person years (range; 5.1 (86) to 57.1 
(73)). Age at death ranged from 31.7 (unable to calculate SD) (86) to 46.8 (SD 
not given or calculable) years (75). 
2.3.2.11 Fontan 
A total of four articles contributed survival data concerning Fontan patients; one 
was a subset of a larger study (43), and three included Fontan patients only (79–
81). A total of 1,092 patients were included across the four studies (range; 106 
(79) to 683 (80)) yielding a total combined patient follow up of 9,636 years 
(unable to calculate for one study (43)). The proportion of female patients 
ranged from 43.9% (81) to 53.3% (43) with a combined 49.9% (204 of 409) across 
the three studies for which sex was reported. 
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Mortality rate ranged from 5.96 (79) to 10.6 (80) deaths per 1000 person years. 
The combined mortality rated across the three included studies was 8.51 per 
1000 person years. 
Age at death was given or could be calculated from two studies and ranged from 
28.0 (IQR 23-36) (43) to 31.8 (SD not calculable) years (81). 
2.3.2.12 Age at death according to study period 
Other than for PDA, 2 or more articles referring to each CHD lesion reported age 
at death.  
Figure 2-3 shows age at death according to the mid-point of each study for which 
it could be calculated. 
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Figure 2-3 - Age at death for each lesion according to the midpoint of each study. Number of 
studies for each lesion given in brackets (*).  
Age at death from earliest to most recent point of study increased for all lesions other than AVSD 
and Ebstein’s anomaly.  
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2.3.3 Cause of death 
Cause of death was reported in 13 articles in total (43,71,73–78,80,82,85–87). 
Table 2-3 summarizes the studies, absolute, and proportional breakdown of CV 
and non-CV death according to the lesion reported. 
Table 2-3 - Cardiovascular and non-cardiovascular death for all CHD and by lesion.  
* no definition of CV / non-CV given in the source data 
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The combined proportion of cardiovascular deaths for the 5 articles which 
reported on all CHD was 66.9% (816 of 1,220 deaths). When all studies were 
combined to include single lesion only studies the proportion of CV deaths was 
63.7% (1,118 of 1,754 deaths). 
For individual lesions, the proportion of cardiovascular deaths ranged from 49.8% 
(237 of 476 deaths) for ASD to 93.9% (46 of 49 deaths) for systemic RV. 
For lesions of simple complexity (ASD, VSD and PDA) the proportion of 
cardiovascular deaths was 50.7% (260 of 513 deaths). For lesions of moderate 
and great complexity the proportion of cardiovascular deaths was 76.4% (282 of 
369 deaths).  
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2.4 Discussion 
This literature review utilised a systematic search of the OVID and Medline 
databases. The ideal patient cohort was to be a cross-sectional representation of 
the ACHD population. For that reason, only articles reporting survival for non-
selected patient cohorts were included. This effectively ruled out surgical 
cohorts unless a non-selected comparator or total cohort was also reported, this 
represents the bulk of the published literature within ACHD and is the primary 
reason that the total number of studies included was low at 22. Ideally an 
analysis using population-based studies only would be optimal, as regional 
cohorts are invariably of specialist centres and bias is towards more complex or 
severe lesions and phenotypes. Due to the lack of unselected population-based 
studies identified in the literature, this degree of selectivity would have 
prohibited meaningful review or analysis. 
Overlap of patient populations between articles was also common. In particular, 
the CONCOR Dutch national registry reported multiple studies with overlapping 
data periods. It is unclear to what extent data overlap exists in less obvious 
cases. The specialist nature of much of the management of ACHD means that 
patients may receive some interventions away from their follow up centre and 
could therefore be included in more than one study. For example; patients with 
systemic RV who are under follow up in Scotland but attend a centre in England 
for an intervention such as a catheter ablation for arrhythmia may well be 
included in more than one cohort. Overall, I felt that the influence of these 
undoubtedly small numbers of patients who are duplicated across data sets was 
less important than the exclusion of entire data sets on their behalf, particularly 
given the overall paucity of data. 
All of the included studies were derived from cohorts in developed countries 
with predominantly Caucasian populations. This review is not therefore 
representative of a worldwide ACHD population cohort. In particular, no data 
from Asian or African cohorts was suitable for inclusion. One Japanese study did 
report a reduced trend in mortality rate from the late-1970s to the mid-1990s 
but unfortunately this was only available as graphical trends for predetermined 
age strata and absolute figures for the total ACHD cohort could not be extracted 
(90).  A TOF cohort from Taiwan reported a 30 year post repair survival of 89.3% 
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however age at death and survival independent from surgery could not be 
calculated (91). 
When considering all CHD lesions combined, a large total patient cohort and 
combined patient follow up was achieved (95,886 patients and 1,143,117 years 
respectively). However, it is worth noting that 74.8% of all patients and 85.9% of 
the cumulative patient follow up was achieved by a single, large study (51). 
Overall, there was a slight predominance of women across the studies at 52.7% 
but this was highly variable depending on lesion, ranging from 73.0% for PDA to 
30.5% for TGA arterial switch (results reported from one article only). The pure 
shunt lesions (ASD, PDA, VSD and AVSD) as well as Ebstein’s anomaly were more 
common in women. Conotruncal lesions (TOF, TGA arterial switch and systemic 
RV) and aortic coarctation conversely were more common in men. The Fontan 
population was a near exact split with 49.9% being women. 
Survival and mortality were presented by various methods across the literature. 
Survival to predefined age points was reported by four studies (69,80,81,87) 
however the predefined age cut-offs varied between studies making comparison 
difficult. Surprisingly, a mid-point estimate of age at death was only available 
for 12 of the 22 included studies. Although a crude measure of survival, mean 
age at death is extremely informative, particularly when considering cross-
sectional cohorts and trends over time. Two studies present standardised 
mortality ratios as corrected for age and sex matched population cohorts 
(43,73). This method has the clinically orientated appeal of implying a lesion 
specific mortality burden for an individual patient in comparison to their 
unaffected peers. 
Measuring survival in terms of mortality rate in ACHD is significantly flawed as 
the point of entry to the data will alter the mortality rate equally as much as 
survival. It is therefore not possible to definitively compare survival between 
data sets based solely on crude mortality rates. Having said that, mortality rates 
do at least provide context to the number and frequency of deaths observed and 
help to describe the patient population. Given the variable age at inclusion to 
the data sets and different recruitment methods across studies, mortality rates 
as reported for all CHD lesions were surprisingly relatively uniform. The highest 
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reported mortality rate (9 deaths per 1000 person years) for all CHD was 
reported in a single centre Czech cohort (74) which was the smallest (646 
patients) and oldest patient cohort in this group with a baseline age of 35.0 
years. The observed mortality rates for the individual lesion groups were 
variable and did not simply correlate with lesion complexity. The highest 
combined mortality rate was for the systemic RV group (18.3 per 1000 person 
years). This is higher than that observed for the Fontan group (8.5 per 1000 
person years) which was actually more comparable to the ASD group (7.9 per 
1000 person years) in this respect. This may be partly explained by lesions such 
as ASD and the ccTGA subset of systemic RV patients often presenting to follow 
up later in life; either at onset of symptoms, or as an incidental finding. They 
would therefore have shorter follow up periods prior to death when compared 
with patients who require Fontan palliation and invariably present in the 
neonatal period and are followed thereafter, amounting greater follow up but 
potentially dying younger. This is supported by the age at death data. Figure 2-3 
illustrates this and more predictably the Fontan group die at a younger age than 
any other at any given data period. The remaining lesions also follow a clinically 
logical pattern with ASD and PDA living to the oldest age, with AVSD and 
Ebstein’s next to Fontan demonstrating the youngest age at death. Observed age 
at death increased as the median year of study progressed for all but two lesions 
(AVSD and Ebstein’s) for which the results are based on sparse data (a total of 27 
and 22 deaths respectively) and so should be interpreted with caution. 
Comparison of age at death according to period of study was not attempted for 
articles reporting all CHD as the study populations were suitably heterogenous to 
render this meaningless. In particular the proportional breakdown of each lesion 
within the cohort would need to be comparable for any conclusions to be drawn. 
The only reasonable comparison of all CHD age at death according to data period 
is provided from two study periods within the same article by Khairy et al (92), 
and suggests an increase from 60 to 75 years between 1990 and 2000 (Table 2-2). 
Throughout the included studies there was little attempt to delineate mortality 
data according to patient characteristics and demographics. Sex differences in 
mortality and circumstances of death were surprisingly sparsely reported. 
Although sex was often included in univariate and multivariate models, absolute 
figures for age at death, mortality rate etc were almost never provided. 
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Therefore, the frequently encountered increased hazard ratio associated with 
male sex is of little practical use as this is also the case in the general 
population and cannot be further interpreted. One study did report age at death 
according to sex amongst ASD patients, finding a significantly higher age at 
death for women (75.8 IQR 65.7-81.5) vrs 69.5 IQR 59.8-77.3) (77). Oliver et al 
(73) looked at sex differences in more detail and although mortality rates and 
age at death were not presented, hazard ratios adjusted by a population cohort 
show the usual female survival benefit to be lost in ACHD (41). This study also 
suggests a slight female preponderance towards CV death (61%) when compared 
to men (56%). This uncommon example of sex stratified mortality data is taken 
from a single centre cohort. 
One Dutch registry reported by Zomer et al (89) reported geographical and 
seasonal variations in mortality (with some increased mortality in rural 
postcodes and little difference with seasonality). No study however reported 
socioeconomic influences on mortality or circumstances of death. Overall the 
reported influence of patient characteristics on mortality was piecemeal and 
lack of standard reporting methodology prevented any real compilation or 
comparison of findings.  
Establishing cause of death as cardiovascular or non-cardiovascular was reliant 
on reporting within the source material. All but one article contributing to the 
cause of death results either defined CV death or reported specific causes of 
death, allowing extrapolation as either CV or non-CV. Cause of death was 
broadly established by one of two methods throughout the studies; 
• Objectively – regional or national databases were interrogated, and predefined cause of 
death data extracted, usually as coded by the ICD system 
• Subjectively – by case-note interrogation or in one case by contacting next of kin. Author 
adjudication of cause of death then prevails 
 
The objective method, such as that used by Nyboe et al (78) has the benefits of 
limiting observer bias, and when the ICD system is used, standardising diagnoses 
by a universally accepted definition. The subjective method such as was used by 
Diller et al (43) has the benefit of ensuring internal validity, where the objective 
method is validated only according to the local or national requirements which 
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may be highly variable in their efficacy. It is likely that regional variations in the 
practice of diagnosing causes of death exist. For instance; in the UK, stating an 
organ failure as the primary cause of death is discouraged unless a clear 
underlying cause for said organ failure is stipulated. Despite this Diller et al (43) 
reported heart failure as the leading cause of death in their patient cohort. a 
result which would likely be significantly different had the objective method 
utilising ICD coding been used. 
An overall predominance of CV death was seen across all studies, but this varied 
according to the CHD lesion and according to lesion complexity. ASD was the 
only lesion to show a slight predominance towards non-CV death at 50.2%. At the 
other end of the complexity spectrum the Fontan and systemic RV groups had a 
strong predilection for CV death at 80.2% and 93.9% respectively. 
No study compared causes of death according to study period. Establishing 
temporal trends in causes of death by combining data from the included studies 
was not possible for several reasons, most of which have already been alluded 
to: study heterogeneity with regards to the breakdown of lesions; discrepancies 
in the way cause of death was established and the necessary biases imposed by 
each; and the regional variations which govern acceptable practice in diagnosing 
cause of death.   
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2.5 Conclusions 
Population based studies of outcomes in unselected ACHD cohorts remain sparse 
amongst the literature. The available data is limited to European, North 
American and Australasian populations. 
A lack of standardisation in reporting of survival and mortality data makes 
analysis difficult, but an estimate of age at death should be considered as a 
minimum measure. Age and sex standardised mortality rates are an informative 
means of reporting in ACHD. 
Age at death appears to be increasing in more contemporary data periods 
however lesion specific data at given time points are of low volume and so this is 
not fully robust. 
Cardiovascular death predominates over non-cardiovascular death. The 
proportion of CV death is greater for lesions of moderate and great complexity, 
as compared with simple complexity. Temporal changes in cause of death have 
not been established. 
Mortality data stratified by patient characteristics such as sex and 
socioeconomic influencers are few and have never been explored on a 
population level. 
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3 Aims and Objectives 
3.1 Aims 
Following a review of the available literature, the following thesis aim was 
devised 
• To describe the mortality and circumstances of death amongst adults with 
congenital heart disease throughout Scotland and explore how this has 
changed over time. 
From this aim, the following objectives were derived 
3.2 Objectives 
• To establish the utility of the Scottish Morbidity Record in the study of 
congenital heart disease in Scotland. 
• To describe the baseline characteristics including comorbidity of adults 
with CHD. 
• To establish univariate and adjusted survival according to the underlying 
congenital lesion and how this has changed over time. 
• To outline the causes of death for adults with congenital heart disease, 
how these have changed over time and how this compares with the 
general population. 
• To establish the influence of patient characteristics (sex and 
socioeconomic deprivation) on cardiovascular and non-cardiovascular 
mortality amongst adults with congenital heart disease. 
• To examine causes of death according to patient characteristics (sex and 
socioeconomic status) and if this has changed over time. 
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4 Methods 
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4.1 Preamble 
This Chapter describes the common methodology encountered throughout my 
thesis. Where more specific techniques or divergencies from this methodology 
exist, they will be clarified within the respective results Chapter.  
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4.2 Introduction 
4.2.1 Congenital Heart Disease in Scotland 
As of August 2016 the population of Scotland was estimated at 5.4 million (93). 
NHS Scotland consists of 14 health boards (Table 4-1) which subtend 
geographical regions. Additionally, there are a number of Special Health Boards 
which are responsible for educational and health improvement mandates as well 
as certain acute and elective services. As of 2002 the National Waiting Times 
Centre, operating out of the Golden Jubilee National Hospital (GJNH) in 
Clydebank, west of Glasgow was established, providing both regional and 
national services.  
Table 4-1 - Scottish health boards and the geographical area covered 
 
 
In 2007 the Scottish Adult Congenital Cardiac Service (SACCS) was instated as a 
branch of the National Services Division (NSD) of NHS Scotland. It was centralised 
in the GJNH and became the national centre for ACHD. By 2010 it was fully 
established as the single advanced centre for adult congenital cardiology in 
Scotland. This remains the case today; employing what is commonly considered 
to be the gold standard structure of a ‘hub and spoke’ health care system for 
adults with congenital heart disease.  
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As the only tertiary centre for ACHD in Scotland, the GJNH alone houses the full 
complement of facilities and expertise for the advanced investigation and 
management of all facets of ACHD care. A single exception is cardiac transplant 
for ACHD patients which is currently referred to the Freeman Hospital in 
Newcastle with which SACCS collaborate on a case-by-case basis.  
As such the GJNH acts as the ‘hub’ with local and regional ACHD services, 
provided within the geographical health board of each respective patient acting 
as the ‘spoke’. The division of care between local and regional teams and the 
tertiary centre at the GJNH is broadly dependent upon the complexity of the 
underlying congenital lesion and ongoing needs of the patient.       
Patients with lesions of least complexity such as small ASDs or PDAs will likely 
receive the majority of their review and investigation by local and regional 
services. Utilisation of the national centre will predominantly be for structural 
intervention; be it surgical or transcatheter, and any advanced investigations 
required in the decision-making process, such as cardiac magnetic resonance 
imaging (cMRI) and cardiopulmonary exercise testing (CPET). 
Patients with lesions of moderate complexity will often have shared care 
between regional centres and the national service, with routine follow up and 
monitoring being co-ordinated locally but advanced non-invasive and invasive 
monitoring as well as all cardiac intervention being centralised at the GJNH. 
Where individuals have ACHD lesions of great complexity, the majority of care 
will be undertaken in the national centre. These patients require relatively 
frequent advanced investigation with modalities such as cMRI, CPET, cardiac 
catheterisation and advanced echocardiography techniques. All cardiac 
intervention and even some non-cardiac intervention will be undertaken at the 
GJNH.    
4.2.2 The Scottish Morbidity Database 
The Information Services Division (ISD) acts on behalf of NHS National Services 
Scotland as collator and custodian of wide ranging health and administrative 
data. As part of the Scottish Informatics Programme, ISD delivers eDRIS 
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(Electronic Data, Research and Innovation Services) which acts as point of 
contact and data administrator for researchers to access anonymised population 
health records via the Scottish Morbidity Database. Health data in Scotland 
enters the Scottish Morbidity Database via one of the Scottish Morbidity Records 
(Table 4-2). The record used is generally determined by the type of care 
provided. Some SMRs have been discontinued since its inception in the 1970s but 
the current Scottish Morbidity Database contains four data sets as shown in 
Table 4-2.  
Table 4-2 - The Scottish Morbidity Database  
 
 
Each SMR episode allows a principle diagnosis, up to 5 secondary diagnoses and 
four operative procedures to be coded. Coding is done via the WHO ICD and 
OPCS systems.  
Alongside the SMRs, the Scottish Morbidity Database contains the NRS Death 
Records. National Records of Scotland (formerly the General Register Office for 
Scotland) is responsible for recording the cause of death for all residents of 
Scotland. Cause of death information is recorded using ICD coding which is 
derived from information provided on the Medical Certificate of Cause of Death 
(MCCD). This allows a primary cause of death (event directly leading to death), 3 
antecedent causes, and multiple contributary but non antecedent causes to be 
compiled and coded. SMR and death records can then be linked and studied. 
Data linkage predominantly relies on the Community Health Index (CHI) number 
but when this is not possible an algorithm-driven system allows for record 
matching based on probabilities using patient identifiable information such as 
surname, date of birth and postcode.   
As part of information governance, ISD periodically carries out a national 
assessment of SMR01 records to uphold standards and consistency. This is carried 
Dataset Year of inception Description 
SMR01 1981 Episode data on hospital 
admissions 
SMR04 1981 Episode data on psychiatric 
admissions 
SMR06 1980 Cancer registrations 
National Record of Scotland - Deaths 1980 Record of deaths 
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out by the Data Quality Assurance (DQA) team and was last published in 2015 
(94). The accuracy of main diagnosis and main operation coding, as well as non-
clinical data collection, is assessed across representative centres from all 
Scottish health boards, including the Golden Jubilee National Hospital. In 2015, 
accuracy to 3 digits for main diagnosis coding was 89% and main operation was 
94%. This study was in line with previous national assessments. The GJNH, 
through which a disproportionately high proportion of ACHD episodes occur 
performed above the Scottish average achieving a diagnostic coding accuracy of 
96% and procedural accuracy of 97%.  
Previously published epidemiology data has relied on diagnostic and procedural 
coding information supplied via privatised health insurance providers (92). It has 
been suggested that financial incentives lead to more complete coding. Internal 
validation of ISD data would suggest favourable accuracy despite remuneration 
incentives being less clear cut. As the NHS provides a free at point of care 
service, our data set has the additional benefit of lacking the financial 
disincentive biases affecting access to care in privatised and semi-privatised 
healthcare systems.  
4.2.3 Scottish Morbidity Record (SMR) 01 
Also known as ‘the General / Acute and In patient Day Case data set’, SMR01 
contains data generated following discharge from any acute in patient or day 
case episode throughout all relevant facilities in Scotland. Practically speaking 
an individual patient episode is not synonymous with what most clinicians would 
refer to as an ‘admission’ which in reality will likely contain multiple episodes 
and so multiple SMR01 records. To avoid confusion an admission is better 
thought of by the term ‘continuous in patient stay’ (CIS). For example; a patient 
admitted to an acute medical ward with pneumonia (episode 1) then transferred 
to a respiratory medicine ward (episode 2) before being discharged home will 
generate 2 separate episodes and so 2 SMR01 records. Each will likely contain 
distinct health data corresponding to diagnoses and procedures coded at point of 
discharge from each episode. Together they amount to a single CIS. Although 
separate records, these can be readily linked (via the CHI number) and identified 
as a single CIS.  Linkage can also be accomplished longitudinally throughout all 
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previous or subsequent episodes and CISs for an individual as well as to records 
within the other data sets compiling the Scottish Morbidity Database (Table 4-2)  
4.2.4 Utility of the Scottish Morbidity Record and data linkage 
The systematic coding and record linkage of all in-patient records in Scotland 
provides a unique substrate for studying patterns in health care and outcomes at 
a population level. World-wide, few if any similar systems exist. Most large 
datasets are registry based or confined to health regions within a country.  
SMR data has been used to study large scale populations in the field of diabetes 
(95), cardiology (96) and psychiatry (97) amongst others. Lewsey et al. (98) 
established a falling rate of recurrent stroke hospitalisation trends among 
128,511 individuals using SMR01 records between 1986 and 2001. Short term 
mortality following incident heart failure admission has recently been described 
in the adult Scottish population (99). Over 115,000 SMR01 records were 
recovered and data linkage cross referenced to death records identified 16,406 
(14.2%) deaths within 30 days.      
One strength of this methodology is that it generates large study population 
numbers even when the discriminator in question is rare. For example SMR data 
has been used to define prognosis in patients with idiopathic pulmonary arterial 
hypertension (100) by reporting outcomes for 374 patients. This is more than 
threefold what is described in similar longitudinal studies utilising other methods 
of recruitment (101). 
There are two predominant limitations to SMR data linkage in the study of 
clinical outcomes; firstly, it cannot be used for individualised clinical 
information such as test results, symptomatology or performance status. As such 
data derived from SMRs must be interpreted with this knowledge in mind. 
Secondly, persons cared for entirely in the out-patient sector will not produce an 
SMR01 record and may be ‘hidden’ from study populations. Consequently, the 
data obtained may not represent the entire population of interest and/or may 
be biased towards more severe phenotypes.  
78 
 
With the advantages and limitations of the utility of SMR in mind, in its current 
form SMR and data linkage should be best suited to studying patient populations 
well defined by diagnostic coding and well defined outcomes, such as death.  
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4.3 Data request and extraction 
4.3.1 Privacy panel application 
Prior to submitting a data extraction request to eDRIS, approval from the Public 
Benefit and Privacy Panel (PBPP) for Health and Social Care was necessarily 
sought. The information governance standards as presented within the Scottish 
Government guidance requires an application to the PBPP when data pertaining 
to individuals for use other than direct clinical concern is required. Additionally, 
access to any of the NHS Scotland databases requires approval. The SMR is an 
example of such a database. 
PBPP approval was sought and subsequently granted for the attainment of 
nonidentifiable information from all Scottish health boards and pertaining to 
multiple NHS Scotland patient databases. The stated purpose of my data request 
was for research and service planning and improvement. 
An application amendment was required to achieve approval based on 
satisfactory anonymisation of individual data. That date specific data (death 
date, admission date and discharge date) be amended to simply month and year 
was considered appropriate, particularly in the event where administrative 
health data related to an individual may be uncommon (such as with certain ICD 
codes encountered in our data proposal) and as such rendered identifiable when 
encountered in combination with an exact date. Date of birth was refused, 
instead providing the individual’s age at each given episode for the same reasons 
of anonymisation. 
A second application for amendment was later sought and approved to extend 
the data period for identification of death records from December 2015 until 
September 2017. 
4.3.2 ICD inclusion 
The identification of health records for inclusion into our dataset was guided by 
the recognition of diagnostic (ICD) or procedural (OPCS) codes specific to 
congenital heart disease. ICD coding has been described in section 1.3.1. Table 
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4-3 summarizes the ICD codes used to identify suitable health records for 
inclusion into the dataset.  
For the purposes of clinical coding it would be considered appropriate that 
previously ‘repaired’ congenital defects are no longer coded as an active 
diagnosis. For example; should a 16-year-old patient presenting with chest pain 
and with a history of an ASD, surgically repaired at age two be admitted to 
hospital. They might be coded as R07.4 (chest pain, otherwise unspecified) in 
the primary diagnostic position and either Q21.1 (atrial septal defect) or Z87.74 
(personal history of congenital or chromosomal malformation) depending on the 
semantics of the clinical documentation.  
A CIS consists of one or more patient episodes. Additional episodes are added to 
a CIS record at the point of transfer to a new ward, consultant or in patient 
facility. Coding takes place at each transfer between episodes and at the point 
of discharge from the CIS. Coding in up to six diagnostic positions is allowed at 
each change of episode. We identified patients based on an inclusion ICD code as 
outlined in Table 4-3 as present in any diagnostic position. Once patient 
identification was achieved, record identification by record linkage (as described 
in the previous Chapter) allowed all corresponding CIS records within the data 
period to be pulled for analysis, irrespective of whether a CHD code was 
represented during these other episodes. 
Table 4-3: ICD codes used to determine inclusion suitability 
 
4.3.3 OPCS inclusion 
Prior studies concerning the epidemiology of CHD have relied solely on ICD 
coding for patient identification (72,102). Section 3.2.2 refers to an example 
where patient identification by ICD coding alone may be vulnerable. Many 
individuals who have a ‘repaired’ CHD lesion are at ongoing risk of future 
sequelae and the tendency to repeated or further interventions later in life 
Inclusion diagnosis
ICD 9 code (up to 
31st March 1996)
ICD 10 code (from 
1st April 1996)
ACHD 745 - 747 Q20 - Q28
History of corrected 
ACHD V13.65 Z87.74
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provides an opportunity to use procedural coding to improve the sensitivity of 
patient identification. 
Table 4-4 summarizes the OPCS codes used for patient identification for 
inclusion into the data set. The process for coding procedures is similar to that 
described for diagnoses (section 3.2.2). Up to four procedures can be coded at 
each change of episode and again we identified those with an inclusion code in 
any one of those positions, pulling the entire CIS record and all linked CIS 
records for that individual within the total data period. 
OPCS 4 has been updated six times since its inception in 1989. Most iterations 
have undergone relatively minor change but from OPCS 4.2 (1989-2006) to OPCS 
4.3 (2006-2007) significant differences in the manner of procedural coding were 
instigated. For instance, reliable coding for transluminal procedures of the heart 
cannot be specifically coded by OPCS 4.2 and earlier. 
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Table 4-4: Description of OPCS codes used for patient identification.  
 
 
4.3.4 Deprivation 
Two postcode-derived methods for determining socioeconomic status in Scotland 
have been established. The Carstairs-Morris index (103), originally developed 
Tetralogy of Fallot 3101, 323.1 K04
Interatrial transposition of great arteries (TGA) 3153, 323 K05
Other TGAs (switch) 323, 3249, 3269, 3299 K06
Repair of total anomalous pulmonary venous 
drainage
3248, 3249, 315, 3222 K07
Repair of partial anomalous pulmonary venous 
drainage
NA K20.2
Repair of double outlet ventricle 3177, 3178, 3179
K08, (K19.8 + Z94.2), (K19.8 
+ Z94.3)
Device ASD closure NA
K13.3, K13.4, (K10.1+Y53.1), 
(K10.4+Y53.1) 
Device closure VSD NA
K13.1, K13.2, (K11.1+Y53.1), 
(K11.4+Y53.1)
Repair of septum 
3152, 3153, 3154, 3157, 
3158, 3159, 3061
K11-16
Repair of univentricular heart 3241, 323 K17
Truncus arteriosus 3222, 326 L01.1
Creation of conduit 3238, 3239 K18,K19
Surgical Patent Ductus closure 3221 L02
Device closure of patent duct NA L03
Fontan-type procedures 323, 3241
K19.2, K19.4, L09, K17.1, 
K17.2, K17.3, K17.7
HLH repair/Norwood type NA K17.4, K17.5, K23.8
Pulmonary valve procedure 3114, 3124, 3134, 3144 K28
Transcatheter Pulmonary Valve Replacement NA K35.7, (K35.8+Z32.4)
Truncal Valve Surgery NA K29.6, K29.7,
Closed shunts 323, 3268, 3231 L05, L06, L07, L08
Pulmonary artery banding 3222, 3201, 3298, 3299 L12.1, L12.2, L12.3
Transluminal pulmonary artery procedures NA L13
Surgical coarctation procedures 3251, 3252 L23.1, L23.2, L23.3, L26
Transluminal aortic stent NA L26.5
Intervention on major systemic to pulmonary 
collateral arteries
NA L69, L70.8
Pulmonary Vein Surgery NA L80
3152, 3153, 3154, 3157, 3159
Surgical closure of secundum and sinus 
venosus atrial septal defects
Operation
Repair of complete atrioventricular septal 
defect
K09, excluding K09.4
K10, K20, K09.4
Surgical closure of ventricular septal defects K11
OPCS3 code (up to 
31st Dec 1988)
OPCS4 code (from 1st 
Jan 1989)
3152, 3153, 3154, 3157, 
3159, 3158
3152, 3153, 3154, 3157, 
3158, 3159
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using 1981 census data and compiled as a composite marker of four indicators 
(Table 4-5) has since been superseded by the SIMD as the primary tool for 
determining relative deprivation and social inequality throughout Scotland (104).  
Table 4-5: Determinants of Carstairs-Morris Index 
 
The SIMD was updated on four occasions from the start of the data period until 
the initial data request (2004, 2006, 2009 and 2012) with one subsequent update 
during the analysis period in 2016. Similar to the Carstairs-Morris index, SIMD is a 
composite statistic derived of indicators. A total of 38 indicators are grouped in 
to 7 ‘domains’ which combine to a single SIMD score (Table 4-6). SIMD scores are 
applied to small postcode areas known as data zones. Scores are ranked from 1 
(most deprived) to 6,976 (least deprived). Given a Scottish population of 5.4 
million, this corresponds to roughly 770 people per data zone. It should be 
stressed that this is a ranking score and so relative and not absolute deprivation 
is implied. Hence it cannot be supposed how much more deprived one area is 
compared to another.  
Variable Description
Over crowding Proportion of those in private households 
living at a density of more than one per room
Male unemployment Proportion of male adults seeking work
Proportion in social class 4 or 5 Proportion of those living in private 
households where the highest level of 
employment is partially skilled or unskilled
Car ownership Proportion of all persons in private housholds 
with no car
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Table 4-6: Domains and weighting contribution to the Scottish Index of Multiple Deprivation 
 
SIMD has been widely used in the study of many conditions and is generally 
considered to be reliable (105–109), winning the Royal Statistical Society’s 
Excellence in Official Statistics Award in 2017 (110). 
For the purpose of analysis within this document, and in a similar way to 
previous published biomedical literature (106,109), SIMD has been divided into 
quintiles; 5 groups of 1,395 data zones each, ranked from 1 (most deprived) to 5 
(least deprived). The data zones are as applied according to the most recent 
incarnation (2012) of SIMD. In cases where outcomes according to deprivation 
were compared according to specific congenital lesions, comparison by SIMD 
quintile was felt inappropriate due to low numbers in each quintile group when 
uncommon conditions were concerned. This may jeopardise anonymity. In such 
cases SIMD was dichotomised into two groups of equal numbers of data zones 
corresponding to ‘higher deprivation’ and ‘lower deprivation’. 
4.3.5 Comorbidity 
Diagnostic information was collated for 7 key comorbidities (diabetes, cancer, 
atrial fibrillation, systemic hypertension, cerebrovascular disease, acute 
myocardial infarction and other ischaemic heart disease). These co-morbidities 
Domain Description Weight
Employment
Propotion of those who are employment deprived and receive certain benefits 
and tax credits
12 (28%)
Income Proportion of people who are income deprived and receive certain benefits 12 (28%)
Comparative illness factor (combined count of Disabled Living Allowance, 
Attendance Allowance, Incapacity Benefit and Severe Disablement Allowance)
Hospital stays related to drug or alcohol misuse
Emergency stays in hospital
Proportion of population prescribed medication for anxiety, depression and 
Proportion of low birthweight births
Standardised mortality ratio
Crime
Crimes of violoence, sexual offences, housebreaking, vandalism, drug offences 
and assault per 10,000 population
2 (5%)
Percentage living in overcrouded housing
Percentage living in houses with no central heating
School pupil attendance
Attainment of school leavers
Working age people with no qualificationsPr portion of persons aged 16-19 not in full time education, employment or 
training
Proportion of 17-21 year olds entering into higher education
Average drive time to a petrol station, GP surgery, post office, a school and a 
retail centre
Public transport time to a GP surgery, a post office and a retail centre 
Health
Access
Education
Housing
6 (14%)
1 (2%)
6 (14%)
4 (9%)
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were chosen to reflect known influencers of cardiovascular mortality (diabetes, 
cancer, AF, ischaemic heart disease and hypertension) with malignancy included 
as the recognised major cause of non-cardiovascular mortality in the general 
population of Scotland (111). Although tobacco smoking and obesity are 
established risk factors for cardiovascular disease and mortality, these were not 
included as prior studies have established significant inaccuracies with their 
coding, particularly as a result of under-reporting and recording in the clinical 
notes (112–114). This may well reflect attitudes and clinician training where 
these variables may be thought of as a social characteristic as opposed to a co-
morbidity per-se.  
Individuals were recognised as having a comorbidity if the corresponding ICD 9 or 
ICD 10 code(s) was identified in any one of the six coding positions on either the 
index inclusion episode or in any episode within the 5 years prior to the index 
episode. The ICD codes used to identify comorbidities are shown in Table 4-7.  
Table 4-7: Comorbidity and corresponding ICD identification code 
 
Comorbidity classification is broadly inclusive of disease subtypes. We did not 
discriminate between Type 1 and type 2 diabetes mellitus, not least as these are 
indistinguishable by ICD 9 coding (up to 31st March 1996). Equally, malnutrition 
and pancreatitis related diabetes are included. Gestational diabetes is the 
notable exception as this is coded via a different section of ICD. The codes 
pertaining to atrial fibrillation (I48 and 427.3) are inclusive of atrial flutter (both 
‘typical’ and ‘atypical’) but do not include supraventricular tachycardias or focal 
atrial tachycardia. 
Cancer coding is inclusive of all malignant neoplasms of solid organ, 
haematopoietic and lymphoid tissue. Benign neoplasms and carcinoma in situ are 
not included. Neuroendocrine tumours are not specifically included as these are 
Comorbidity ICD 9 code ICD 10 code
Diabetes 250 E10-E14
Cancer 140-208 C00-C99
Cerebrovascular disease 430-438 I60-I69, G45
Atrial fibrillation 427.3 I48
Hypertension 401 I10-I13
Acute myocardial infarction 410 I21, I22
Other ischaemic heart disease 411-414 I20, I23-I25
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not differentiated by the ICD 10 coding system but may be included if they have 
been coded as a solid malignant tumour in an identified organ. A specific ICD 9 
code is provided for neuroendocrine tumours but was not included due to its 
unavailability through ICD 10. It is possible that a small number of 
neuroendocrine/carcinoid patients may have been labelled with a cancer 
comorbidity after April 1st 1996 where they would have been omitted prior to 
this.  
Cerebrovascular disease refers to ischaemic or atraumatic haemorrhagic strokes 
as well as transient ischaemic attacks. Spontaneous subdural haemorrhage is 
included. Strokes occurring during pregnancy and the puerperium were not 
included.  
Acute myocardial infarction is inclusive of ST segment elevation (STEMI) and 
non-ST segment elevation (NSTEMI) myocardial infarction. These are not 
differentiated by ICD 9 and have therefore been considered in combination 
throughout this document. The subcategorization of myocardial infarction into 
types I – VI as stated in the Fourth universal definition (115) and accepted in 
common practice are not differentiated by ICD coding.  
4.3.6 Mortality data 
As discussed previously, data linkage allows data extraction to include 
information from the NRS database of births, marriages and deaths. Death 
certification is a legal process which starts with the issuing of the MCCD. This is 
usually completed by a member of the attending medical team when the death 
occurs in hospital or by the usual medical practitioner (general practitioner) 
when the death occurs in the community. If a death is sudden or unexplained 
the Procurator Fiscal (PF) will be involved in decision making and a postmortem 
examination may be required, at which point the responsibility for issuing the 
MCCD will fall to the PF. The MCCD is then presented by a representative 
(usually family of the deceased) to the local council registrar who then registers 
the death and issues a Certificate of Registration of Death. Under normal 
circumstances it is a legal requirement that the death should be registered 
within 8 days of the date of death. This may need to be extended if further 
examinations are planned. Since 2015 the Death Certification Review service has 
87 
 
been in place in Scotland.  This is to uphold standards of MCCD accuracy. As a 
result, around one in eight MCCDs are randomly selected for review. A team of 
medical reviewers then either; approve the MCCD, amend the MCCD, or order a 
fully revised MCCD.  
We used data linkage to the ICD/OPCS identified population (sections 4.3.2 and 
4.3.3) to ascertain all individuals who had died up until the point of a data 
extraction amendment (30th September 2017). For all such individuals, additional 
data obtained included; month and year of death, age at death, whether or not 
a post mortem examination was performed, the time from in patient episode 
until the date of death in days, and the causes of death (coded as per ICD 9 and 
10). 
Additionally, the NRS database of births, marriages and deaths was separately 
searched to identify any individual who had not been identified to have had a 
CIS episode but had died and had an ICD code corresponding to congenital heart 
disease (Table 4-3) listed as the primary or any secondary cause of death.  
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4.4 Lesion classification 
The considerable heterogeneity of congenital heart disease has been discussed. 
Even within most congenital diagnoses, considerable variability exists. There is 
additionally some discourse between the range and separation of congenital 
heart disease as it exists in clinical practice and as it is segregated by clinical 
coding. This document is intended to inform and reflect clinical practice and as 
such lesions have been separated to reflect this. Previous unselected, 
epidemiology studies which utilise ICD coding rather that hospital databases 
have been limited in classifying diagnoses as procedural information has been 
lacking (116,117). Only by combining ICD coding and procedural information 
(OPCS coding) can individuals be identified as Fontan patients or having TGA 
with arterial or atrial switch.  
Overall, the lesion groups used within this document are similar to those 
reflected in prior literature (9,33,41,63,118–121). In total 13 major groups were 
segregated (ASD, PDA, VSD, aortic lesions, Ebstein’s anomaly, AVSD, TOF, TGA 
with arterial switch, systemic RV, Fontan, complex lesions, valvular lesions, and 
other lesions).  
4.4.1 ASD 
The ICD and OPCS codes used to identify ASDs are summarised in Table 4-8. The 
ICD 9 code 745.5 and ICD 10 code Q21.1 refer to all defects of the interatrial 
septum other than ostium primum defects and are inclusive of; secundum 
defects, coronary sinus defects, sinus venosus defects and persistence of the 
foramen ovale. The ICD 9 code 747.42 and ICD 10 code Q26.3 refer to a partial 
anomalous pulmonary venous drainage (PAPVD). The decision to include these in 
the ASD cohort relates to the tendency of PAPVD to exist alongside a defect of 
the atrial septum and share the physiological principles of left to right shunting 
at atrial level (see Table 1-3). The OPCS code K10 refers to any surgical repair of 
the interatrial septum and K20.1 to repair of a persistent sinus venosus. 
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Table 4-8: Codes used to categorise ASD 
 
4.4.2 PDA 
The codes used to categorise PDA are summarized in Table 4-9. The code L03.2 
referring to percutaneous stenting of a PDA was only available from OPCS 4.3 
onwards and would therefore not be identified prior to 2006. 
Table 4-9: Codes used to identify PDA 
 
4.4.3 VSD 
Ventricular septal defects can be either congenital or acquired. These are dealt 
with by separate sections of the ICD coding system. Acquired VSDs would 
correctly be identified with the ICD 9 code 429.71 and ICD 10 codes I23.2 or 
I51.0 and were not included. The codes we used to categorise congenital 
ventricular septal defects are summarized in Table 4-10. Note the Gerbode 
defect (left ventricle to right atrial defect) is specifically included in the ICD 9 
system but not ICD 10. 
Table 4-10: Codes used to identify VSD 
 
Code Description
745.5 Defect of interatrial septum 
747.42 Partial anomalous pulmonary venous connection
Q21.1 Defect of interatrial septum 
Q26.3 Partial anomalous pulmonary venous connection
K10 Surgical repair of interatrial septum
K20.1 Surgical repair of persistent sinus venosus
ICD 9
ICD 10
OPCS
Code Description
ICD 9 747.0 Patent ductus arteriosus
ICD 10 Q25.0 Patent ductus arteriosus
L02 Surgical closure of patent ductus arteriosus
L03.1 Percutaneous occlusion of patent ductus
L03.2 Percutaneous stent of patent ductus
OPCS
Code Description
ICD 9 745.4 Ventricular septal defect including Gerbode defect
ICD 10 Q21.0 Ventricular septal defect  
OPCS K11 Surgical and percutaneous repair of interventricular septum
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4.4.4 Aortic lesions 
Although the most common congenital lesion of the aorta is a thoracic 
coarctation, a broad range of anomalies may be encountered. The codes used to 
identify aortic lesions are summarised in Table 4-11. There is no obvious 
clarification between aortic coarctation and aortic stenosis, with the latter 
sharing an ICD code with other lesions such as a vascular ring (Kommerell’s 
diverticulum) and sinus of Valsalva aneurysms, as such these are necessarily 
included together. 
Table 4-11: Codes used to identify aortic lesions 
 
 
4.4.5 Ebstein’s anomaly 
Ebstein’s anomaly is one of the few congenital lesions to have a single, well 
defined ICD definition and code. No OPCS code is sufficiently specific to a repair 
of Ebstein’s anomaly to aid inclusion. Table 4-12 summarised the ICD codes 
used. 
Table 4-12: Codes used to identify Ebstein's anomaly 
 
4.4.6 Atrioventricular septal defect 
ICD coding does not discriminate between ostium primum ASDs alone and those 
with a ventricular component (complete AVSD). AVSD and ostium primum ASD 
Code Description
747.1 Coarctation of aorta including interrupted arch
747.2
Other anomalies of aorta including stenosis, atresia, Kommerell's 
diverticulum and sinus of Valsalva aneurysms
Q25.1 Coarctation of aorta  
Q25.2 Atresia of aorta
Q25.3 Stenosis of aorta
Q25.4
Other anomalies of aorta including stenosis, atresia, vascular ring 
and sinus of Valsalva aneurysms
L23.1 Repair and end to end anstamosis of aorta
L23.2 Repair of aorta using subclavian flap
ICD 9
ICD 10
OPCS
Code Description
ICD 9 746.2 Ebstein's anomaly
ICD 10 Q22.5 Ebstein's anomaly
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share features which complicate these lesions above other types of ASDs 
(atrioventricular valve abnormalities and atrioventricular conduction 
abnormalities for example). As such their inclusion in a single group is 
unavoidable, reasonable and conventional to the literature (9). The OPCS code 
K09 encompasses all repairs involving the atrioventricular septum and should 
therefore be specific to true AVSD. Table 4-13 summarised the codes used to 
classify patients with AVSD. 
Table 4-13: Codes used to identify atrioventricular septal defect 
 
4.4.7 Tetralogy of Fallot 
As with many congenital heart defects, tetralogy of Fallot represents a spectrum 
of disease. The degree of right ventricular outflow tract obstruction varies from 
minimal infundibular stenosis to complete pulmonary atresia. Likewise, the 
degree of aortic override may be minimal or even constitute a double outlet 
right ventricle. The codes used to categorise tetralogy of Fallot have been 
chosen to represent this spectrum of disease. Unfortunately, the ICD codes for 
double outlet right ventricle do not discern between Fallot type DORV and that 
more closely related to complete transposition of the great vessels and has 
therefore not been included here. OPCS coding does make this distinction and 
has been included here (Table 4-14). 
Table 4-14: Codes used to identify tetralogy of Fallot 
 
4.4.8 Transposition of the great arteries with arterial switch 
The physiology and long-term prospects of individuals born with transposition of 
the great arteries is significantly dependent upon the manner in which it is 
Code Description
ICD 9 745.6
Endocardial cushion defect including ostium primum ASD, absent 
atrial septum and atrioventricular canal
ICD 10 Q21.2 Atrioventricularseptal defect including ostium primum defect
OPCS K09 Repair of the atrioventricular septum including ostium primum repair
Code Description
ICD 9 745.2 Tetralogy of Fallot including with pulmonary atresia
ICD 10 Q21.3 Tetralogy of Fallot including with pulmonary atresia
K04
Repair of Tetralogy of Fallot with or without 
transanular patch and with or without conduit
K08.2 Repair of Fallot type double outlet right ventricle
OPCS
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surgically repaired. Those who undergo atrial inversion (Mustard or Senning 
operations) will be rendered with a systemic right ventricle and will be 
considered in the subsequent section. Those who undergo either arterial switch 
(Jatene procedure) or interventricular tunnel with RV to PA conduit (Rastelli) 
operations will restore physiological and anatomic function of a systemic LV and 
have been included together in this section. Clearly the dependence of a surgical 
procedure on establishing an effective diagnosis poses a problem when using ICD 
coding as surgical procedures are not considered and only original anatomy is 
accounted for. For that reason, only those who have both the ICD pertaining to 
TGA and an OPCS code referencing repositioning of a great vessel or the use of 
an RV conduit have been included in this section (Table 4-15). 
Table 4-15: Codes used to identify transposition of the great arteries with arterial switch. 
Both an ICD code and an OPCS code must be identified to be included 
 
4.4.9 Systemic right ventricle 
There are two groups of individuals for whom a systemic right ventricle would be 
considered the primary lesion. Those with transposition of the great arteries 
following atrial inversion surgery, as outlined in the prior section (4.4.8) and 
those with unrepaired congenitally corrected transposition of the great arteries 
(ccTGA).  
 
Table 4-16 summarises the manner in which individuals were identified as having 
a systemic right ventricle. 
Code Description
ICD 9 745.1
Transposition of the great vessels including double outlet right 
ventricle with dextraposition of the aorta
ICD 10 Q20.3 Discordant ventriculoarterial connection
&
K06.1 Repositioning of transposed great arteries
K06.2
Left ventricle to aorta tunnel with right ventricle to pulmonary 
anastamosis
K06.3
Left ventricle to aorta tunnel with right ventricle to pulmonary 
valved conduit
OPCS
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Table 4-16: Codes used to identify systemic right ventricles.  If the ICD code refers to 
complete transposition of the great arteries then a relevant OPCS code must also be identified 
 
4.4.10 Fontan  
Although Fontan patients represent a well-defined cohort of CHD patients, they 
defy categorisation by ICD methodology. In a similar manner to those with TGA, 
OPCS coding is essential to allow further categorisation. As Fontan patients have 
a vast array of underlying lesions we must rely almost solely on OPCS coding. 
One exception is among individuals with hypoplastic left heart syndrome, for 
whom the clinical phenotype is suitably severe that we have considered any 
individual listed with this diagnosis who has survived to adulthood to have 
undergone Fontan surgery as this is the only reasonable hypothesis.  
Unfortunately, prior to OPCS 4, no code was suitably descriptive to confidently 
categorise Fontan surgery and so few will be identified prior to its inception 
(1989). Table 4-17 summarises the strategy for identifying Fontan lesions. 
Table 4-17: Codes used to categorise as Fontan 
 
Code Description
ICD 9 745.1 Transposition of the great arteries
ICD 10 Q20.3 Discordant ventriculoarterial connection
&
315.3 Operation on atrial septum of heart
K05
Reconstruction of atrium or atrial inversion for transposition of 
the great arteries
OR
ICD 9 745.12 Corrected transposition of the great arteries
ICD 10 Q20.5 Discordant atrioventricular connection (ventricular inversion)
OPCS
Code Description
ICD 9 746.7 Hypoplastic left heart syndrome
ICD 10 Q23.4 Hypoplastic left heart syndrome
K17.1
Total cavopulmonary connection with extracardiac 
connection
K17.2
Total cavopulmonary connection with lateral atrial 
tunnel
K17.7
Conversion of atrial pulmonary anastamosis to total 
pulmonary connection
K18.2
Creation of valved conduit between right atrium to 
pulmonary artery
K19.2
Creation of conduit between right atrium and 
pulmonary artery
OPCS
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4.4.11 Valvular lesions 
OPCS codes regarding valve interventions are not specific to congenital heart 
disease and so cannot be included. ICD codes referring to congenital valve 
lesions are summarised in Table 4-3. These codes are distinct from those 
corresponding to acquired valve disorders which would be represented by 
sections 424 of ICD 9 and I34-I37 of ICD 10.  
ICD codes for tricuspid stenosis and atresia, and pulmonary atresia have been 
included in the category of ‘complex lesions’ as per convention amongst similar 
literature (41,122). Isolated subaortic and subpulmonary lesions have been 
considered most appropriately amongst valvular lesions due to the shared 
indications for intervention and physiological similarities with stenotic valve 
lesions. 
Table 4-18: Codes used to identify valvular lesions 
 
 
Code Description
746.0 Anomalies of pulmonary valve
746.3 Stenosis of aortic valve
746.4 Insufficiency of aortic valve and bicuspid valve
746.5 Mitral stenosis
746.6 Mitral insufficiency
746.81 Subaortic stenosis
746.83 Infundibular pulmonary stenosis
Q22.1 Pulmonary stenosis
Q22.2 Pulmonary insufficiency
Q22.3 Other malformation of pulmonary valve
Q22.8 Other malformation of tricuspid valve
Q22.9 Malformation of tricuspid valve, unspecified
Q23.0 Stenosis of aortic valve
Q23.1 Insufficiency of aortic valve and bicuspid valve
Q23.2 Mitral stenosis
Q23.3 Mitral insufficiency
Q23.8 Other malformation of mitral and aortic valve
Q23.9 Malformation of aortic and mitral valve, unspecified
Q24.3 Infundibular pulmonary stenosis
Q24.4 Subaortic stenosis
ICD 9
ICD 10
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4.4.12 Complex lesions 
Many of the codes included under the category of complex lesions are 
encountered in more specific categories and will only default to this category if 
no procedural information is known. For instance, complete transposition of the 
great arteries will only be included in this category if no OPCS code pertaining to 
atrial or arterial inversion can be identified. A further example would be an 
individual with tricuspid atresia would default to ‘complex lesions’ if no 
identifying OPCS code for a Fontan type operation could be identified. 
There are a few examples of complex lesions identifiable by ICD 10 coding which 
were not identifiable by ICD 9, such as hypoplastic right heart syndrome and 
aortopulmonary septal defect. As such, these exceptionally rare lesions would be 
coded with non-specific lesion codes and would be likely to be included in the 
‘other lesions’ category if coded prior to April 1st 1996. 
Unifocalisation procedures (recruitment of aortopulmonary collaterals into a 
neo-pulmonary trunk) have been included here as they are most commonly 
encountered as a surgical strategy for pulmonary atresia with major 
aortopulmonary collateral arteries. The truncated form of the OPCS code for 
repairs of double outlet right ventricles (K08) has been included with complex 
lesions but will only default to this category if the more specific form of the 
code (K08.2), relating to Fallot type DORV is absent. The double switch 
operation may be used in some individuals with ccTGA, particularly when 
complicated by additional lesions which mandate surgical intervention and these 
individuals have been included in this, complex category. 
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Table 4-19: Codes used to identify complex lesions 
 
4.4.13 Other lesions 
Categorisation will default to ‘other lesions’ when either the code description is 
non-specific, referring to ‘other obstructive anomalies of the heart’ (ICD 9 code 
746.84) for example, or when the code used is non-specific 
(shortened/truncated codes), often referring to abnormalities of a region of the 
heart. Similarly, procedural coding may reflect interventions which may be used 
for an array of CHD such as atrial septostomies or again be included in truncated 
form, preventing more specific categorisation. 
  
Code Description
745.0 Common truncus
745.19 Other transposition complexes
745.11 Double outlet right ventricle
745.3 Single ventricle
745.7 Cor biloculare
746.1 Tricuspid atresia and stenosis
746.7 Hypoplastic left heart syndrome
747.3
Anomalies of the pulmonary artery (hypoplasia, stenosis and 
atresia)
746.01 Pulmoary valve atresia
747.41 Total anomalous pulmonary venous connection
745.10 Complete transposiion of the great areteries
Q20.0 Common arterial trunk
Q20.1 Double outlet righ ventricle (Taussig-Bing syndrome)
Q22.4 Tricuspid atresia and stenosis
Q23.4 Hypoplastic left heart syndrome
Q25.5 Pulmoary atresia
Q26.2 Total anomalous pulmonary venous connection
Q20.2 Double outlet left ventricle
Q20.4 Double inlet ventricle (single ventricle)
Q20.6 Isomerism of atrial appendages (with asplenia or polysplenia)
Q21.4 Aortopulmonary septal defect
Q22.6 Hypoplastic right heart syndrome
Q20.3 Discordant ventriculoarterial connections
L01.1 Correction of persistent truncus arteriosus
K06.4
Atrial inversion and repositioning of transposed great artery 
(double switch)
L69.2 Pulmonary unifocalisation
K07
Correction or intervention to total anomalous pulmoary venous 
connection
K08 Repair of double outlet right ventricle
ICD 9
ICD 10
OPCS
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Table 4-20: Codes used to categories as 'other lesions' 
 
Code Description
745.8 Other bulbus cordis and cardiac septal closure defects
745.9 Unspecified defect of septal closure
746.82 Cor triatriatum
746.84 Other obstructive anomalies of the heart
746.85 Coronary artery anomalies
746.9 Unspecified anomaly of heart
747.4
Anomalies of great veins (absence and persistence of 
cavae)
Q20.8
Other malformations of cardiac chambers and 
connections
Q20.9
Malformation of cardiac chambers and connections, 
unspecified
Q21.8 Other malformation of cardiac septa
Q21.9 Malformation of cardiac septa, unspecified
Q25.8 Other malformation of great arteries
Q25.9 Malformation of great arteries, unspecified
Q26.1 Persistent left superior vena cava
Q26.4
Anomalous pulmonary venous connection, 
unspecified
Q24.5 Malformation of coronary vessels
K12
Surgical and percutaneous closure of unspecified 
septum
K13 Percutaneous repair of unspecified septum
K14 Open atrial septostomy or septectomy
K15 Closed atrial septostomy or septectomy
K18 Creation and revision of varius cardiac conduits
K19
Creation or intervention to cariac conduit and Rastelli 
type repair
L05 Systemic arterial to pulmonary arterial shunt, various
L06
Creation or takedown of aorta to pulmonary arterial 
connection
L07
Creation, closure or dilation of subclavian artery to 
pulmonary arterial shunt
L08
Creation or percutaneous intervention to subclavian 
artery to pulmonary artery shunt
L12.1 Application of band to pulmonary artery
L12.2 Adjustment of band to pulmonary artery
L12.3 Removal of band to pulmonary artery
L69 Intervention to major systemic to pulmonary collateral
L70.8
Intervention to major systemic to pulmonary collateral 
and unifocalisation
K20.3 Repair of cor triatriatum
K20.8 Repair of septum or coronary sinus
K20.9 Unspecified refashioning of septum
K20.4 Repair of coronary sinus abnormality
ICD 9
ICD 10
OPCS
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4.4.14 Hierarchy of lesion categories 
Those individuals assigned to more than one lesion category were recoded in a 
hierarchical manner until each individual was assigned a single ‘major diagnosis’ 
group. This was done to reflect specificity of grouping; an individual coded as 
both ‘complex’ and ‘Fontan’ would be recoded to Fontan only, as well as 
complexity of lesion; an individual coded as both ASD and TOF would be recoded 
as TOF. 
Figure 4-1 summarises the hierarchy of lesion categorisation. Although similar 
methods of categorising lesions have been used previously (9) no convention 
exists. As per Figure 4-1, the hierarchy corresponds to increasing lesion 
complexity, with simple lesions at the bottom and complex lesions at the top. 
The exception to this is with Tetralogy of Fallot which is considered to be of 
moderate complexity however lies above TGA with arterial switch, systemic RV 
and otherwise unspecified complex lesions. This is to reflect the specificity of 
the procedural codes for TOF. This may be of importance as both TOF and TGA 
may have DORV type morphology. If the repair of DORV is of tetralogy ‘type’ this 
is specifically referenced by the OPCS code and therefore more reliably 
identified as TOF. If the repair does not specify TOF type (or no OPCS code is 
identified) then the lesion will default to complex and not be ‘upgraded’ to TOF.  
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Figure 4-1: Hierarchy of lesion categories  
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4.5 Classifying lesion complexity 
Attempts to classify CHD by complexity most commonly use or approximate the 
system outlined by Task Force 1 of the 32nd Bethesda Conference (122). As our 
data is stratified solely by electronic record coding our approximation of this 
system is matched as closely as this allows and is very similar to published 
literature (73). 
Table 4-21 outlines the lesions included in the three strata of CHD complexity. 
As compared to the Bethesda classification ours is somewhat simplified. This is a 
consequence of two main limitations to our data set. Firstly, we are unable to 
clarify the severity of valvular lesions as we did not have access to imaging 
results and severity is not considered by ICD coding. For this reason, we have 
categorised all isolated pulmonary valve stenosis as simple where the Bethesda 
system would include moderate and severe pulmonary stenosis as moderately 
complex. The second reason is that our inability to individually corroborate 
electronic records with medical notes means we are unable to rule out if a 
defect has received an intervention. OPCS coding will allow identification of 
when a procedure has definitely occurred however the absence of a code does 
not rule out that the same intervention has occurred at some point, either prior 
to the data period (or prior to the code’s inception) or out with Scotland (which 
has occurred with certain CHD procedures over the years). As such we have 
categorised all PDAs as simple where the Bethesda system would categorise 
those without intervention as moderately complex.  
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Table 4-21: Categorisation of lesions by lesion complexity 
 
  
Complexity Lesion
ASD (secundum septum)
Isolated congenital aortic valve disease
Isolated congenital pulmonary stenosis
Anomalous pulmonary venous drainage
Atrioventricular septal defect
Tetralogy of Fallot
Ebstein's anomaly
Valvular lesions (unless isolated pulmonary stenosis or aortic valve disease)
Aortic coarctation
Sub and supravalvular aortic stenosis
Transposition of the great ateries (irrespective of repair)
Congenitally corrected transposition of the great arteries
Fontan
Eisenmenger syndrome
Truncus arteriosus
Univentricular heart
Hypoplatic left heart syndrome
Tricuspid atresia 
Pulmonary atresia
Aortopulmonary window
Simple
Moderate
Severe
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4.6 Classifying cause of death 
4.6.1 Major groupings 
It was identified that 80.0% of the deaths amongst the study cohort could be 
categorised under seven major headings, corresponding to ICD 9 and 10 codes. 
These headings are also used in the reporting of deaths as recorded by the NRS 
and as reported in the annual report of vital statistics at a population level 
(123). The headings used were: death attributed to congenital heart disease, 
ischaemic heart disease, cerebrovascular and peripheral vascular disease, other 
cardiovascular disease, malignancy, respiratory, and infection. The remaining 
deaths were grouped together as ‘other’.  
The codes used to categorise causes of death into major groups are described in 
Table 4-22. 
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Table 4-22: Major groupings of causes of death, ICD codes and description.  
 
4.6.2 Cardiovascular and non-cardiovascular death 
Deaths were also categorised as by cardiovascular and non-cardiovascular 
causes. CV deaths included all CHD, IHD, CVD/PVD and ‘other cardiac’ deaths as 
defined in Table 4-22. Additionally, for the purposes of analysis by CV and non-
CV deaths, pulmonary embolus was included as CV (ICD 9 code 415, ICD 10 code 
I26). All other deaths were categorised as by non-CV causes however deaths 
where the cause could not be determined were excluded from this system of 
categorisation (ICD 9 code 798, ICD 10 code R99). This definition of 
cardiovascular mortality has been used previously when ICD coding via death 
certification has been relied upon (124–126). A notable exception or perhaps 
oversight in previous work where congenital heart disease is not the focus, is 
Cause of death ICD 9 codes ICD 10 codes Description
Congenital malformation of cardiac chambers and connections
Congenital malformation of cardiac septa
Congenital malformation of pulmonary and tricuspid valves
Congenital malformation of aortic and mitral valves
Other congenital malformations of the heart
Congenital malformations of the great arteries
IHD 410 - 414 I20 - I25 Ischaemic heart disease
Cerebrovascular disease (ischaemic or atraumatic haemorrhage)
Disease of the arteries, arterioles and capilliaries
Vascular disorders of the intestine
Rheumatic heart disease
Hypertensive diseae
Pericarditis and other pericardial disease
Myocarditis
Cardiomyopathy
Conduction disorders of the heart
Cardiac arrhythmias
Heart failure
Malignant neoplasms
Neoplasms in situ
Bacterial infections and parasitic diseases
Bacterial meningitis
Infective encephalitis
Lung absces, pyothorax and acute and chronic pneumonias
Infections of the skin and subcutaneous tissue
Acute and subacute endocarditis
Infectious arthropathies
Infections of the perinatal period
Pulmonary heart disase 
Diseases of pulmonary circulation
Diseases of the upper respiratory tract
Chronic lower respiratory tract disorders
Pleural disorders
745, 746, 
747.0, 747.1, 
747.2, 747.3, 
747.4
Q20 - Q25CHD
I6 - I7, K5543 - 44CVD/PVD
I0-I1, I30-31, 
I40, I42, I44 - 
I51, I81, I95
39 - 40, 420, 
425-429, 
458, 514
Other cardiac
C, D0 - D414 - 23Malignancy
A - B, G00, 
G03, J0 - J2, 
J85 - J86, 
L00, L02, 
L03, L08, 
M00, P36, 
P39, I33, I38
0, 10 - 13, 
320 - 322, 
324 - 326, 
46, 48, 68, 
510, 513, 
711, 771, 
421, 422
Infection
I26-I28, J3-
J7, J80, J82, 
J84, J9
415-417, 
453, 511-
512, 515-
519, 49-50
Respiratory
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that deaths due to congenital heart disease are not generally included into the 
definition of CV mortality.  
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4.7 Follow up and time to censorship 
An individual’s follow up period was defined as starting at the 1st day of their 
first CIS which was discharge coded after January 1st, 1986 (ergo, follow up may 
start prior to January 1st, 1986). This was true even if none of the inclusion 
codes as defined in Table 4-3 were encountered during that particular CIS. By 
the nature of CHD it is present from birth and so utilising data linkage to identify 
all episodes for an individual and extending the period of follow up back to the 
earliest encounter within the data period was felt to be appropriate. 
As explained in section 4.3, dates were limited to month and year only for 
reasons of anonymisation and so the start of follow up was approximated to the 
1st of the month in question. For those individuals who were first encountered 
prior to age 16, their follow up start was determined to be the 1st of January of 
the year in which they turned 16. Again, this approximation was due to the 
necessary anonymisation as recommended by the privacy panel, prohibiting 
access to dates of birth as explained in section 4.3. 
Follow up was continued until either death or administrative censorship on the 
30th September 2017. ISD data is unable to account for other forms of 
censorship, such as by emigration.  
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4.8 Statistics 
This section describes the statistical methodology common throughout this 
thesis. Where deviations or significant alterations to these methods was 
necessary, they will be outlined in the relevant results Chapter. 
4.8.1 Preamble, descriptives and significance 
All statistical tests were carried out using STATA 14 (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP). Continuous 
variables are presented as mean with standard deviation where the distribution 
is normal and by median and interquartile range (IQR) when non-normal. 
Comparison between groups was carried out by way of independent sample T-
test, Pearson’s Chi squared test or Mann Whitney U test as appropriate. 
Comparison of rates of change were carried out using the proportion Chi squared 
test, in the manner previously advocated by Fan et al (127). For all statistical 
methods a two-tailed p value of <0.05 was considered to be of statistical 
significance. 
4.8.2 Population data 
Population numbers, deprivation statistics and cause of death data were derived 
from the NRS table of vital events 6.4 for each year between 1986 and 2017. 
This information is freely available in online form from 2001 and in print prior to 
2001. 
4.8.3 Kaplan Meier 
Kaplan Meier estimates were left truncated at the point of first episode within 
the data period. At times it was considered appropriate to extend left back to 
age 16 and where this was the case it will be highlighted in the appropriate 
result Chapter. As all Kaplan Meier estimates in this work concern mortality, 
estimates are right censored.  
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4.8.4 Cox regression  
Uni and multivariate models of survival were calculated using Cox regression and 
output presented as hazard ratios with 95% confidence intervals. The Breslow 
method was used to account for ties and the assumption of proportional hazard 
was checked visually using log(-log(survival)), “log-minus-log” plots. 
4.8.5 Standardised mortality ratios 
Where appropriate, age standardised mortality ratios were calculated by 
dividing the observed number of deaths amongst the ACHD population by the 
expected number of deaths calculated using population mortality rates. As the 
duration of follow up was highly variable between individuals and each person 
may contribute to multiple age cohorts throughout the data set, these 
calculations were limited to mortality occurring within the first year of inclusion 
into the data set. Expected mortality was calculated using the mean of the 
yearly population mortality rates for each age cohort during the time period in 
question (the total data-period, the first half of the data period and the second 
half of the data period) as obtained via the NRS table of vital events 6.4 (as 
outlined in section 4.8.2). 
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5 Circumstances of death and survival for all 
ACHD lesions and changes over time 
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5.1 Introduction 
As established by the preceding literature review, survival for all ACHD and 
according to underlying lesion is the most established method of reporting in the 
published data. Population level data however remains scarce and has never 
been established for the Scottish population. Data regarding cause of death is 
more sparse still and temporal changes are not reported in the identified 
literature. 
In clinical practice patients are most commonly categorised according to their 
underlying congenital heart lesion, often in combination with their surgical and 
interventional history. This allows the clinician to consider common and 
important problems specific to this group upon review or when presented with a 
change in symptoms or signs. The nature of congenital heart disease however is 
that although the majority of patients are easily characterised by a lesion or a 
dominant lesion if multiple coexist, many other rare lesions do exist and some 
congenital heart disease defies classification in this manner altogether. For this 
reason, reporting data at an individual lesion level would neither be practical 
nor useful. The 13 major groupings described in this Chapter have been 
explained in section 4.4 and are broadly according to convention as described in 
the existing literature (50,51,75) and according to my experience in clinical 
practice.  
This Chapter will establish the baseline characteristics of the total study 
population and according to their major underlying congenital lesion. Temporal 
changes in survival and causes of death will be outlined.  
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5.2 Methods 
The preceding Chapters have described the methods by which patients are 
identified using ICD and OPCS coding. As these coding systems have evolved and 
exist in several iterations across my data period comparisons over time at lesion 
level is affected. Due to the particular heterogeneity within the OPCS system, 
lesions dependant on this method of coding (Fontan and TGA arterial switch) are 
not readily identified by the earliest version (OPCS3). Consequently, these 
lesions are not individually reported in temporal analyses within this Chapter. 
Due to the significant variation in age at first encounter, this Chapter has 
presented Kaplan Meier curves not as observed, left truncated graphics but 
rather as being extended left to start at age 16 and then using age at death or 
age at censorship to illustrate survivorship. The alternative, to present fully left 
truncated estimates would misleadingly suggest those who present to the data 
set in later life (as you might expect with less severe CHD such as ASDs) to 
experience relatively poorer survival. As these lesions have been present from 
birth and it is time to presentation or recognition by the data set which is 
altered, extending survival leftward was preferred in this Chapter. As a result, 
these graphs should not be used to truly estimate the real-life survival for each 
lesion as this would be an over-estimate due to a survivor bias, as comparable 
individuals may have died during the ‘left extended’ phase and hence would be 
hidden from this data set. The Kaplan-Meier analyses are thus meant as a 
relative guide as to the univariate survival of each lesion when compared to CHD 
as a whole. 
Section 5.3.4 describes deaths where a CHD code was identified from death 
records (having been listed as a cause on the MCCD) but the individual does not 
have an SMR01 record during the data period. As death recording has no place 
for procedural coding (OPCS) only ICD coding is utilised for patient identification 
and lesion grouping. As such, for this section only, the lesions which require 
procedural data will not be delineated. Fontan, TGA with arterial switch and the 
TGA with atrial switch are the groups affected and will be included in the 
‘complex’ category.  
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5.3 Results 
5.3.1 Demographics and baseline characteristics 
A total of 16,210 patients were identified from 1986 to 2015 of which 4162 
(25.7%) died. The baseline characteristics of the total study population, those 
who survived the data period and those who died are summarized in Table 5-1.  
More women than men were identified (50.9% and 49.2%, p=0.03) and mean age 
at inclusion was higher for women than men (40.6, SD 24.4 and 37.6, SD 22.4), 
p<0.01). A higher proportion of women than men died during follow up (27.2% 
and 24.2%, p<0.01).  
Those with shunt lesions; ASD, PDA, and AVSD as well as Ebstein’s anomaly were 
predominantly women, whereas those with conotruncal lesions (TOF and 
systemic RV) as well as aortic and Fontan cohorts were predominantly men. For 
the combined cohorts of ‘complex lesions’ and ‘other lesions’ there was no 
significant difference in sex distribution (49.7% (p=0.85)and 48.5% (p=0.23) 
female respectively) (Table 5-2). 
A quintile group of SIMD could be assigned for 16,045 (99.0%) individuals. Among 
the 165 individuals for which SIMD data was not available, more were male 
(55.8%) and they were younger (median 23, IQR 16-49) when compared to the 
total study population. The most common SIMD quintile observed was 1-most 
deprived (4355 (27.1%) individuals) and least common was 5-least deprived (2516 
(15.7%) individuals). A higher proportion of individuals in the more deprived 
socioeconomic quintiles died during follow up (26.2% and 28.0% for SIMD 1 and 2 
respectively) when compared with the least deprived (24.5% and 22.5% for SIMD 
4 and 5 respectively), p<0.01. 
AF (9.9%) and ischaemic heart disease without myocardial infarction (10.0%) 
were the most commonly observed comorbidities. Cancer (2.5%) and diabetes 
(3.7%) were less commonly observed. The majority of patients with diabetes 
(58.8%), cancer (73.1%), AF (54.7%) and prior myocardial infarction (65.6%) died 
during the data period.  
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Atrial septal defect was the most common lesion identified, representing 25.7% 
of the total study cohort. TGA with arterial switch and Ebstein’s anomaly were 
the least frequently observed lesions, representing 0.2% and 0.7% of the total 
study cohort respectively. Patients with aortic lesions were the most frequently 
observed to die (52.5%) during the study period. Few patients with PDA (5.7%) 
and no patients with TGA arterial switch died during follow up. 
 
Table 5-1: Baseline characteristics for all patients and for those alive and dead at the end of 
follow up 
 
Column1 All (%) Alive (%) Dead (%)
All 16210 12048 (74.3) 4162 (25.7)
Age at inclusion (IQR) 34 (16-59) 19 (16-45) 67 (52-77)
Female 8242 (50.9) 6004 (72.9) 2238 (27.2)
Male 7968 (49.2) 6044 (75.9) 1924 (24.2)
SIMD quintile 16045
1 most deprived 4355 (27.1) 3215 (73.8) 1140 (26.2)
2 3441 (21.5) 2474 (71.9) 967 (28.1)
3 2997 (18.7) 2222 (74.1) 775 (25.9)
4 2736 (17.1) 2066 (75.5) 670 (24.5)
5 least deprived 2516 (15.7) 1950 (77.5) 566 (22.5)
Comorbidity
Diabetes 606 (3.7) 250 (41.3) 356 (58.8)
Cancer 401 (2.5) 108 (26.9) 293 (73.1)
AF 1609 (9.9) 728 (45.3) 881 (54.8)
CVD 931 (5.7) 613 (65.8) 318 (34.2)
HTN 946 (5.8) 572 (60.5) 374 (39.5)
AMI 896 (5.5) 308 (34.4) 588 (65.6)
other IHD 1619 (10.0) 843 (52.1) 776 (47.9)
Lesion
ASD 4172 (25.7) 3365 (80.7) 807 (19.3)
PDA 983 (6.1) 927 (94.3) 56 (5.7)
VSD 2244 (13.8) 1584 (70.6) 660 (29.4)
Aortic 2143 (13.2) 1017 (47.5) 1126 (52.5)
Ebstein’s 105 (0.7) 71 (67.6) 34 (32.4)
AVSD 600 (3.7) 491 (81.8) 109 (18.2)
TOF 564 (3.5) 495 (87.8) 69 (12.2)
TGA arterial switch 35 (0.2) 35 (100) -
Systemic RV 133 (0.8) 115 (86.5) 18 (13.5)
Complex 1285 (7.9) 1042 (81.1) 243 (18.9)
Fontan 167 (1.0) 151 (89.4) 16 (9.6)
Valvular 2163 (13.3) 1598 (73.9) 565 (26.1)
Other 1616 (10.0) 1157 (71.6) 459 (28.4)
113 
 
 
5.3.2 Follow up, mortality and age at death 
A total of 168,177 person years of follow up were observed across the entire 
study population. Cumulative follow up ranged from 196 person years for TGA 
arterial switch, to 43,483 person years for ASD. Cumulative follow up and 
mortality rates for each CHD lesion are summarised in Table 5-2. 
Mean age at inclusion varied from 16 (SD 0) for TGA with arterial switch to 51.5 
(SD 27.9) for aortic lesions. Mean age at death for the total study cohort was 
68.1 (SD 19.1) years and varied from 22.2 (SD 5.1) years for the systemic RV 
cohort to 77.0 (SD 14.8) years for aortic lesions. For comparison, the population 
estimates of age at death from 2016-2018 in Scotland were 77.0 for men and 
81.1 for women. 
The observed mortality rate for the total study population was 24.7 (95% CI 24.0-
25.5) deaths per 1000 person years. No deaths were observed for the TGA 
arterial switch group but otherwise the mortality rate ranged from 5.0 (95% CI 
3.8-6.5) for PDA to 57.6 (95% CI 54.3-61.0) deaths per 1000 person years for the 
aortic lesion cohort.  
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Table 5-2: Follow up and mortality rate for all CHD and all lesion groups 
 
  
Mean age at death during the earliest study cohort (1986-1990) was 61.4 (SD 
19.3) compared to 68.5 (SD 19.5) during the most recent study period (2015-
2017), p<0.01. The breakdown of distribution of deaths according to 5 year age 
cohorts for the earliest and most recent time period studied are summarised in 
Figure 5-1. A cohort from the general population of Scotland covering the same 
time period is shown for comparison. From 1986 - 1990 death was most 
frequently encountered in the 75-79 years age bracket (13.3% of all deaths). In 
the most recent time period >84 years was the most common age at death for all 
CHD (20.44%), as it is in the general population.  
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Figure 5-1: Distribution of age at death cohorts compared to the general population for the 
earliest (1986-1990) and most recent (2015-2017) time periods 
 
Deaths in early adulthood are more clearly shown in Figure 5-2. In total, 23.0% of 
all deaths from 1986-1990 were in those under the age of 45. This is compared 
to 14.1% of deaths from 2015-2017. A higher percentage of deaths were 
witnessed for all age cohorts below 45 years in the earliest compared to most 
recent time period except amongst death at age 20-24. 
116 
 
 
Figure 5-2: Comparison of age at death between the earliest and most recent time cohorts 
for all congenital heart disease (CHD) lesions 
 
Overall, the median age at death increased from 72 (IQR 59-81) to 74 (IQR 58-83) 
years between the first and second half of the data period (p<0.01). Significant 
increases in age at death were seen for ASD (68 (IQR 58-77) to 74 (IQR 62-82)), 
p<0.01, and VSD (68.5 (IQR 57-76) to 73(IQR 55-83), p<0.01). Point estimates of 
age at death increased for all other lesions except PDA however statistical 
significance was not achieved.  
The unadjusted survival of individual lesions from age 16 is demonstrated in 
Figure 5-3, Figure 5-4 and Figure 5-5. When compared to the total patient 
cohort, survival was greater for ASD (HR 0.81, 95% CI 0.75-0.88 p<0.01), valvular 
(HR 0.82, 95% CI 0.75-0.90 p<0.01) and aortic lesions (HR 0.78, 95% CI 0.72-0.83 
p<0.01). It was lower for VSD (HR 1.78, 95% CI 1.36-1.61 p<0.01), Ebstein’s 
anomaly (HR 2.74, 95% CI 1.95-3.84 p<0.01), AVSD (HR 1.67, 95% CI 1.38-2.02, 
p<0.01), TOF (HR 3.24, 95% CI 2.54-4.12 p<0.01), systemic RV (HR 6.72, 95% CI 
4.20-10.76 p<0.01), Fontan (HR 3.53, 95% CI 2.16-5.79 p<0.01) and complex 
lesion (HR 1.89, 95% CI 1.67-2.14 p<0.01). There was no significant difference in 
survival when compared to the reference group for PDA (HR 1.04, 95% CI 0.80-
1.36 p=0.77) and ‘other’ lesions (HR 1.04, 95% CI 0.95-1.15 p=0.38) 
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Figure 5-3: Kaplan Meier survival curves (ASD, PDA, VSD and aortic lesions) 
A – ASD compared to all other lesions, B – PDA compared to all other lesions, C- VSD compared to all other lesions, D – Aortic compared 
to all other lesions 
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Figure 5-4: Kaplan Meier survival curves (Ebstein's anomaly, AVSD, TOF, Systemic RV) 
A – Ebstein’s anomaly compared to all other lesions, B – AVSD compared to all other lesions, C – TOF compared to all other lesions, D – 
Systemic RV compared to all other lesions 
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Figure 5-5: Kaplan Meier survival curves (complex lesions, Fontan, valvular and 'other' CHD) 
A – Complex lesions compared to all other lesions, B – Fontan compared to all other lesions, C – valvular compared to all other lesions, D 
– ‘other’ CHD compared with all other lesions 
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Standardised mortality ratios were calculated from the 1 year mortality rate 
observed for age cohorted ACHD patients as compared with the expected 
mortality calculated from the age equivalent general population. Table 5-3, 
Table 5-4, and Table 5-5 outline the observed as well as the expected mortality 
for each age cohort as well as the standardised MR for; the total data period; 
the first half of the data period; and the second half of the data period 
respectively. For the total data period the one-year age standardised MR as 
compared to the general population was 5.22 (95% CI 4.92-5.52). This is 
accounted for by the equivalent standardised MR of 6.71 (95% CI 6.23-7.22) for 
the first half of the data period, significantly higher than the second half of the 
data period (4.05, 95% CI 3.69-4.43, p<0.01). 
Table 5-3: Observed and expected deaths according to age cohorts for adult congenital 
heart disease, standardised using population mortality rates.  Standardised mortality ratio is 
observed/expected ACHD deaths. 
 
 
Table 5-4: Observed and expected deaths during the first half of the data period (1986-2000) 
according to age cohorts for adult congenital heart disease, standardised using population 
mortality rates.  Standardised mortality ratio is observed/expected ACHD deaths. 
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Table 5-5: Observed and expected deaths during the second half of the data period (2001-
2017) according to age cohorts for adult congenital heart disease, standardised using 
population mortality rates.  Standardised mortality ratio is observed/expected ACHD deaths. 
  
A multivariate regression model for all-cause mortality, adjusted for sex, age, 
year of presentation, comorbidity (diabetes, cancer, AF, CVD, HTN, AMI and 
other IHD), congenital lesion and socioeconomic group, is summarized in Table 
5-6. 
Male sex confers a small increased risk of all-cause mortality (HR 1.14, 95% CI 
1.07-1.21, p<0.01) compared with female. When stratifying risk of mortality 
according to underlying lesion, the largest patient cohort of ASD was used as the 
reference and HRs for other lesions are relative to this. Figure 5-6 illustrates the 
relative hazard of each lesion as well as sex. Overall the lowest risk was noted 
for PDA (HR 0.88, 95% CI 0.67-0.16, p=0.36) and the highest for Fontan 
circulations (HR 2.20, 95% CI 1.34-3.63, p<0.01) and Ebstein’s anomaly (HR 2.45, 
95% CI 1.74-3.46, p<0.01). 
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Figure 5-6: Forest plot of multivariate hazard ratios for all-cause mortality according to sex 
and individual lesion 
 
The risk of all-cause mortality decreased as year of first presentation increased. 
As is illustrated in Figure 5-7, a reduction in hazard occurred between each of 
the six time cohorts and amount to a 65% reduction in instantaneous risk of all-
cause mortality between the earliest and most recent data periods.  
 
 
Figure 5-7: Forrest plot of multivariate hazard ratios for all-cause mortality according to year 
of inclusion to data set 
 
Mortality was higher in the presence of diabetes (HR 1.71, 95% CI 1.53-1.91, 
p<0.01), cancer (HR 1.79, 95% CI 1.58-2.02, p<0.01), acute myocardial infarction 
(HR 1.39, 95% CI 1.26-1.52, p<0.01), and atrial fibrillation (HR 1.24, 95% CI 1.15-
1.35, p<0.01). No significant difference in mortality was observed in the 
presence of hypertension (HR 0.96, 95% CI 0.86-1.07, p=0.44), cerebrovascular 
disease (HR 1.09, 95% CI 0.97-1.22, p=0.17) or ischaemic heart disease without 
myocardial infarction (HR 0.93, 95% CI 0.86-1.01, p=0.08). 
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Table 5-6: Breakdown of death according to demographics, lesion, data period and 
deprivation with multivariate hazard ratios for all-cause mortality 
Column1 All (%) Dead (%) HR [95% CI] (p value)
Female 8169 (50.9) 2216 (27.1) 1
Male 7876 (49.1) 1902 (24.2) 1.14 [1.07-1.21] (<0.01)
Age 1.07 [1.07-1.07] (<0.01)
Year of Presentation
1986-1990 3206 (20.0) 834 (26.0) 1
1991-1995 2892 (18.0) 892 (30.8) 0.86 [0.78-0.95] (<0.01)
1996-2000 2978 (18.6) 842 (28.3) 0.72 [0.65-0.80] (<0.01)
2001-2005 2158 (13.5) 641 (29.7) 0.55 [0.49-0.62] (<0.01)
2006-2010 2453 (15.3) 576 (23.5) 0.46 [0.41-0.52] (<0.01)
2011-2015 2358 (14.7) 333 (14.1) 0.35 [0.30-0.40] (<0.01)
Comorbidity
Diabetes 605 (3.8) 356 (58.8) 1.71 [1.53-1.91] (<0.01)
Cancer 401 (2.5) 293 (73.1) 1.79 [1.58-2.02] (<0.01)
AF 1593 (9.9) 872 (54.7) 1.24 [1.15-1.35] (<0.01)
CVD 925 (5.8) 315 (34.1) 1.09 [0.97-1.22] (0.17)
HTN 940 (5.9) 372 (39.6) 0.96 [0.86-1.07] (0.44)
AMI 885 (5.5) 580 (65.5) 1.39 [1.26-1.52] (<0.01)
Other IHD 1613 (10.1) 773 (47.9) 0.93 [0.86-1.01] (0.08)
Lesion
ASD 4141 801 (19.3) 1
PDA 972 54 (5.6) 0.88 [0.67-1.16] (0.36)
VSD 2210 648 (29.3) 1.99 [1.78-2.22] (<0.01)
Aortic 2123 1117 (52.6) 1.39 [1.26-1.54] (<0.01)
Ebstein's 104 34 (32.7) 2.45 [1.74-3.46] (<0.01)
AVSD 596 108 (18.1) 1.50 [1.23-1.84] (<0.01)
TOF 552 68 (12.3) 1.96 [1.52-2.53] (<0.01)
Complex 1432 257 (18.0) 1.75 [1.51-2.02] (<0.01)
Fontan 166 16 (9.6) 2.20 [1.34-3.63] (<0.01)
Valvular 2144 561 (26.2) 1.27 [1.14-1.42] (<0.01)
Other 1605 454 (28.3) 1.37 [1.22-1.54] (<0.01)
SIMD Quintile
1 - most deprived 4355 1140 (26.2) 1
2 3441 967 (28.1) 0.91 [0.84-0.99] (0.04)
3 2997 775 (25.9) 0.87 [0.79-0.95] (<0.01)
4 2736 670 (24.5) 0.76 [0.69-0.84] (<0.01)
5 - least deprived 2516 566 (22.5) 0.67 [0.60-0.74] (<0.01)
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5.3.3 Cause of death 
Seven diagnoses of cause of death accounted for 80.0% of deaths amongst the 
study population and 70.9% of deaths in the general population. The proportional 
distribution of cause of death for the entire study population, as well as for 
individual CHD lesion, and compared to the Scottish population for each of these 
seven diagnoses (congenital heart disease, ischaemic heart disease, peripheral 
and cerebrovascular disease, other cardiac disease, respiratory disease, 
infection and malignancy) and by all ‘other’ causes, are summarised in Figure 
5-8. 
Amongst the general population, malignancy was the most frequent cause of 
death, representing 28.7% of all deaths. In the study population, malignancy was 
the most frequent cause of death amongst the PDA cohort alone, representing 
21.4% of deaths. 
Across the study population, IHD was the most frequent cause of death (24.1% of 
all deaths). IHD was also the predominant cause of death for VSD (41.8%), AVSD 
(19.3%), ASD (17.0%), aortic lesions (28.1%), valvular lesions (21.2%) and ‘other’ 
CHD (20.5%). IHD was the second most frequent cause of death in the general 
population (11.9%) and significantly less frequent than in the study population 
(p<0.01). 
Death directly attributed to congenital heart disease predominated for more 
complex lesions; accounting for 77.8% of deaths in systemic RV patients, 55.1% in 
the TOF cohort, 52.9% for Ebstein’s anomaly, 50.0% in the Fontan group and 
32.5% of deaths in the complex CHD cohort. In the general population, death due 
to congenital heart disease represented only 0.03% of total deaths in adults 
Peripheral and cerebrovascular disease related death was most commonly 
observed for Fontan circulations (12.5%), PDA (12.5%) and aortic lesions (12.0%). 
Infection deaths were most highly represented in valvular CHD, representing 9% 
of the total in that cohort and are significantly more frequent than the 5.6% in 
the general population (p<0.01). 
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Over the total data period the majority (53.9%) of deaths were due to 
cardiovascular causes, p<0.01. This is significantly greater than for the general 
population (39.2%) over the same time period (p<0.01). 
Cardiovascular death predominates for most congenital lesions, achieving 
statistical significance for; systemic RV (77.8%, p=0.02), Ebstein’s anomaly 
(76.5%, p<0.01), VSD (65.3%, p<0.01), and aortic lesions (56.0%, p<0.01). And 
approaching statistical significance for; complex lesions (56.4%, p=0.05), Fontan 
circulation (68.8%, p=0.13), AVSD (56.9%, p=0.15), and valvular lesions (51.3%, 
p=0.53). 
Non-cardiovascular death was more common for; ASD (56.9%, p,0.01), ‘other’ 
CHD (52.3%, p=0.33) and PDA (51.9%, p=0.79), achieving statistical significance 
for ASD only. 
 
Figure 5-8: Proportional distribution of causes of death for all CHD, by individual lesion, and 
compared to the general population. 
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The proportion of cardiovascular deaths reduced over time. Figure 5-9 shows the 
changing proportion of cardiovascular to non-cardiovascular deaths throughout 
the study period. 
During the earliest data period of 1986-1990, 72.9% of deaths among the study 
population were due to cardiovascular causes. By 2006-2010, the proportion of 
cardiovascular and non-cardiovascular deaths were equal (50.4% and 49.6%, 
p=0.83). By the most recent data period of 2016-2017, only 40% of deaths were 
due to cardiovascular causes. This remains significantly greater than the 26% of 
deaths among the general population of Scotland in 2016, p<0.01. 
 
Figure 5-9: Proportional distribution of cardiovascular and non-cardiovascular death 
according to year of death and compared to the general population (as reported in 2016). 
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Figure 5-10 compares the proportion of cardiovascular deaths in the study 
population and the general population during each time period.  
From the first to the most recent data period, the proportion of cardiovascular 
deaths in the ACHD population fell by 33.1%, and in the general population by 
22.7%, p<0.01. This corresponds to a 1.07% reduction in cardiovascular death per 
year in the ACHD population and a 0.73% reduction per year in the general 
population p=0.02.  
 
Figure 5-10: Percentage of cardiovascular deaths according to year of death for adult 
congenital heart disease (ACHD) and the general population 
 
5.3.4 Deaths occurring without an SMR01 record 
From the time point where this information was available (after Dec 1999), 198 
individuals were identified as having CHD from death records. Median age at 
death was 52.5 years (IQR 40-68). Age at death did not change significantly 
between the first half (median 51, IQR 39-68) and second half (median 52.5, IQR 
40-67) of the data period (1999-2007 and 2008-2015), p=0.72. When combined 
with deaths identified by SMR01 records, these 198 deaths represent 4.5% of the 
total deaths amongst those with CHD. To breakdown these results by all 
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individual congenital lesions or demographics may jeopardise confidentiality 
however, valvular or ‘other CHD lesions’ were implicated in the majority (122, 
61.6%) of these deaths. 
Valvular CHD was implicated in 52 deaths identified from death records. All but 
2 of these individuals were found to have lesions of the aortic valve. The 
majority (38, 73.1%) of deaths were attributed to the valve lesion and all but 7 
(86.5%) were by CV causes. The mean age at death amongst these individuals 
was 54.8 (SD 16.5) years. These 52 deaths represent 8.4% of the total deaths 
amongst individuals with valvular CHD when inclusive of those with an SMR01 
record. 
A total of 70 individual were coded with ‘other’ CHD on death certification 
alone. The majority of these codes pertain to ill-defined and unspecified 
congenital anomalies of the heart, however 22 (31.4%) had congenital anomalies 
of the coronary arteries. Mean age at death for the whole cohort was 50.0 (SD 
18.7) years and 52.3 (SD 19.5) years amongst those with coronary anomalies. The 
70 deaths presented here corresponds to 13.2% of the total number of deaths 
included for ‘other’ CHD lesions when inclusive of those with an SMR01 record. 
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5.4 Discussion 
5.4.1 Baseline characteristics and follow up 
A total patient cohort of 16,210 followed for 168,177 years represents a 
substantial study population. Although this does not represent the entire ACHD 
cohort in Scotland, only those who generated an SMR01 record via an in patient 
stay, no larger Scottish cohort has been reported. When compared with other 
non-selected adult studies world-wide, only one article reports a larger patient 
cohort (51) and total follow up. Although these studies were not designed to 
estimate the prevalence of ACHD in Scotland, 16,210 individuals equates to 
0.36% or 3.59 per 1000 of the adult Scottish population based on 2018 figures. 
This is similar to previous estimates of prevalence including that by Marelli et al 
(9) of 4.09 per 1000 in the adult Quebec population. This would suggest that a 
substantial, albeit not a complete representation of the ACHD population of 
Scotland was achieved. The future ability to cross reference this with local 
databases would prove useful to capture the magnitude of missed cases or any 
bias this may impose. 
A marginal but statistically significant female preponderance was observed 
(50.9%, p=0.03) and again this is common in the reported literature (41,44,128) 
with no identified comparable published article presenting a population with 
significantly more men. Similar to the articles discussed in the preceding 
literature review, sex distribution was highly variable depending upon lesion. 
The pattern of sex distribution in our study cohort matches that reported in the 
previously analysed literature other than for Fontan patients which was equally 
represented between the sexes in the literature but predominantly male in our 
cohort (59.9%, p=0.01). 
As with CHD diagnoses, co-morbidity was established by ICD coding as recorded 
upon discharge from a hospital episode. As such it will represent an 
underestimate of the true prevalence of the condition within the cohort. If the 
individual has not had an admission where the co-morbidity in question was the 
primary diagnosis, should it not be deemed significant, or if was simply missed 
on admission, then it is conceivable that it would not be coded. For instance a 
previous estimate of the prevalence of diabetes in the Scottish population 
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quoted 5.4% (129) but was only 3.7% in our cohort. In contrast our study 
prevalence of AF at 9.9% is significantly greater than the 3-6% identified from 
acute hospital admissions in the UK population previously (130,131), with the 
upper value of 6% established from a regional Scottish population. Despite this, 
for the reasons mentioned above, the true prevalence of AF in the ACHD 
population is likely to be even higher as it is inevitable that some instances were 
missed by clinical coding. It has previously been established that AF and atrial 
flutter become increasingly prevalent in the ACHD population as age increases, 
as age at time of repair increases and as complexity of lesion increases (132). 
Unfortunately, National Records of Scotland do not collate data regarding 
comorbidity prevalence and so estimates as above can only be extrapolated from 
the journal literature. As such, comparison of the effect of co-morbidity on 
mortality with that of the general population is not possible. Future studies 
would benefit from a population matched cohort to allow direct comparison. 
Comorbidities were more common amongst the study population as age 
increases. Coupled with finding of improved temporal survival in this cohort 
(equating to an aging patient population) this would suggest an increasingly 
complex and multimorbid patient cohort. 
Socioeconomic classification as determined by SIMD is not equally distributed 
throughout the study cohort. The highest quintile of deprivation is 
disproportionately represented, being observed for 27.1% of the ACHD 
population, significantly greater than the 20.0% population determined quintile, 
p<0.01. No data regarding socioeconomic status has been identified in the 
literature for adults with CHD but one article has reported similar findings in 
children (133), however outcomes were not reported.  
5.4.2 Survival and mortality 
Over the total study period 25.2% of the entire cohort died. This is higher than in 
the previously reported literature. It may be that our study population is 
comprised of more severe disease phenotypes as inclusion is dependent on a 
hospital admission. In many other cohorts, mild disease which is simply followed 
in clinic, but never requires admission will also be included in the denominator. 
Another reason would be that the median baseline age in our study cohort of 34 
131 
 
years is higher than the comparable literature as reported in the previous 
Chapter where the average age on all accounts was below 30 years.  
Age at death increased throughout the study period. Although the increase in 
age at death between the earliest and most recent study period, and from the 
first to the second half of the study period was highly statistically significant for 
the entire study cohort, this was not the case for each individual lesion. Once 
divided into 13 diagnostic groups, too few deaths were observed in each of the 
seven time cohorts to allow accurate comparison. For this reason, lesion specific 
age at death was limited to the first and second half of the data period. 
Necessarily this limited the magnitude of change between the two time periods. 
Increased mean and median age at death was nevertheless observed for the two 
largest patient cohorts: ASD and VSD. Increases in point estimates amongst the 
smaller lesion cohorts did not achieve statistical significance.  
Death occurred more frequently throughout the data period when co-morbidity 
was present. Once adjusted for demographics, lesion, age and socioeconomic 
deprivation the conferred risk persisted for diabetes, AF, cancer and myocardial 
infarction. The risk associated with AF is worthy of particular mention as the 
observed prevalence within our cohort was certainly higher than the general 
population. This is no surprise as the CHD population have unique exposure to 
conditions which predispose to the development of AF. Atrial enlargement in 
conditions such as ASD, or as a haemodynamic consequence of surgical 
interventions such as Fontan palliation provide a substrate for the development 
of AF. It is equally known that scar and suture in the atria such as occurs after 
atrial switch procedures and anomalous pulmonary vein repairs, increase the risk 
of AF and other atrial tachyarrhythmias (132,134). The increased mortality 
observed in patients with AF could be explained in two ways: 
• AF increases in prevalence as the disease progresses and is a marker of disease. This is 
particularly true of Fontan and atrial switch patients where AF is frequently a marker of the 
broader problem of failing haemodynamics 
• AF directly increases mortality 
 
Benjamin et al. have previously described a 1.5 to 1.9 fold increase in mortality 
associated with AF even after adjusting for underlying heart disease, inferring 
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causality of AF itself (135). This did not however include adjustment for 
congenital heart disease, and it seems likely that AF as a marker of disease 
severity is at least partially responsible for the increased mortality that we 
observed. This may be further supported by the lack of increased risk we 
witnessed for stroke, classically considered to be a key mechanism of excess 
mortality associated with AF. 
Neither hypertension nor ischaemic heart disease in the absence of acute 
myocardial infarction increased the risk of mortality following adjustment. This 
may be explained as the recognition of these common and well-established risk 
factors allows treatment and therefore risk reduction compared to the 
comparator group where unchecked risk may be a feature. 
Age standardised mortality for those with ACHD was dramatically higher than the 
general population. Deaths were observed at a rate of more than five times what 
would be expected from the population mean throughout the data period. 
Although this clearly represents excess mortality amongst those with ACHD, the 
true SMR may be slightly less. As the SMRs are based on mortality observed 
during a single year of follow up from the point that an individual is first 
recognised to the data set, there may be a bias towards an excess risk of 
mortality. This results from inclusion to the data set most commonly occurring 
as a result of a hospital admission, an inherently ‘risky’ point in time. What is 
clear however is that the age standardised mortality ratio decreased in the 
second half of the data period. This is reflected by a statistically significant 
reduction in robustly adjusted mortality hazard  for those presenting in more 
contemporaneous time periods. This is a finding echoed in prior studies (51) 
however the magnitude of improvement we demonstrated is even greater, likely 
due at least in part to our longer follow up period and therefore greater time 
differential from the start to the end of follow up.  
Socioeconomic deprivation was not only disproportionately high amongst our 
study population but was associated with a significantly increased mortality risk. 
This will be explored in detail in subsequent Chapters. 
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5.4.3 Cause of death 
Ischaemic heart disease was the most common cause of death in the study 
population and was significantly more common than for the general population. 
Acute coronary syndrome has previously been demonstrated to be increased in 
the CHD population (136,137). There has been some speculation as to causality 
in the previously published literature, however mechanisms remain speculative. 
Previous epidemiological studies have suggested higher rates of hypertensions 
and diabetes amongst ACHD patients as a potential contributor (138). Other 
feasible physiological mechanisms may include cyanosis increasing the 
vulnerability of the myocardium despite compensatory mechanisms, and higher 
rates of atrial arrhythmia and the presence of shunts increasing the possibility of 
coronary embolic events.  
The best-established association between CHD and IHD stems from the increased 
risk with aortic coarctation (139), although more contemporary evidence has 
questioned the direct causal relationship. Roifman et al(140) state that the 
increased risk is nullified when traditional risk factors, particularly hypertension, 
are adjusted for. Irrespective of the mode of association there is agreement in 
the literature that this population suffer disproportionately with IHD. Indeed, 
this was one of the lesions where IHD death was most highly represented in our 
cohort. What is less easily explained is the exceptionally high frequency of IHD 
deaths among the VSD cohort. An increased rate of IHD in the VSD population has 
previously been noted (136) but a relative abundance compared with aortic 
lesions is contrary to published literature (140). It must be considered that an 
error of diagnostic coding at source may be responsible for a proportion of this 
excess. Ventricular septal defects are a well-recognised and frequently fatal 
consequence of myocardial infarction. As such it is feasible that a proportion of 
deaths due to ischaemic heart disease where non-congenital VSD was a feature 
were incorrectly coded as Q21.0 (congenital ventricular septal defect) rather 
than the correct code, I23.2 (ventricular septal defect complicating a myocardial 
infarction). It is also noted that the median age of inclusion to the data set for 
those with VSD who died due to IHD was 71.5 (IQR 64-76.5) and for those who 
died of non IHD causes the age at first inclusion to the data was 57 (IQR 35-71.5) 
p<0.01.This would suggest two heterogenous groups. Also, during the first half of 
the data period, 55.0% of deaths in those with VSD were due to IHD, however 
134 
 
during the second half of the data period only 30.8% were due to IHD. It could be 
suggested that this represents a general decline in population deaths associated 
with ischaemic VSDs as a result of more widespread availability of primary 
percutaneous coronary intervention in more recent years (141), further 
suggesting a coding discrepancy as at least part of the reason for the 
unexpectedly hight rate of IHD deaths in those with VSD. 
Although IHD is the overall predominant cause of death, for lesions of greater 
complexity (Fontan, systemic RV, TOF, Ebstein’s anomaly and ‘complex’), death 
directly attributed to congenital heart disease was clearly predominant (Figure 
5-8). The specific mode of death amongst these patients cannot be further 
determined due to the epidemiological and anonymised nature of the study. 
Previous non-population studies which have allowed for case note review to 
further determine cause of death in circumstances such as this have determined 
heart failure and sudden cardiac death to predominate when death as a result of 
congenital heart disease is documented (50,75). 
Cause of death among less complex lesions such as ASD and PDA more closely 
mirror those of the general population (Figure 5-8) where, for instance, 
malignancy represents a larger proportion. Age at death in these lesions is also 
higher and it is logical that cause of death is less influenced by the underlying 
congenital defect. 
Interestingly, the congenital lesion which expressed the highest proportion of 
deaths related to infection was the valvular cohort at 9.0%, which is also more 
than in the general population (5.6%). Valvular congenital heart disease has been 
shown previously to confer a particularly high risk of infective endocarditis 
(142,143) which likely outstrips other forms of CHD; even when prosthetic 
material is used for surgical repair (142). It is therefore expected that a 
proportion of the excess of infectious deaths in this cohort will be related to 
infective endocarditis. 
Although CV death predominates over the course of the entire study period this 
is significantly reduced in more contemporary analyses. The rate of reduction in 
cardiovascular deaths in the study population outstrips that of the general 
population. Although trends in cardiovascular deaths have not previously been 
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reported in the published literature, time point estimates in the proportion of 
cardiovascular deaths appears similar to previous studies (Section 2.3.3). For 
instance Diller et al (50) reported 63.5% of deaths by CV causes at a study mid-
point of 2002 in an English cohort, this is compared with 59.4% during the 
corresponding time cohort in my analyses. 
CHD was identified from death records in 198 individuals (4.5% of all deaths). 
Although it is likely that some of these individuals were known to have CHD, 
having simply not generated an in-patient episode during the data period, 
sudden death in CHD remains of significant importance and has previously been 
implicated in as many as 20% of cases (144). The frequency by which CHD 
presents post-mortem in adulthood is not established. In one study of 182 post-
mortem examinations resulting from sudden death at 35 years or less, 12.1% had 
previously unknown CHD, more than half of which were coronary anomalies and 
the majority of the remainder were anomalies of the aortic valve (145). This 
appears to be in line with our findings. Although only 4% of the total number of 
CHD deaths in this document occurred without an SMR01 record, a 
disproportionate number were due to valvular CHD (representing 8.4% of the 
total valvular CHD deaths), or ‘other’ CHD lesions (representing 13.2% of the 
total mortality) amongst which coronary anomalies were prominent.  
Median age at death was drastically lower amongst this patient cohort when 
compared to those with SMR01 records (median 52.5 and 74 years respectively). 
This was consistent across all CHD subtypes including when valvular and coronary 
anomalies were implicated. This would suggest that sudden, premature death 
amongst previously unidentified CHD lesions, particularly of valvular and 
coronary aetiologies are noteworthy and may merit further study. 
The proportion of cardiovascular deaths decreased throughout the data period. 
Although the proportion of cardiovascular deaths also decrease in the general 
population over the same time period, the rate of change observed for the study 
population is greater. This important observation is additive to the finding of 
improved survival which we have demonstrated for the ACHD patients of 
Scotland. Not only are patients living longer but the progressive convergence of 
cause of death with that of the general population would suggest a more 
generalised homogenisation. This is likely to reflect more holistic improvements 
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in care, monitoring, and support than with survival benefit alone, which has thus 
far been primarily attributed to surgical advances. 
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6 Survival and causes of death according to sex 
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6.1 Introduction 
It has long been established that sex plays an important role in non-congenital 
cardiovascular disease. Over recent decades temporal shifts in the sex 
distribution of deaths attributable to cardiovascular disease have been reported 
(most extensively for the US population). In general, women have fared poorly 
compared to men who have seen a gradual decline in deaths due to 
cardiovascular disease since the early 1980s. Similar improvements were not 
seen for women until around the year 2000. Since this time however, 
improvements for women appear to be dramatic and have fallen into line with 
those seen for men (Figure 6-1) (61). 
 
Figure 6-1: Cardiovascular deaths in the US population adapted from data reported by the 
American Heart Association (61). 
 
Despite the well-established differences in outcomes for men and women with 
non-congenital cardiovascular disease and the obviously important role that sex 
plays in the prevalence of underlying congenital defects, as touched on in the 
preceding literature review and results Chapter; the paucity of published 
literature dedicated to examining sex and mortality in congenital heart disease 
is striking.  
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Historically, the sex differences in outcomes for men and women with congenital 
heart disease have been documented according to clinical experience and expert 
consensus. A published lecture by Prof Jane Somerville was the first to 
concentrate specifically on the gender differences in outcomes for ACHD 
patients. Although sparse in the available data at the time, a higher incidence 
and mortality associated with Eisenmenger’s syndrome and a reduced mortality 
associated with aortic valve disorders among women was proposed (146). 
In more recent years three articles from prominent research groups have 
examined sex and outcomes among adults with congenital heart disease, 
however mortality findings have been contradictory; Oliver et al suggests excess 
mortality among women in their large, single centre study (147); Engelfriet et al 
found that men experienced greater mortality in their examination of the 
multinational European Heart Survey database (62); and Verheugt et al 
demonstrated no statistically significant difference in mortality for men and 
women via the Dutch national CONCOR registry (63). It seems reasonable to 
state with some confidence that the relationship between sex and mortality in 
adults with congenital heart disease has not yet been well-established.  
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6.2 Results 
6.2.1 Baseline demographics according to sex 
Of the 16,210 individuals identified between 1986 and 2015, more were female 
(50.9%) than male (49.2%), p=0.03. Throughout the entire data period the mean 
adult population of Scotland was 1,982,089 men and 2,186,207 women. 
Therefore, adjusted for the general population distribution males with ACHD 
represent 4.02 per 1000 population, compared with 3.77 per 1000 amongst 
women. The distribution of baseline characteristics according to sex are 
summarised in Table 6-1. Women were older at first inclusion into the data set 
(40.6, SD 24.4 compared with 36.7, SD 22.2, p<0.01). 
Regarding comorbidity, more men than women were diagnosed with diabetes 
(4.1% and 3.4% respectively), p=0.01. Ischaemic heart disease without 
myocardial infarction was also significantly more common in men than women 
(11.4% and 8.7% respectively), p<0.01. Cancer (male 2.6%, female 2.4%, p=0.55), 
AF (male 9.8%, female 10.0%, p=0.62), CVD (male 5.6%, female 5.9%, p=0.36) 
AMI (male 5.8%, female 5.3%, p=0.16) and hypertension (male 5.7%, female 6.0%, 
p=0.35) were equally represented in the male and female cohorts. 
A significantly higher proportion of women than men reside in areas of high-level 
socioeconomic deprivation. A breakdown of sex distribution according to SIMD 
quintile is provided in Table 6-1 and is graphically illustrated by Figure 6-2. 
Figure 6-3 shows the absolute percentage of each sex residing within postcode 
sectors of each SIMD quintile. In total 43.4% of men reside in the top half (more 
affluent) of SIMD sectors compared with only 40.2% of women (p<0.01). 
The distribution of underlying congenital lesions according to sex has been 
touched on in the previous Chapter. Briefly, a statistically significant male 
predisposition is observed for; aortic lesions (52.3%, p<0.01), TOF (58.0%, 
p<0.01), systemic RV (66.9%, p<0.01), valvular lesions (58.3%, p<0.01) and 
Fontan circulations (59.9%, p<0.01). A significant female predisposition exists 
for; ASD (57.5%, p<0.01), PDA (62.2%, p<0.01) and AVSD (55.2%, p=0.03). 
Ebstein’s anomaly (female 60%, male 40%, p=0.06), TGA arterial switch (female 
42.9%, male 57.1%, p=0.34), VSD (female 50.4%, male 49.6% p=0.65) and 
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complex but not otherwise classified (female 49.7%, male 50.4%, p=0.80) lesions 
are not significantly different between sex. 
Table 6-1: Baseline characteristics and demographics according to sex Percentages for all 
patients are given as column percentages. Male and female percentages refer to row percentages 
i.e. male:female proportion. P values refers to the male:female proportion. 
 
 
Column1 All (%) Male (%) Female (%) p value
All 16210 7968 (49.2) 8242 (50.9) 0.03
Age at entry, 
mean (SD) 39.1 (23.5) 36.7 (22.2) 40.6 (24.4) <0.01
SIMD quintile
1-most 4355 (27.1) 2031 (46.6) 2324 (53.4) <0.01
2 3441 (21.5) 1648 (47.9) 1793 (52.1) 0.10
3 2997 (18.7) 1506 (50.3) 1491 (49.8) 0.18
4 2736 (17.1) 1410 (51.5) 1326 (48.5) 0.01
5-least 2516 (15.7) 1281 (50.9) 1235 (49.1) 0.06
Comorbidity
Diabetes 606 (3.7) 328 (54.1) 278 (45.9) 0.01
Cancer 401 (2.5) 203 (50.6) 198 (49.4) 0.55
AF 1608 (9.9) 781 (48.6) 827 (51.4) 0.62
CVD 931 (5.7) 444 (47.7) 487 (52.3) 0.36
HTN 946 (5.8) 451 (47.7) 495 (52.3) 0.35
AMI 896 (5.5) 461 (51.5) 435 (48.6) 0.16
Other IHD 1619 (10.0) 906 (56.0) 713 (44.0) <0.01
Lesion
ASD 4172 (25.7) 1774 (42.5) 2398 (57.5) <0.01
PDA 983 (6.1) 372 (37.8) 611 (62.2) <0.01
VSD 2244 (13.8) 1113 (49.6) 1131 (50.4) 0.65
Aortic 2143 (13.2) 1120 (52.3) 1023 (47.7) <0.01
Ebstein's 105 (0.7) 42 (40.0) 63 (60.0) 0.06
AVSD 600 (3.7) 269 (44.8) 331 (55.2) 0.03
TOF 564 (3.5) 327 (58.0) 237 (42.0) <0.01
TGA switch 35 (0.2) 20 (57.1) 15 (42.9) 0.34
Systemic RV 133 (0.8) 89 (66.9) 44 (33.1) <0.01
Complex 1285 (7.9) 647 (50.4) 638 (49.7) 0.80
Fontan 167 (1.0) 100 (59.9) 67 (40.1) <0.01
Valvular 2163 (13.3) 1262 (58.3) 901 (41.7) <0.01
Other 1616 (10.0) 833 (51.6) 783 (48.5) 0.04
142 
 
 
Figure 6-2: Proportional distribution of male and female sex within each quintile of 
socioeconomic deprivation Percentages are given as proportional distribution of males and 
females within each quintile group i.e. total to 100% within each SIMD quintile. 
 
 
 
Figure 6-3: Proportional distribution of SIMD quintiles for male and female sex Percentages 
are given as absolute proportion of each sex in the quintile group i.e. total to 100% within each sex 
category 
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6.2.2 Follow up, mortality and age at death according to sex 
6.2.2.1 Observed mortality and age at death 
A higher proportion of women than men died during follow up (27.2% and 24.2%, 
p<0.01). Table 6-2 compares those individuals who survived and those who died 
during the data period and compares males and females.  
Women who died during the data period were significantly older at inclusion into 
the data set than men who died (65.8, SD 19.5 and 57.7, SD 20.9 years, p<0.01).  
For each recorded comorbidity a higher proportion of women died than men. 
This achieved statistical significance for all except cancer and cerebrovascular 
disease. A particular excess of female death was noted when AMI was diagnosed 
(73.6% compared with 58.1% for men, p<0.01), ischaemic heart disease without 
acute myocardial infarction was present (53.9% compared with 43.3% for men, 
p<0.01), when AF was diagnosed (60.7% compared with 48.4%, p<0.01), or if 
hypertension was coexistent with ACHD (47.5% compared with 30.8%, p<0.01). 
The relative distribution of socioeconomic deprivation between men and women 
is described above. A higher proportion of women than men died in each SIMD 
quintile and the magnitude of difference was relatively consistent across the 
quintile groups, achieving statistical significance in only the second most deprive 
(SIMD 2) quintile (30.1% females died compared with 26.2% of men, p=0.01). 
The distribution of deaths by sex according to underlying lesion is also 
summarised in Table 6-2. A greater proportion of women than men with aortic 
lesions died during follow up (62.0% and 43.9%, p<0.01). This was also true for 
valvular lesions (33.7% and 20.7%, p<0.01) and the combined cohort of ‘other’ 
CHD (31.6% and 25.5%, p=0.01).   
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Table 6-2: Comparison of baseline characteristics according to sex for those who survived 
and those who died during the data period.  p values refer to comparison of percentages of 
deaths between men and women 
 
  
Alive (%) Dead (%) Alive (%) Dead (%) p value
All 6044 (75.9) 1924 (24.2) 6004 (72.3) 2238 (27.2) <0.01
Age at entry, 
mean (SD) 30.4 (18.4) 57.7 (20.9) 31.2 (18.7) 65.8 (19.5) <0.01
SIMD quintile
1-most 1520 (74.8) 511 (25.2) 1695 (72.9) 629 (27.1) 0.15
2 1220 (74.0) 428 (26.2) 1254 (69.9) 539 (30.1) 0.01
3 1137 (75.5) 369 (24.5) 1085 (72.8) 406 (27.2) 0.09
4 1084 (76.9) 326 (23.1) 982 (74.1) 344 (25.9) 0.09
5-least 1013 (79.1) 268 (20.9) 937 (75.9) 298 (24.1) 0.05
Comorbidity
Diabetes 151 (46.0) 177 (54.0) 99 (35.6) 179 (64.4) 0.01
Cancer 58 (28.6) 145 (71.4) 50 (25.3) 148 (74.8) 0.45
AF 403 (51.6) 378 (48.4) 325 (39.3) 502 (60.7) <0.01
CVD 298 (67.1) 146 (32.9) 315 (64.7) 172 (35.3) 0.61
HTN 312 (69.2) 139 (30.8) 260 (52.5) 235 (47.5) <0.01
AMI 193 (41.9) 268 (58.1) 115 (26.4) 320 (73.6) <0.01
Other IHD 514 (56.7) 392 (43.3) 329 (46.1) 384 (53.9) <0.01
Lesion
ASD 1436 (81.0) 338 (19.1) 1929 (80.4) 469 (19.6) 0.68
PDA 345 (92.7) 27 (7.3) 582 (95.3) 29 (4.8) 0.10
VSD 784 (70.4) 329 (29.6) 800 (70.7) 331 (29.3) 0.88
Aortic 628 (56.1) 492 (43.9) 389 (38.0) 634 (62.0) <0.01
Ebstein's 26 (61.9) 16 (38.1) 45 (71.4) 18 (28.6) 0.31
AVSD 211 (78.4) 58 (21.6) 280 (84.6) 51 (15.4) 0.05
TOF 287 (87.8) 40 (12.2) 208 (87.8) 29 (12.2) 1.00
TGA switch 20 (100) - 15 (100) - -
Systemic RV 77 (86.5) 12 (13.5) 38 (86.4) 6 (13.6) 0.98
Complex 518 (80.1) 129 (19.9) 524 (82.1) 114 (17.9) 0.34
Fontan 90 (90.0) 10 (10.0) 61 (91.0) 6 (9.0) 0.82
Valvular 1001 (79.3) 261 (20.7) 597 (66.3) 304 (33.7) <0.01
Other 621 (74.6) 212 (25.5) 536 (68.5) 247 (31.6) 0.01
Male Female
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Table 6-3 summarizes follow up, crude mortality rates and age at death 
according to sex and as subdivided by lesion complexity and socioeconomic 
deprivation.  
Overall cumulative follow up was slightly higher for women (85,850 years) than 
men (82,327 years). This is accounted for by those with simple lesions. For 
lesions of moderate and great complexity males accumulated more follow up. 
Crude mortality rate was higher for women (26.1 deaths per 1000 person years) 
than men (23.4 deaths per 1000 person years). When compared by lesion 
complexity; simple and complex lesions demonstrate similar mortality rates 
according to sex, however lesions of moderate complexity have a higher 
mortality rate for women (37.4 deaths per 1000 person years) than men (25.2 
deaths per 1000 person years). Mortality rates for women were slightly higher 
than for men across all SIMD quintiles. 
Mean age at death was higher for women than men (71.5, SD 18.0 and 64.2, SD 
19.7 years, p<0.01). A statistically significant increased age at death for females 
was maintained across all lesion complexities and socioeconomic groups (Table 
6-3). 
Figure 6-4 and Figure 6-5 illustrate the mean age at death for men and women 
during the first and second half of the data period. The point estimate of mean 
age at death increased for both sexes and all degrees of lesion complexity from 
the first to the second half of the data period. For all men, the mean age at 
death increased from 61.8 (SD 20.2) to 65.2 (SD 19.3) years, p<0.01. For men 
with simple lesions, age increased from 60.7 (SD 17.6) to 65.7 (SD 17.4) years, 
p<0.01. For men with moderately complex lesions there was a non-statistically 
significant increase from 62.6 (SD 21.4) to 66.5 (SD 19.9), 0.08. The increase in 
age at death for men with lesions of great complexity was however highly 
statistically significant (32.8, SD 21.8 years to 47.1, SD 23.5 years, p=0.01). 
For women, the mean age at death increased from 71.0 (SD 17.3) to 71.8 (SD 
18.3) during the first and second half of the data period but this was not 
statistically significant, p=0.32. For women with simple lesions mean age at 
death increased from 67.3 (SD 14.9) to 70.6 (SD 17.6) years, p=0.01. No 
significant increase was seen for women with moderately complex lesions (74.6, 
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SD 18.1 to 75.8, SD 17.7 years, p=0.51) or lesions of great complexity (46.6, SD 
22.0 to 54.4, SD 20.3, p=0.11) despite demonstrating the greatest absolute 
increase in point estimate, this is bearing in mind the relatively lower number of 
women with complex lesions demonstrated in the data set. 
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Table 6-3: Follow up and age at death according to sex 
P value corresponds to the comparison of age at death 
 
  
N
Follow 
up 
(years)
Mortality rate 
per 1000 years 
(95%CI)
Mean age 
at death 
(SD) N
Follow 
up 
(years)
Mortality rate 
per 1000 years 
(95% CI)
Mean age 
at death 
(SD) p value
All 7968 (49.2) 82327 23.4 (22.3-24.4) 64.2 (19.7) 8242 (50.9) 85850 26.1 (25.0-27.2) 71.5 (18.0) <0.01
Lesion 
complexity
Simple 3841 (47.3) 39046 18.8 (17.5-20.2) 64.3 (17.6) 4280 (52.7) 46301 17.2 (16.0-18.4) 69.5 (16.9) <0.01
Moderate 1799 (51.0) 19061 25.2 (23.1-27.6) 65.6 (20.3) 1730 (49.0) 17204 37.4 (34.6-40.4) 75.6 (17.8) <0.01
Complex 695 (52.5) 7734 14.6 (12.2-17.6) 43.9 (23.8) 629 (47.5) 7146 15.2 (12.7-18.4) 52.5 (20.9) <0.01
SIMD quintile
1-most 2031 (46.6) 21549 23.7 (21.7-25.9) 61.5 (19.0) 2324 (53.4) 24515 25.7 (23.7-27.7) 68.8 (18.0) <0.01
2 1648 (47.9) 16680 25.7 (23.3-28.2) 63.5 (20.2) 1793 (52.1) 18522 29.1 (26.7-31.7) 71.6 (18.2) <0.01
3 1506 (50.3) 15356 24.0 (21.7-26.6) 64.7 (20.0) 1491 (49.8) 15235 26.6 (24.2-29.4) 71.9 (17.6) <0.01
4 1410 (51.5) 14089 23.1 (20.8-25.8) 67.2 (19.1) 1326 (48.5) 13952 24.7 (22.2-27.4) 74.1 (16.9) <0.01
5-least 1281 (50.9) 13512 19.8 (17.6-22.4) 66.6 (19.4) 1235 (49.1) 12722 23.4 (20.9-26.2) 73.9 (18.0) <0.01
Male Female
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Figure 6-4: Mean age at death during the first and second half of the data period for all men 
and according to lesion complexity. Significance level for each change provided  
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Figure 6-5: Mean age at death during the first and second half of the data period for all 
women and according to lesion complexity. Significance level for each change provided. 
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6.2.2.2 Survival according to sex 
The Kaplan Meier survival estimates for men and women during the data period 
are illustrated by Figure 6-6. Unadjusted binary risk of death was significantly 
lower for men than women when all lesions are included (OR 0.85, 95% CI 0.80 - 
0.92 p<0.01). For simple and complex lesions there is no significant difference in 
risk for all-cause mortality (OR 1.04, 95% CI 0.92 – 1.16, p=0.54 and 0.97, 95% CI 
0.72 – 1.30, p=0.83 respectively). For moderately complex lesions there was a 
highly statistically significant lower risk of death for men compared to women 
(OR 0.62, 95% CI 0.53-0.71, p<0.01).
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Figure 6-6: Unadjusted Kaplan Meier survival estimates for men and women during the data period  
A: All CHD. B: Simple CHD. C: Moderately complex CHD. D: Complex CHD 
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Figure 6-7 compares the adjusted hazard for all-cause, cardiovascular and non-
cardiovascular mortality as conferred by sex. Estimates are adjusted for; age, 
underlying congenital lesion, comorbidity (diabetes, cancer, atrial fibrillation, 
acute myocardial infarction, cerebrovascular disease and ischaemic heart 
disease without acute myocardial infarction and hypertension), year of 
presentation and socioeconomic grouping (as summarized in Table 6-4). 
Male sex confers an increased risk of all-cause mortality (HR 1.12, 95% CI 1.05 – 
1.19, p<0.01) and non-CV mortality (HR 1.19, 95% CI 1.08 – 1.30, p<0.01). No 
significant difference in risk of CV mortality was conferred by sex (male; HR 
1.07, 95% CI 0.98 – 1.16, p=0.07). 
 
Figure 6-7: Adjusted hazard for all-cause, cardiovascular and non-cardiovascular mortality 
according to sex 
 
Table 6-4 summarizes the contribution of risk conferred by baseline 
characteristics, underlying CHD lesion, year of presentation and socioeconomic 
grouping for all patients, and for men and women. A similar pattern of risk is 
seen for age and comorbidity for both men and women. Diabetes, cancer, atrial 
fibrillation and AMI increase the risk of all-cause mortality in both men and 
women and to a similar degree. Point estimates of risk are higher for men in 
relation to diabetes, cancer and AF but male and female confidence intervals 
overlap on all accounts. Point estimate for risk related to AMI is higher for 
women but again confidence intervals overlap. No significant increase in risk for 
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all-cause mortality was seen for CVD, HTN or ischaemic heart disease without 
AMI for men or women.  
The risk associated with underlying CHD lesion again follows a similar pattern for 
men and women. The risk of Fontan circulation appears to be higher for women 
(HR 3.11, 95% CI 1.34 – 7.01, p=0.01) than men (HR 1.76, 95% CI 0.94 – 3.33, 
p=0.08) but confidence intervals are wide and overlapping. 
Male and female mortality hazard according to socioeconomic group is 
illustrated in Figure 6-8. A significant reduction in risk is noted for men and 
women in higher socioeconomic quintiles. The magnitude of risk reduction 
appears greater for men than women with men in SIMD 5 having a 38% lower 
instantaneous risk of all-cause mortality and women a 29% lower risk relative to 
those in SIMD 1 although this difference does not achieve statistical significance. 
  
Figure 6-8: Adjusted hazard of all-cause mortality by socioeconomic grouping for men and 
women 
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Table 6-4: Adjusted hazard ratios according to baseline characteristics, year of presentation 
and socioeconomic status for all, men and women 
 
  
Column1 All Male Female
Age 1.07 [1.06-1.07] (<0.01) 1.06 [1.06-1.07] (<0.01) 1.07 [1.07-1.07] (<0.01)
Year of Presentation
1986-1990 1 1 1
1991-1995 0.86 [0.78-0.95] (<0.01) 0.88 [0.76-1.01] (0.08) 0.85 [0.74-0.97] (0.02)
1996-2000 0.72 [0.65-0.80] (<0.01) 0.71 [0.61-0.82] (<0.01) 0.74 [0.64-0.86] (<0.01)
2001-2005 0.55 [0.49-0.62] (<0.01) 0.53 [0.44-0.63] (<0.01) 0.57 [0.49-0.67] (<0.01)
2006-2010 0.46 [0.41-0.52] (<0.01) 0.43 [0.36-0.51] (<0.01) 0.49 [0.42-0.58] (<0.01)
2011-2015 0.35 [0.31-0.41] (<0.01) 0.34 [0.28-0.42] (<0.01) 0.36 [0.30-0.44] (<0.01)
Comorbidity
Diabetes 1.72 [1.54-1.93] (<0.01) 1.78 [1.52-2.09] (<0.01) 1.67 [1.42-1.94] (<0.01)
Cancer 1.81 [1.60-2.04] (<0.01) 1.91 [1.60-2.29] (<0.01) 1.77 [1.49-2.10] (<0.01)
AF 1.24 [1.15-1.35] (<0.01) 1.29 [1.14-1.45] (<0.01) 1.20 [1.08-1.34] (<0.01)
CVD 1.09 [0.97-1.23] (0.14) 1.07 [0.90-1.27] (0.45) 1.11 [0.95-1.31] (0.18)
HTN 0.95 [0.85-1.06] (0.34) 0.93 [0.77-1.11] (0.40) 0.96 [0.83-1.10] (0.54)
AMI 1.39 [1.26-1.53] (<0.01) 1.36 [1.18-1.56] (<0.01) 1.42 [1.25-1.62] (<0.01)
Other IHD 0.94 [0.87-1.02] (0.16) 0.91 [0.80-1.02] (0.10) 0.96 [0.86-1.08] (0.49)
Lesion
ASD 1 1 1
PDA 0.86 [0.65-1.14] (0.31) 1.19 [0.79-1.78] (0.41) 0.73 [0.50-1.07] (0.11)
VSD 2.01 [1.80-2.24] (<0.01) 1.97 [1.67-2.31] (<0.01) 2.00 [1.71-2.32] (<0.01)
Aortic 1.41 [1.28-1.56] (<0.01) 1.36 [1.17-1.59] (<0.01) 1.38 [1.21-1.58] (<0.01)
Ebstein's 2.46 [1.74-3.47] (<0.01) 2.39 [1.45-3.97] (<0.01) 2.58 [1.60-4.14] (<0.01)
AVSD 1.52 [1.24-1.86] (<0.01) 1.56 [1.17-2.07] (<0.01) 1.42 [1.05-1.90] (0.02)
TOF 1.98 [1.54-2.55] (<0.01) 1.72 [1.23-2.43] (<0.01) 2.20 [1.50-3.23] (<0.01)
Complex 1.77 [1.53-2.05] (<0.01) 1.69 [1.37-2.07] (<0.01) 1.78 [1.44-2.19] (<0.01)
Fontan 2.25 [1.37-3.71] (<0.01) 1.76 [0.94-3.33] (0.08) 3.11 [1.34-7.01] (0.01)
Valvular 1.29 [1.15-1.44] (<0.01) 1.20 [1.01-1.42] (0.03) 1.32 [1.13-1.53] (<0.01)
Other 1.39 [1.15-1.44] (<0.01) 1.18 [0.99-1.40] (0.07) 1.57 [1.34-1.84] (<0.01)
SIMD Quintile
1 - most deprived 1 1 1
2 0.91 [0.84-0.99] (0.03) 0.95 [0.84-1.09] (0.50) 0.88 [0.78-0.99] (0.03)
3 0.87 [0.80-0.96] (<0.01) 0.85 [0.74-0.97] (0.02) 0.89 [0.79-1.01] (0.08)
4 0.77 [0.70-0.84] (<0.01) 0.73 [0.63-0.84] (<0.01) 0.80 [0.70-0.91] (<0.01)
5 - least deprived 0.67 [0.61-0.75] (<0.01) 0.62 [0.54-0.72] (<0.01) 0.71 [0.62-0.82] (<0.01)
HR [95% CI] (p value)
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6.2.3 Cause of death according to sex 
As in the preceding Chapter, causes of death are grouped into seven categories 
(as a result of CHD, ischaemic heart disease, peripheral and cerebrovascular 
disease, other cardiac disease, infection, malignancy, respiratory) as well as 
‘other’ causes.  In total 74% of deaths in the male general population and 81% of 
deaths in the male study population were by one of these seven specific 
categories, and 68% of deaths in the female general population and 81% of 
deaths in the female study population fell into these categories. Cause of death 
according to congenital lesion is summarized for men in Figure 6-9 and for 
women in Figure 6-10. 
Over the duration of the study period 55.6% of female deaths and 53.0% of male 
deaths were due to cardiovascular causes (p=0.10). CV death was more common 
among men with CHD (53.0%) than the male general population (38.8%), p<0.01. 
This was also true for women (55.6%) compared with the general population 
(39.5%), p<0.01. 
Malignancy was the most common cause of death in the general population for 
men (30.6%) and women (26.9%). In the study population malignancy accounted 
for significantly fewer deaths in both men (15.3%, p<0.01) and women (11.8%, 
p<0.01), being significantly more common in men, p<0.01. 
Among the study cohort, ischaemic heart disease was the most common cause of 
death for both men (25.6%) and women (22.8%), being significantly more 
common for men, p=0.04. This was also significantly higher than for the male 
(14.2%, p<0.01) and female (9.6%, p<0.01) general population.  
For lesions of greater complexity (systemic RV, Fontan, Ebstein’s anomaly, TOF 
and ‘complex’), death attributed to CHD predominates for both men and 
women.  
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Figure 6-9: Men - cause of death according to underlying congenital lesion as well as for all 
patients and compared to the general population 
 
Figure 6-10: Women - cause of death according to underlying congenital lesion as well as 
for all patients and compared to the general population 
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6.2.4 Changing causes of death over time, according to sex 
The changing proportion of cardiovascular and non-cardiovascular deaths 
throughout the data period are summarized in Figure 6-11 for men and Figure 
6-12 for women. 
In the earliest data period (1986-1990), 68.1% of men and 77.3% of women died 
due to cardiovascular causes (p=0.10). By the most contemporary data period 
(2016-2017), 39.5% of men and 40.0% of women died by cardiovascular causes 
(p=0.93). 
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Figure 6-11: Men - Changing proportion of cardiovascular and non-cardiovascular deaths 
over time and compared with men in the general population 
 
 
Figure 6-12: Women - Changing proportion of cardiovascular and non-cardiovascular 
deaths over time and compared to women in the general population 
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The proportion of deaths due to cardiovascular causes fell throughout the data 
period for men and women with CHD, and for men and women in the general 
population (Figure 6-13).  
From the beginning to the end of the data period, CV deaths in men decreased 
by 28% amongst those with ACHD compared with 21% for the general population, 
p<0.01. This constitutes a 0.93% per year decline for those with ACHD compared 
with 0.70% per year amongst the general population, p=0.38. 
A similar pattern was observed for women, where CV deaths amongst those with 
ACHD decreased by 37% over the total data period, compared with 24% for the 
general population, p<0.01. This equates to a mean yearly change of 1.23% per 
year for those with ACHD and 0.80% per year amongst the general population, 
p=0.89. 
 
Figure 6-13: Percentage of cardiovascular deaths over time; for men and women with CHD 
and for the general population 
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6.3 Discussion 
6.3.1 Differences in demographics and baseline characteristics 
between men and women 
A slight albeit statistically significant higher proportion of our data set were 
women (50.9%) than men (49.2%), p=0.03. It does not however follow that 
congenital heart disease is more prevalent amongst women. In fact, when 
indexed to the mean Scottish adult population throughout the study period, 4.02 
per 1000 men were included compared with 3.77 per 1000 women. Marelli et al 
have previously suggested that the higher proportion of women with CHD persists 
when indexed to population numbers (representing 4.55 and 3.61 per 1000 of the 
female and male population of Quebec respectively) (9). The likely explanation 
for the discrepancy in our findings is that Marelli et al include data from primary 
care and out-patients. As discussed previously, inclusion in our data is reliant on 
an in patient hospital episode. As such a bias away from milder CHD will be 
expected and it is in the milder CHD lesions (ASD, PDA, VSD) where women 
predominate. The female predisposition amongst lesions at the simpler end of 
the spectrum (Table 6-3) is also the likely reason why women are slightly but 
significantly older at presentation to our data set. 
The sex distribution of each lesion is discussed in the previous Chapter and is 
according to convention. Only the Fontan group presents a sex distribution 
distinct from that suggested by my prior literature review. Where we note a 
slight but significant male predominance, convention is towards an equal sex 
distribution.  
A significantly higher proportion of men than women in our data were found to 
have diabetes. However, of those with diabetes 54.1% were male and 45.9% 
female, which is entirely in line with the 54.5% male and 45.5% female UK 
population estimates (148). In contrast, where AF is more common in men of the 
general population (149) we found this to be mitigated in those with CHD where 
no difference was found. This stands to reason as CHD is established to be a  
major risk factor for AF, such that background variation may almost be 
negligible (150).  
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More women than men reside in postcodes conferring higher socioeconomic 
deprivation. 28.2% of women and 25.5% of men in our data set reside in SIMD 1, 
representing the quintile of most deprived postcodes in Scotland. By comparison, 
within the general population an equal proportion of men (19.4%) and women 
(19.7%) reside in postcodes corresponding to SIMD 1. This inequality is not 
therefore explained by background population levels and requires further study 
as to the reasons why.  
6.3.2 Differences in mortality and survival between men and 
women 
As illustrated by Table 6-2, more women than men died during the data period. 
As described above however, women were older and demographics are not 
evenly distributed between the sexes. In fact, age at death is significantly higher 
for women than men. This is true for the total cohort and across all complexities 
of lesions and socioeconomic groups (Table 6-3). Age at death however, 
increased more for men than women throughout the data period. As different 
lesions are not expressed uniformly throughout the data period this was also 
compared according to lesion complexity and remains true for all cohorts (Figure 
6-4 & Figure 6-5). In the general population of Scotland, the mean age at death 
for women in the mid 1980s was 6.2 years greater than for men, reducing to 4.1 
years by 2015. In our data set the discrepancy in age at death between men and 
women, was 8.2 years during the first half and 6.1 years by the second half of 
the data period. Therefore, the magnitude of difference in life expectancy 
between men and women is greater in our study than in the general population 
but the trend of a narrowing gap closely mirrors and is likely explained by 
population trends (151). 
Figure 6-6 illustrates the observed mortality throughout the data period for men 
and women. This, and the non-adjusted, binary regression for all-cause mortality 
would suggest that women have reduced survival, particularly for those with 
lesions of moderate complexity, compared with men. This is entirely mitigated 
by adjusting for age and when fully adjusted as in Figure 6-7 men clearly and 
significantly have reduced survival compared with women. Figure 6-7 also 
illustrates that this excess male mortality is accounted for by non-cardiovascular 
death. Indeed, when comparing the relative contribution of baseline 
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characteristics to survival in men and women, as in Table 6-4, acute myocardial 
infarction confers higher mortality in women than in men, which is also a 
commonly accepted paradigm amongst the general population (152).  
The impact of socioeconomic group on mortality will be explored in detail in the 
next Chapter. When comparing sex differences on the survival of different 
socioeconomic groups; not only do women experience higher levels of 
socioeconomic deprivation but the survival benefit of affluence is seen to a 
lesser extent for women than for men (Figure 6-8). The interaction of sex and 
socioeconomic factors has never been studied in the accessible literature 
regarding ACHD previously and to try to explain this observation would be 
conjecture. Clearly, further study is required. 
The introduction to this Chapter referred to three articles assessing the effect of 
sex on mortality in congenital heart disease (62,63,73). All three articles 
controlled estimates of survival for age only. Although the model used in this 
Chapter is designed to control more intricately for biases in the data set, a 
sensitivity analysis controlling for age only does not alter the principal finding of 
statistically significant excess mortality for men when compared with women, as 
was the finding of Engelfriet & Mulder using European Heart Survey data (62).  
6.3.3 Differences in cause of death for men and women 
Patterns of cause of death are broadly similar for men and women with CHD. In 
both cases cardiovascular death predominates overall and is significantly more 
common than for the comparable group in the general population. Ischaemic 
heart disease was the most common single cause of death for both men and 
women and again was more common than in population deaths. 
When comparing changes over time, earlier data periods saw a higher proportion 
of death by cardiovascular causes amongst women than men, falling to similar 
levels in contemporary analysis. As such, the overall tendency towards 
homogenisation with population levels of cardiovascular and non-cardiovascular 
deaths highlighted in the preceding Chapter is disproportionately contributed to 
by the early decline in CV death noted for women with CHD.  
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6.4 Conclusions 
According to our data, more women than men have CHD. However, after 
adjusting for the greater adult female population in Scotland, CHD is slightly 
more prevalent in men than women. 
Age at death is higher for women with CHD than men and the life expectancy 
gap is greater than in the general population. Age at death is increasing over 
time for men and women with CHD and the gap is closing at a similar rate as in 
the general population. 
Adjusted survival estimates suggest a higher mortality for men compared to 
women with CHD. This is predominately as a result of increased non-
cardiovascular mortality in men. 
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7 Socioeconomic status and the association with 
mortality in adults with CHD 
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7.1 Introduction 
The concept of socioeconomic grouping is complex and variable both between 
and within different societies and cultures. I refer to socioeconomic deprivation 
although many other terms such as ‘social class’ or ‘socioeconomic group’ are 
referred to within the vast literature. 
On an individual basis, the variables of level of education, occupation, and the 
closely associated income are the most commonly accepted determinants of 
socioeconomic deprivation. For the purposes of population level analysis, using a 
postcode derived measure of socioeconomic deprivation has the obvious 
advantages of allowing largescale grouping and comparison to allow correlation 
of measures. The component metrics incorporated into postcode or area 
determined measures of socioeconomic deprivation are again variable from 
country to country. In Scotland the most widely accepted and intricate measure 
of postcode determined socioeconomic deprivation is the SIMD. Recognising the 
complexity of quantifying socioeconomic deprivation, this measure uses 38 
separate indicators to rank 6,505 small areas or ‘datazones’ each with roughly 
760 residents of the Scottish population from 1 (most deprived) to 6,505 (least 
deprived). The 38 indicators are derived from 7 domains: 
• Income 
• Employment 
• Health 
• Education 
• Skills and training  
• Housing 
• Crime 
 
This ranking can then be used individually or grouped into equal, relative 
measures of socioeconomic deprivation within the Scottish population (such as 
deciles, quintiles or vigintile).  
Socioeconomic deprivation is closely linked to health inequality and as such is 
known to predispose to excess mortality (153) and excess cardiovascular 
mortality (154). The NHS was founded on 3 guiding principles with the primary 
aim of negating inequalities in health. That it should; 1 – meet the needs of 
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everyone, 2 – be free at the point of delivery, and 3 – be based on need and not 
the ability to pay. In spite of this, evidence would suggest that health inequality 
continued to widen from the inception of the NHS in 1948 until at least the end 
of the 20th century (153,155). 
Despite the extensive literature and political debate regarding socioeconomic 
deprivation and health inequality in the UK, this has received very little 
attention in the research surrounding congenital heart disease. A small number 
of studies have looked at the relative birth prevalence of congenital heart 
disease according to socioeconomic deprivation (156,157). However, the 
socioeconomic effect on outcomes including mortality in adults with congenital 
heart disease have never been assessed.  
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7.2 Methods 
In addition to the common methodology as set out in section 4, further efforts 
have been made within this Chapter to ensure the robustness of the 
categorisation of socioeconomic deprivation. 
As touched upon in section 4.3.4, two postcode markers of socioeconomic 
deprivation have been used at a population level in Scotland. SIMD is now the 
most commonly encountered and highly nuanced measure. Predating SIMD, the 
Carstairs-Morris index uses four domains to determine socioeconomic deprivation 
(Table 4-5). In contrast to the SIMD, none of the determinants of the Carstairs-
Morris index are directly derived from health data. As a result, I have included 
key results in this Chapter as determined both by SIMD and Carstairs-Morris. This 
was by way of mitigating the potential bias of poorer health outcomes associated 
with SIMD being attributed to the determinants of SIMD itself. The most up-to-
date iteration of Carstairs-Morris derived postcode boundaries of 2011 was used. 
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7.3 Results 
7.3.1 Baseline characteristics according to socioeconomic 
deprivation 
An area grouping of socioeconomic deprivation could be established for 16,045 
(99.0%) of the total study population. The baseline characteristics and 
demographics of individuals resident in each datazone SIMD quintile are 
summarized in Table 7-1. ACHD was not evenly distributed across the SIMD 
quintiles (p<0.01 for correlation across all quintiles) with significantly more of 
the cohort residing in areas of highest deprivation (27.1% in SIMD 1) than lowest 
deprivation (15.7% in SIMD 5), p<0.01. This is also true when using the Carstairs-
Morris determinant, with 25.0% residing in the most deprived and 17.2% in the 
least deprived quintiles. 
Women with ACHD were more likely to reside in areas of high deprivation than 
men, with 28.2% of women in the study residing in SIMD 1 compared to 25.5% of 
men, p<0.01.  
In total 53.4% of the SIMD 1 study cohort were female, this is compared to 51.8% 
in the general population. 
Individuals from areas of higher socioeconomic deprivation were younger at first 
entry into the data set than those from areas of low socioeconomic deprivation. 
Median age at presentation was 29 (IQR 16-55) (mean 36.5 (SD 22.6)) in SIMD 1, 
compared with 37 (IQR 16-61) (mean 40.8 (SD 23.7)) in SIMD 5, p<0.01. 
The complexity of underlying CHD lesion was not significantly different 
according to deprivation (Table 7-1).  
Individuals with lower socioeconomic deprivation had a lower prevalence of 
diabetes (2.7% in SIMD 5 compared with 4.4% in SIMD 1, p<0.01) and higher rates 
of AF (10.8% in SIMD 5 compared with 8.2% in SIMD 1, p<0.01). Rates of cancer, 
AMI and IHD without AMI did not vary according to SIMD quintile. The rate of CVD 
did not vary significantly across all SIMD quintiles but on direct comparison of 
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highest and lowest levels of socioeconomic deprivation there was a significantly 
higher prevalence (6.1% in SIMD 1 and 4.9% in SIMD 5, p=0.03). For HTN, again no 
significant trend was noted across all SIMD quintiles however on direct 
comparison prevalence was higher in SIMD 5 (6.4%) than in SIMD 1 (5.1%), p=0.03. 
In total 4,118 (25.7%) of those for whom SIMD data was available died during 
follow up. Despite being younger, the proportion of those who died during follow 
up was significantly higher amongst those residing in areas of higher 
socioeconomic deprivation (26.2% in SIMD 1 and 22.5% in SIMD 5, p<0.01).  
 
Table 7-2 compares the survival within each SIMD quintile according to baseline 
characteristics. This confirms that the lower rate of death in areas of lower 
socioeconomic deprivation remain true for men (p=0.02) and women (p=0.01). 
Observed mortality reduces as deprivation decreases for CHD lesions of 
moderate complexity (p<0.01) but not for lesions of simple (p=0.21) or great 
(p=0.24) complexity. 
With higher deprivation, observed mortality was lower for those with AF 
(p<0.01), CVD (p=0.02), HTN (p=0.01), and ischaemic heart disease without AMI 
(p<0.01). But not cancer (p=0.80), diabetes (p=0.23), or AMI (p=0.64). 
  
170 
 
Table 7-1: Comparison of baseline characteristics and demographics according to Scottish index of multiple deprivation (SIMD).  SIMD 1 represents the most 
deprived and SIMD 5 the least 
 
 
All (%) Dead (%) Female (%) Age mean (SD) Simple (%) Modearate (%) Complex (%) Diabetes (%) Cancer (%) AF (%) CVD (%) HTN (%) AMI (%) Other IHD (%)
All 16045 4118 (25.7) 8169 (50.9) 39.2 (23.5) 8033 (62.6) 3494 (27.2) 1306 (10.2) 605 (3.8) 401 (2.5) 1593 (9.9) 925 (5.8) 940 (5.9) 885 (5.5) 1613 (10.1)
SIMD 1 (most) 4335 (27.1) 1140 (26.2) 2324 (53.4) 36.5 (22.6) 2202 (63.9) 892 (25.9) 353 (10.2) 193 (4.4) 101 (2.3) 358 (8.2) 266 (6.1) 223 (5.1) 213 (4.9) 384 (8.8)
SIMD 2 3441 (21.5) 967 (28.1) 1793 (52.1) 39.7 (23.9) 1695 (61.5) 794 (28.8) 268 (9.7) 147 (4.3) 84 (2.4) 341 (9.9) 213 (6.2) 204 (5.9) 199 (5.8) 381 (11.1)
SIMD 3 2997 (18.7) 775 (25.9) 1491 (49.8) 40.0 (23.5) 1483 (61.8) 666 (27.8) 251 (10.5) 111 (3.7) 73 (2.4) 314 (10.5) 169 (5.6) 188 (6.3) 164 (5.5) 313 (10.4)
SIMD 4 2736 (17.1) 670 (24.5) 1393 (48.5) 40.5 (23.9) 1353 (62.3) 590 (27.2) 229 (10.5) 85 (3.1) 67 (2.5) 309 (11.3) 155 (5.7) 164 (6.0) 162 (5.9) 296 (10.8)
SIMD 5 (least) 2516 (15.7) 566 (22.5) 1281 (49.1) 40.8 (23.8) 1300 (63.2) 552 (23.8) 205 (10.0) 69 (2.7) 76 (3.0) 271 (10.8) 122 (4.9) 161 (6.4) 147 (5.8) 239 (9.5)
p value <0.01 <0.01 <0.01 <0.01 <0.01 0.48 <0.01 0.19 0.15 0.28 0.01
Lesion Complexity Comorbidity
0.42
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Table 7-2: Survival to the end of the data period according to baseline characteristics for each SIMD quintile 
 
  
Alive (%) Dead (%) Alive (%) Dead (%) Alive (%) Dead (%) Alive (%) Dead (%) Alive (%) Dead (%) p value
All 3215 (73.8) 1140 (26.2) 2474 (71.9) 967 (28.1) 2222 (74.1) 775 (25.9) 2066 (75.5) 670 (24.5) 1950 (77.5) 566 (22.5) <0.01
Mean age at entry 
(SD) 28.3 (17.1) 59.6 (20.1) 30.8 (18.6) 62.4 (20.7) 32.0 (18.9) 62.8 (20.5) 32.5 (19.4) 65.1 (19.2) 33.9 (20.0) 64.5 (20.2) 0.30
Female 1695 (72.9) 629 (27.1) 1254 (69.9) 539 (30.1) 1085 (72.8) 406 (27.2) 982 (74.1) 344 (25.9) 937 (75.9) 298 (24.1) 0.01
Male 1520 (74.8) 511 (25.2) 1220 (74.0) 428 (26.0) 1137 (75.5) 369 (24.5) 1084 (76.9) 326 (23.1) 1013 (79.1) 268 (20.9) 0.02
Lesion complexity
Simple 1772 (80.5) 430 (19.5) 1353 (79.8) 342 (20.2) 1219 (82.2) 264 (17.8) 1117 (82.6) 236 (17.4) 1064 (81.9) 236 (18.2) 0.21
Moderate 599 (67.2) 293 (32.9) 502 (63.2) 292 (36.8) 451 (67.7) 215 (32.3) 411 (69.7) 179 (30.3) 416 (75.4) 136 (24.6) <0.01
Complex 294 (83.3) 59 (16.7) 215 (80.2) 53 (19.8) 209 (83.3) 42 (16.7) 191 (83.4) 38 (16.6) 181 (88.3) 24 (11.7) 0.24
Comorbidity
Diabetes 84 (43.5) 109 (56.5) 55 (37.4) 92 (62.6) 39 (35.1) 72 (64.9) 36 (42.4) 49 (57.7) 35 (50.7) 34 (49.3) 0.23
Cancer 27 (26.7) 74 (73.3) 24 (28.6) 60 (71.4) 21 (28.8) 52 (71.2) 14 (20.9) 53 (79.1) 22 (29.0) 54 (71.1) 0.80
AF 140 (39.1) 218 (60.9) 139 (40.8) 202 (59.2) 150 (47.8) 164 (52.2) 146 (47.3) 163 (52.8) 146 (53.9) 125 (46.1) <0.01
CVD 177 (66.5) 89 (33.5) 129 (60.6) 84 (39.4) 112 (66.3) 57 (33.7) 97 (62.6) 58 (37.4) 95 (77.9) 27 (22.1) 0.02
HTN 127 (57.0) 96 (43.1) 108 (52.9) 96 (47.1) 114 (60.6) 74 (39.4) 107 (65.2) 57 (34.8) 112 (69.6) 49 (30.4) 0.01
AMI 71 (33.3) 142 (66.7) 65 (32.7) 134 (67.3) 52 (31.7) 112 (68.3) 61 (37.8) 101 (62.4) 56 (38.1) 91 (61.9) 0.64
Other IHD 186 (48.4) 198 (51.6) 170 (44.6) 211 (55.4) 166 (53.0) 147 (47.0) 170 (57.4) 126 (42.6) 148 (61.9) 91 (38.0) <0.01
SIMD 1 SIMD 2 SIMD 3 SIMD 4 SIMD 5
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7.3.2 Age at death according to socioeconomic deprivation 
As stated above, a disproportionate number of the study cohort reside in areas 
of high socioeconomic deprivation. This translates to a greater duration of 
cumulative follow up for those residing in the corresponding lower SIMD quintile 
groups. Table 7-3 summarises follow up, crude mortality rates and age at death 
as observed for each SIMD quintile. As socioeconomic deprivation decreases, 
crude mortality rate falls and mean and median age at death is higher. Mean age 
at death is significantly greater for those resident in SIMD 5 (70.4 +/- 19 years) 
than SIMD 1 (65.6 +/- 18.8), p<0.01. A similarly higher age at death is noted 
when comparing a Carstairs-Morris quintile of low socioeconomic deprivation 
(70.3 +/- 19.7 years) with high (65.8 +/- 19.2 years), p<0.01. 
Table 7-3: Follow up, mortality rate and age at death according to SIMD quintile group.  
SIMD 1 refers to the most deprived and SIMD 5 the least 
 
Mean age at death increased during the data period from 66.9 years to 68.8 
years, p<0.01. Figure 7-1 illustrates how the mean age at death changed from 
the first to the second half of the data period. Point estimates for mean age at 
death increased for all SIMD quintiles. The greatest magnitude of increase was 
seen for SIMD 5, representing the lowest socioeconomic deprivation, from 67.2 
to 72.1 years, p<0.01.  
Cummulative 
follow up (years)
Mortality rate (per 
1000 person years)
Age at death, 
mean (SD)
Age at death, 
median (IQR)
SIMD 1 46065 24.8 (23.4-26.2) 65.6 (18.8) 70 (55-79)
SIMD 2 35202 27.5 (25.8-29.3) 68.0 (19.5) 74 (58-82)
SIMD 3 30592 25.3 (23.6-27.2) 68.5 (19.2) 74 (59-82)
SIMD 4 28042 23.9 (22.2-25.8) 70.7 (18.3) 76 (63-83)
SIMD 5 26234 21.6 (19.9-23.4) 70.4 (19.0) 75 (61-85)
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Figure 7-1: Mean age at death for all ACHD and according to Scottish index of multiple 
deprivation (SIMD) during the first and second half of the data period 
 
7.3.3 Survival according to socioeconomic deprivation 
Unadjusted survival estimates for all-cause mortality according to SIMD over the 
30 year data period are illustrated in Figure 7-2. Survival was lower for those 
with higher socioeconomic deprivation (SIMD deciles 1-5) when compared to 
those with less socioeconomic deprivation (SIMD 6-10) (OR 1.20, 95% CI 1.11-
1.29, p<0.01). Figure 7-3 illustrates survival from age 16 for those in the data 
set. 
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Figure 7-2: Kaplan-Meier estimation of survival as observed during the data period.  
‘Highest deprivation’ refers to SIMD deciles 1-5 and ‘lowest deprivation’ deciles 6-10 
 
Figure 7-3: Kaplan-Meier estimation of survival from age 16 according to socioeconomic 
deprivation.  
'Highest deprivation' refers to SIMD deciles 1-5 and 'lowest deprivation' deciles 6-10 
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Figure 7-4 illustrates survival from age 16 for each SIMD quintile. A significant 
reduction in risk of all cause mortality is observed for each increment of lower 
socioeconomic deprivation (OR 0.95, 95% CI 0.93-0.97, p<0.01). 
 
Figure 7-4: Kaplan-Meier estimation of survival from age 16 according to SIMD quintile. 
SIMD 1 refers to the highest deprivation and SIMD 5 the least 
 
As discussed earlier in this Chapter, baseline characteristics and demographics 
are not equally distributed according to socioeconomic deprivation. Table 7-4 
provides a breakdown of multivariate, adjusted hazards for all cause mortality 
including SIMD quintile. It also compares the interaction of these variables for 
those exposed to high levels of socioeconomic deprivation (SIMD decile 1-5) and 
those exposed to lower levels (SIMD 6-10).  
A sustained and statistically significant reduction in hazard for all cause 
mortality is seen for lower deprivation quintiles. With SIMD1 (most deprivation) 
as the reference, the adjusted hazard ratio for SIMD 5 is 0.67 (95% CI 0.60-0.74, 
p<0.01). This represents a 33% reduction in instantaneous risk of all cause 
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mortality for those exposed to the lowest levels of deprivation compared to the 
most deprived areas. Figure 7-5 provides graphical illustration of the adjusted 
hazard for all cause mortality as calculated for each SIMD quintile. A similar 
pattern is seen when Carstairs-Morris quintile is used in the model in place of 
SIMD (HR for quintile 2, 0.90, 95% CI 0.82-0.99, p=0.03; HR for quintile 3, 0.89, 
95% CI 0.81-0.97, p=0.01; HR for quintile 4, 0.80, 95% CI 0.73-0.88, p<0.01; HR 
for quintile 5, 0.75, 95% CI 0.68-0.83, p<0.01). 
Adjusted HRs for cardiovascular mortality also reduced significantly as 
deprivation decreases (HR for SIMD 5, 0.71, 95% CI 0.62-0.82, p<0.01). The 
greatest reduction in hazard was seen for non-cardiovascular mortality (HR for 
SIMD 5, 0.62, 95% CI 0.53-0.72, p<0.01). 
According to Table 7-4 a similar pattern of hazard is conferred by baseline 
characteristics for those in low and those in high SIMD groups. However, the 
increased hazard associated with male sex amongst those with higher 
socioeconomic deprivation (HR 1.21, 95% CI 1.11-1.31, p<0.01) is not seen for 
those with lower socioeconomic deprivation (HR 1.03, 95% CI 0.93-1.14, p=0.60). 
Additionally, those with IHD without AMI have a lower risk of all cause mortality 
in areas of low socioeconomic deprivation (HR 0.82, 95% CI 0.71-0.94, p<0.01) 
but not high socioeconomic deprivation (HR 1.01, 95% CI 0.91-1.12, p=0.88). 
Again, a similar risk of all cause mortality attached to underlying congenital 
lesion is seen in those with higher and those with lower socioeconomic 
deprivation. One exception appears to be the Fontan cohort, for whom the risk 
of all cause mortality (when compared to the reference lesion ASD) is greater 
amongst those experiencing high (HR 2.80, 95% CI 1.61-4.90, p<0.01) than those 
experiencing low (HR 1.21, 95% CI 0.39-3.80, p=0.74) socioeconomic deprivation. 
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Table 7-4: Multivariate hazard ratios for all-cause mortality comparing highest (SIMD deciles 
1-5) and lowest (SIMD deciles 6-10) levels of socioeconomic deprivation 
 
Column1 All Highest deprivation Lowest deprivation
Female 1 1 1
Male 1.13 [1.06-1.21] (<0.01) 1.21 [1.11-1.31] (<0.01) 1.03 [0.93-1.14] (0.60)
Age 1.07 [1.06-1.07] (<0.01) 1.07 [1.06-1.07] (<0.01) 1.07 [1.06-1.07] (<0.01)
SIMD Quintile
1 - most deprived 1 NA NA
2 0.92 [0.84-1.00] (0.05) NA NA
3 0.87 [0.80-0.96] (<0.01) NA NA
4 0.77 [0.70-0.85] (<0.01) NA NA
5 - least deprived 0.67 [0.60-0.74] (<0.01) NA NA
Year of Presentation
1986-1990 1 1 1
1991-1995 0.87 [0.79-0.96] (<0.01) 0.81 [0.71-0.91] (<0.01) 0.98 [0.84-1.15] (0.83)
1996-2000 0.72 [0.65-0.80] (<0.01) 0.70 [0.61-0.80] (<0.01) 0.75 [0.63-0.89] (<0.01)
2001-2005 0.54 [0.48-0.60] (<0.01) 0.55 [0.47-0.63] (<0.01) 0.54 [0.44-0.65] (<0.01)
2006-2010 0.45 [0.40-0.51] (<0.01) 0.46 [0.39-0.53] (<0.01) 0.45 [0.37-0.55] (<0.01)
2011-2015 0.34 [0.30-0.39] (<0.01) 0.34 [0.28-0.41] (<0.01) 0.33 [0.27-0.42] (<0.01)
Comorbidity
Diabetes 1.68 [1.50-1.88] (<0.01) 1.52 [1.33-1.75] (<0.01) 2.13 [1.75-2.60] (<0.01)
Cancer 1.78 [1.57-2.01] (<0.01) 1.74 [1.48-2.06] (<0.01) 1.84 [1.53-2.21] (<0.01)
AF 1.25 [1.15-1.35] (<0.01) 1.21 [1.10-1.35] (<0.01) 1.28 [1.13-1.46] (<0.01)
CVD 1.10 [0.98-1.23] (0.12) 1.14 [0.99-1.32] (0.07) 1.04 [0.85-1.27] (0.71)
HTN 0.96 [0.86-1.08] (0.51) 1.02 [0.89-1.17] (0.81) 0.88 [0.73-1.05] (0.15)
AMI 1.38 [1.25-1.51] (<0.01) 1.48 [1.30-1.67] (<0.01) 1.29 [1.11-1.49] (<0.01)
Other IHD 0.93 [0.86-1.01] (0.09) 1.01 [0.91-1.12] (0.88) 0.82 [0.71-0.94] (<0.01)
Lesion
ASD 1 1 1
PDA 0.88 [0.66-1.56] (0.35) 0.87 [1.11-1.31] (0.42) 0.91 [0.57-1.48] (0.71)
VSD 1.94 [1.74-2.16] (<0.01) 1.87 [1.62-2.15] (<0.01) 2.08 [1.75-2.48] (<0.01)
Aortic 1.38 [1.25-1.53] (<0.01) 1.42 [1.25-1.61] (<0.01) 1.34 [1.15-1.58] (<0.01)
Ebstein's 2.43 [1.72-3.44] (<0.01) 2.48 [1.54-3.97] (<0.01) 2.46 [1.48-4.08] (<0.01)
AVSD 1.50 [1.23-1.84] (<0.01) 1.48 [1.14-1.92] (<0.01) 1.59 [1.15-2.20] (0.01)
TOF 1.94 [1.50-2.50] (<0.01) 1.81 [1.33-2.47] (<0.01) 2.27 [1.46-3.54] (<0.01)
Complex 1.74 [1.50-2.01] (<0.01) 1.82 [1.51-2.19] (<0.01) 1.66 [1.32-2.10] (<0.01)
Fontan 2.18 [1.33-3.60] (<0.01) 2.80 [1.61-4.90] (<0.01) 1.21 [0.39-3.80] (0.74)
Valvular 1.24 [1.11-1.39] (<0.01) 1.26 [1.10-1.46] (<0.01) 1.24 [1.04-1.49] (0.02)
Other 1.37 [1.21-1.54] (<0.01) 1.41 [1.21-1.64] (<0.01) 1.32 [1.09-1.60] (<0.01)
HR [95% CI] (p value)
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Figure 7-5: Forrest plot comparing adjusted hazard ratios for all-cause mortality according 
to Scottish index of multiple deprivation (SIMD) quintile.  
SIMD 1 refers to the highest levels of deprivation and SIMD 5 the lowest 
 
7.3.4 Cause of death according to socioeconomic deprivation 
Cause of death for each congenital lesion is summarised for those with lower 
deprivation in Figure 7-6 and higher deprivation in Figure 7-7. Data regarding the 
general population (of all socioeconomic groups) is provided for comparison.  
For the total CHD cohort, IHD was the most frequent cause of death irrespective 
of high (24.7%) or low (22.8%) level socioeconomic deprivation. In both groups, 
malignancy was the next most frequent specific cause of death (13.5% for higher 
and 13.4% for lower deprivation). In fact, there was no significant difference in 
the proportional distribution of cause of death according to high and low level 
socioeconomic deprivation, p=0.10. This is also true when comparing cause of 
death for high and low level socioeconomic deprivation for each of the CHD 
lesion groups (ASD p=0.79, PDA p=0.69, VSD p=0.43, aortic lesions p=0.39, 
Ebstein’s anomaly p=0.20, AVSD p=0.07, TOF p=0.40, systemic RV p=0.48, Fontan 
p=0.87, complex lesions p=1.00, valvular lesions p=0.61, other lesions p=0.84). 
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Figure 7-6: Proportional distribution of cause of death for each congenital lesion and 
compared to the general population-  Lower deprivation (SIMD deciles 6-10). 
 
Figure 7-7: Proportional distribution of cause of death for each congenital lesion and 
compared to the general population –  Higher deprivation (SIMD deciles 1-5). 
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Over the total data period, death due to cardiovascular causes predominates for 
those exposed to higher levels of socioeconomic deprivation (53.8%) and those 
exposed to lower levels (55.2%), with no significant difference between the two 
groups (p=0.38). 
Cause of death according to SIMD quintile, irrespective of underlying lesion is 
summarised in Figure 7-8. 
 
Figure 7-8: cause of death according to Scottish index of multiple deprivation (SIMD) 
quintile and compared to the general population 
 
Figure 7-9 illustrates the changing proportion of CV to non-CV deaths throughout 
the data period for those with lower levels of socioeconomic deprivation (SIMD 
deciles 6-10), and Figure 7-10 those with higher level (SIMD 1-5). In both cases, 
data from the general population (of all SIMD groups) is provided for comparison. 
The proportion of cardiovascular deaths fell throughout the data period for both 
lower (from 74.4% to 39.7%) and higher (from 72.0% to 39.9%) socioeconomic 
deprivation groups. The proportion of cardiovascular to non-cardiovascular 
deaths did not vary significantly between the higher and lower socioeconomic 
groups at any time cohort other that 2001-2005 where a higher proportion of 
cardiovascular deaths were seen in the lower socioeconomic deprivation group 
(65.1% compared with 56.4%, p=0.03). Over the course of the data period CV 
deaths fell by 1.16% per year amongst those with lower socioeconomic 
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deprivation and by 1.07% per year amongst those with higher level 
socioeconomic deprivation (p=0.84). 
 
 
Figure 7-9: Proportional distribution of cardiovascular and non-cardiovascular deaths over 
time and compared to the general population in 2016 Lower deprivation (SIMD deciles 6-10). 
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Figure 7-10: Proportional distribution of cardiovascular and non-cardiovascular deaths over 
time and compared with the general population in 2016 Higher deprivation (SIMD deciles 1-5). 
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7.4 Discussion 
A limited number of studies have previously demonstrated an increased birth 
incidence of congenital heart disease amongst those from areas of high 
socioeconomic deprivation (158,159). It has been postulated in these prior 
studies that there may be an environmental causative aetiology related to 
socioeconomic deprivation. Alternatively, Sheridan et al. suggest that 
consanguinity is a major contributing factor to non-chromosomal congenital 
anomaly (although not specific to heart disease) (160) and Knowles et al suggest 
higher levels of consanguinity in areas of higher socioeconomic deprivation as 
one possible explanation (133). Although UK based, these studies are 
predominantly composed of patient cohorts from southern England and proposed 
explanations are not necessarily reproducible in the Scottish population. 
Our finding that high level socioeconomic deprivation persists in adulthood 
provides a further potential explanation. Although few congenital heart defects 
express Mendelian patterns of inheritance, it is well established that incidence is 
increased in the offspring of those effected (161). It may therefore be the case 
that higher levels of socioeconomic deprivation are as a result of reduced 
availability or attainment in education, as has previously been described by 
Oster et al (162), or employment, as described by Kamphuis et al. (46), amongst 
those with CHD. Socioeconomic deprivation ensues and resultant birth incidence 
amongst these individuals is naturally higher than the population average.  
Despite the founding and driving principles which manifest equal access to 
healthcare in the NHS, health inequalities in the UK are well documented and 
this has been shown to include excess mortality for cardiovascular disease in 
general (154). Our findings confirm excess mortality amongst adults with 
congenital heart disease who experience higher socioeconomic deprivation. Our 
Kaplan-Meier estimation of survival according to socioeconomic deprivation 
suggest a significant effect, and this is augmented by the adjusted models, 
particularly by accounting for the younger age in the higher socioeconomic 
deprivation groups. This excess in mortality is not exclusive to those 
experiencing the very highest levels of deprivation but appear to be on a 
continuum as socioeconomic deprivation increases. What is not clear from these 
analyses is whether mortality in ACHD is disproportionately influenced by 
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socioeconomic deprivation as compared to the general population. 
Unfortunately, NRS do not stratify mortality data, including mortality rates, by 
SIMD. This would permit calculation of standardised MRs. Another option in 
future analyses would be to utilise a population matched cohort, which would 
provide a substrate by which to compare adjusted hazard ratios according to 
SIMD for those with ACHD and those without. 
Tackling the question as to why CHD patients experience higher levels of 
socioeconomic deprivation is complex. Despite improved early identification and 
management of CHD, the majority of moderately and greatly complex CHD 
requires surgical intervention in childhood. This has an educational implication 
for school age children who may need to take significant time away for health 
reasons. This is backed up by previous evidence suggesting that basic secondary 
school and higher educational attainment is significantly reduced in long term 
survivors of CHD (163). Education is both a direct facet of socioeconomic 
deprivation (being factored into many composite measures, including SIMD) and 
has obvious implications for future income which is the single biggest 
determinant. A similar pattern is seen with employment: Individuals with CHD 
show less job participation than the general public and those with complex CHD 
less than those with simple (46). As most recognised metrics of socioeconomic 
deprivation are postcode derived (including SIMD), for epidemiological purposes 
the socioeconomic status of children and young adults will often be defined by 
that of their parents as long as they share a household. The demands of looking 
after a dependant with congenital heart disease are often major and it has been 
shown that significant childhood illness (albeit not specific to CHD) does 
significantly impact parental earning potential (164). And even out with shared 
house occupancy, parental socioeconomic status is an established determinant in 
the child’s ‘socioeconomic potential’ (165). 
In Scotland, care for adults with CHD is delivered via a ‘hub and spoke’ 
structure. What this means in real terms is that most patients will receive at 
least some of their care in the single referral centre at the Golden Jubilee 
National hospital in Clydebank, and for those with more complex disease this 
may be the majority or all of their care. For those individuals who reside remote 
to this site, a significant financial burden may result, both in relation to 
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travelling costs and time out of employment, which despite the efforts of the 
clinical and management teams cannot be completely negated. 
Although the age at death has increased over time for all levels of 
socioeconomic deprivation, worryingly the greatest increase in age at death is 
seen for those experiencing least socioeconomic deprivation, raising the 
possibility that the effect of socioeconomic deprivation is increasing. It may be 
argued that the younger age at death in areas of higher socioeconomic 
deprivation could be explained by the phenomenon where individuals born with 
the most severe forms of CHD survive childhood to die early in adulthood where 
they previously would not have survived to inclusion in cohorts such as this. This 
would appear unlikely as lesion severity was seen to be evenly distributed 
throughout the strata of socioeconomic deprivation. 
Women with CHD are exposed to greater levels of socioeconomic deprivation 
than men with CHD (see sections 6.2.1 and 6.3.1). This is not the case in the 
general population. The reasons for this are not clear and likely to be complex. 
The prospect that women may suffer a disproportionate financial burden due to 
perceived or actual disability is concerning.  One theory centres around 
pregnancy and fertility. It is regularly proposed that the gender pay gap within 
the general population may be at least in part explained by maternity and the 
impact that this has on employment (166). In CHD, maternity and fertility are 
affected. Pregnancies are frequently more complex and spontaneous miscarriage 
rates are higher (167). It is logical, albeit conjecture, that this may magnify any 
proposed effect that maternity imposes on earning capacity, the most heavily 
weighted of the socioeconomic deprivation domains. 
In terms of comorbidity, diabetes was more common when socioeconomic 
deprivation was high. Although HTN, AMI and other forms of IHD were not more 
common in areas of high socioeconomic deprivation these established risk 
factors for mortality are directly correlated to increasing age and since 
individuals from areas of high socioeconomic deprivation were significantly 
younger, this apparent equivalence in comorbidity may actually suggest a 
relative excess where socioeconomic deprivation is high. Interestingly, on 
multivariate regression, ischaemic heart disease without AMI appears protective 
against all cause mortality when socioeconomic deprivation is low but not high. 
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This may represent more aggressive risk factor modification within this cohort, 
reflecting better access to health services and therapies. 
Although socioeconomic deprivation is associated with excess all cause and 
cardiovascular mortality, the greatest excess is seen with non-cardiovascular 
mortality. Indeed, the proportion of CV deaths is comparable between high and 
low deprivation groups and changes over time are mirrored. This may suggest 
that the increased mortality associated with socioeconomic deprivation is 
significantly or even completely driven by background population effect, albeit 
with disproportionate deprivation amongst CHD patients.  
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7.5 Conclusions 
Adults with CHD experience higher socioeconomic deprivation than the general 
population. Women with ACHD experience higher socioeconomic deprivation 
than men. 
Deprivation is associated with excess mortality amongst individuals with CHD. 
Comparative studies are needed to establish to what degree the association 
between mortality and socioeconomic deprivation is governed by population 
effect and to what degree it is specific to CHD. Irrespective of the cause, the 
disproportionate deprivation suffered by CHD patients must be addressed. This is 
a complex issue, but as clinicians we can start by remaining mindful to the 
socioeconomic and financial implications of our decisions and recommendations. 
Individualising care to minimise time away from education and employment and 
permitting local care where possible or requested may go some way to 
minimising the burden for our patients. From an institutional and organisational 
perspective, the findings presented here should be borne in mind when 
advocating for the needs of our patient population. 
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8 Survival and circumstances of death according 
to lesion complexity 
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8.1 Introduction 
The diverse range which constitutes the spectrum of congenital heart disease 
proves one of its greatest barriers to study. This has been touched on in earlier 
Chapters but merits further discussion here. The number of individual ICD codes 
which correspond to congenital lesions ranges into the hundreds and even within 
each code significant variability may exist. This thesis has already described the 
unequivocal increase in prevalence of ACHD over time but in spite of this, most 
individual congenital heart lesions/diagnoses remain uncommon or frankly rare. 
This poses a problem when one wishes to consider outcomes, as a well-defined 
patient population of sufficient size to allow generalisation is rarely 
forthcoming. This predicament is not limited to ACHD as an academic pursuit, 
and in fact it is from clinical practice that the most commonly rendered solution 
has been established. The 2001 ‘Task force’ for the changing profile of 
congenital heart disease acknowledged and attempted to redress the problem of 
health service allocation where disease classification had previously proven 
unhelpful (42). The resultant system of classifying all ACHD as one of three 
categories pertaining to simple, moderate, or great complexity, provides a 
much-simplified reference aid with the intended purpose of informing health 
services at a provision level as to the anticipated requirement for referral 
centres and ACHD specialists. It is worth emphasising that this classification 
system was devised to predict need for specialist services and pertains to 
complexity of care needs and inference of outcomes such as mortality was never 
proposed. 
Irrespective of the intended utility of the ‘Bethesda’ classification of ACHD it has 
become common place in the literature that cohorts be stratified by this system 
or a modification of this system (118,121,147,168). In general a positive 
correlation between lesion complexity and excess mortality has been reported 
(44,121). However, there has been some ambiguity as to the relative 
implications on mortality conferred by lesion complexity when compared to the 
general population. This has been most notable amongst those with ‘simple’ 
lesion which have been variably reported to confer similar survival prospects to 
the general population (88,169) and significantly higher mortality (118,170,171). 
The changing survival prospects over time have never been directly factored into 
this debate.  
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8.2 Results 
8.2.1 Baseline characteristics and demographics according to 
lesion complexity 
Classification of lesion complexity could be achieved for 12,974 (78.9%) of the 
total study population. Simple CHD was most common, representing 62.6% with 
complex CHD least common with 10.2%.  
A comparison of the baseline characteristics according to lesion complexity is 
shown in Table 8-1. Significant heterogeneity across the complexity groups is 
observed for all baseline characteristics other than SIMD quintile group. Women 
are more common amongst those with simple CHD (proportion women 52.7%), 
and men amongst complex CHD (proportion women 47.5%), p<0.01. Age at entry 
to the data set was younger amongst those with complex CHD (mean 25.9, SD 
17.8, median 16, IQR 16-28.5) compared to simple (mean 37.3, SD 21.5, median 
33, IQR 16-35) or moderate (mean 39.8, SD 26, median 29, IQR 16-65). 
Comorbidity was more common in simple and moderate CHD than was seen for 
complex CHD. This was true for all recorded comorbid diagnoses. There was no 
significant difference in baseline socioeconomic grouping across complexity of 
CHD (p=0.42).  
Table 8-1: Study population characteristics according to lesion complexity 
 
All (%) Simple (%) Moderate (%) Complex (%) p value 
All 12974 8121 (62.6) 3529 (27.2) 1324 (10.2) <0.01
Female 6639 (51.2) 4280 (52.7) 1730 (49.0) 629 (47.5) <0.01
Age at entry, 
mean (SD) 36.8 (22.9) 37.3 (21.5) 39.8 (26.1) 25.9 (17.8) <0.01
Comorbidity
Diabetes 423 (3.3) 265 (3.3) 139 (3.9) 19 (1.4) <0.01
Cancer 276 (2.13) 151 (1.9) 109 (3.1) 16 (1.2) <0.01
AF 1250 (9.6) 728 (8.9) 434 (12.3) 88 (6.7) <0.01
CVD 763 (5.9) 613 (7.6) 132 (3.7) 18 (1.4) <0.01
HTN 696 (5.4) 381 (4.7) 283 (8.0) 32 (2.4) <0.01
AMI 589 (4.5) 409 (5.0) 171 (4.9) 9 (0.7) <0.01
Other IHD 997 (7.3) 596 (7.3) 365 (10.3) 36 (2.7) <0.01
SIMD quintile 12833
1 - most deprived 3447 (26.9) 2202 (27.4) 892 (25.5) 353 (27.0)
2 2757 (21.5) 1695 (21.1) 794 (22.7) 268 (20.5)
3 2400 (18.7) 1483 (18.5) 666 (19.1) 251 (19.2) 0.417
4 2172 (16.9) 1353 (16.8) 590 (16.9) 229 (17.5)
5 - least deprived 2057 (16.0) 1300 (16.2) 552 (15.8) 205 (15.7)
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Individuals with moderate lesions were more frequently observed to die during 
follow up (1124 of 3529, 31.9%) than simple (1529 of 8121, 18.8%) or complex 
(218 of 1324, 16.5%) CHD, p<0.01. Table 8-2 illustrates the demographics and 
baseline characteristics for those who survived and those who died during follow 
up for simple, moderate and complex CHD. Those who died during follow up 
were older at entry to the data set for each lesion complexity. Individuals with 
complex CHD who died during follow up were younger at entry to the data set 
than those with simple or moderate CHD who died, p<0.01.  
The proportion of men and women who died during follow up were comparable 
among those with simple lesions (18.6% and 19.1% respectively, p=0.12) and 
complex lesions (16.3% and 16.7% respectively, p=0.59). For moderate lesions, 
more women died than men (37.2% and 31.9%, p<0.01). For all socioeconomic 
groupings the proportion of those who died during follow up was greater 
amongst those with moderate lesions than simple or complex, p<0.01. A greater 
proportion of those with moderately complex CHD who have comorbidity died 
during follow up that those with simple or complex CHD. This was significant for 
all recorded comorbidity other than cancer (p=0.21).  
Table 8-2: Demographics of those with simple, moderate, and complex lesions for those 
who survived and those who died during follow up.  The p value compares the proportion of 
those who died 
  
Alive (%) Dead (%) Alive (%) Dead (%) Alive (%) Dead (%) p value
All 6592 (81.2) 1529 (18.8) 2405 (68.2) 1124 (31.9) 1106 (83.5) 218 (16.5) <0.01
Mean age at 
entry (SD) 31.8 (18.3) 60.9 (18.2) 27.6 (18.1) 65.8 (21.3) 22.9 (14.6) 41.3 (23.5) <0.01
Female 3485 (81.4) 795 (18.6) 1087 (62.8) 643 (37.2) 524 (83.3) 105 (16.7) <0.01
Male 3107 (80.9) 734 (19.1) 1318 (73.3) 481 (31.9) 582 (83.7) 113 (16.3) <0.01
SIMD
1 1772 (80.5) 430 (19.5) 599 (67.2) 293 (32.9) 294 (83.3) 59 (16.7) <0.01
2 1353 (79.8) 342 (20.2) 502 (63.2) 292 (36.8) 215 (80.2) 53 (19.8) <0.01
3 1219 (82.2) 264 (17.8) 451 (67.7) 215 (32.3) 209 (83.3) 42 (16.7) <0.01
4 1117 (82.6) 236 (17.4) 411 (69.7) 179 (30.3) 191 (83.4) 38 (16.6) <0.01
5 1064 (81.9) 236 (18.2) 416 (75.4) 136 (24.6) 181 (88.3) 24 (11.7) <0.01
Comorbidity
Diabetes 131 (49.3) 134 (50.6) 38 (27.3) 101 (72.7) 7 (36.8) 12 (63.2) <0.01
Cancer 50 (33.1) 101 (66.9) 26 (23.9) 83 (76.2) 6 (29.7) 10 (62.5) 0.21
AF 413 (56.7) 315 (43.3) 126 (29.0) 308 (71.0) 55 (62.5) 33 (37.5) <0.01
CVD 503 (82.1) 110 (17.9) 42 (31.8) 90 (68.2) 10 (55.6) 8 (44.4) <0.01
HTN 269 (70.6) 112 (29.4) 122 (43.1) 161 (56.9) 19 (59.4) 13 (40.6) <0.01
AMI 112 (27.4) 297 (72.6) 40 (23.4) 131 (76.6) 6 (66.7) 3 (33.3) 0.02
Other IHD 367 (61.6) 229 (38.4) 114 (31.2) 251 (68.8) 21 (58.3) 15 (41.7) <0.01
Simple Moderate Complex
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8.2.2 Follow up and age at death 
A cumulative follow up of 136,247 years was achieved amongst those for whom 
complexity could be determined. Those with simple lesions accumulated the 
greatest follow up (85,347 years) followed by moderate (36,265 years) then 
complex (14,635 years) CHD. The observed, crude mortality rate was greatest 
for those with moderate complexity (31.0 deaths per 1000 person years, 95% CI 
29.2-32.9) followed by simple (17.9 deaths per 1000 person years, 95% CI 17.0-
18.8) then complex CHD (14.9 deaths per 1000 person years, 95% CI 13.0-17). 
Table 8-3 summarises follow up, crude mortality rate and age at death according 
to complexity of CHD.  
Table 8-3: Comparison of follow up, crude mortality rate and age at death for each lesion 
complexity 
 
Mean age at death was lower for those with complex CHD (48.1 years, SD 22.8, 
median 45.5, IQR 28-69) than simple (67.0 years, SD 17.4, median 71, IQR 57-
80), or moderate (71.3 years, SD 19.6, median 77, IQR 63-85), p<0.01, with the 
higher age at death amongst moderate compared to simple lesions also being 
significant, p<0.01. Figure 8-1 compares the mean age at death during the first 
and second half of the data period for each lesion complexity. A significant 
increase in mean age at death was observed for all degrees of complexity from 
the first to the second half of the data period (simple; 64.3 and 68.2 years, 
p<0.01, moderate; 68.9 and 71.9 years, p=0.03, complex;.39.7 and 50.5 years, 
p<0.01). 
N
Follow up 
(years)
Mortality rate per 1000 
years (95%CI)
Mean age at 
death (SD)
All 12974 136247 21.1 (20.3-21.9) 67.3 (19.6)
Lesion complexity
Simple 8121 85347 17.9 (17.0-18.8) 67.0 (17.4)
Moderate 3529 36265 31.0 (29.2-32.9) 71.3 (19.6)
Complex 1324 14635 14.9 (13.0-17.0) 48.1 (22.8)
p<0.01
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Figure 8-1: Mean age at death for all patients and according to lesion severity, comparing 
the first and second half of the data period Significance level for each change provided. 
 
8.2.3 Survival according to lesion complexity 
Multivariate, adjusted hazard ratios for all-cause mortality conferred by baseline 
characteristics for each degree of CHD complexity are summarized in Table 8-4.  
Male sex did not confer a risk of mortality for moderate or complex CHD (p=0.07 
and 0.58 respectively) but did confer an increased mortality risk for simple 
lesions (HR 1.41, 95% CI 1.27-1.57, p<0.01). Survival was better amongst those in 
socioeconomic groups with lowest deprivation across all degrees of lesion 
complexity. Amongst those with simple lesions, a consistent reduction in hazard 
was noted for each increment of SIMD. Amongst those with moderate and 
complex lesions the interaction was more complex.  
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Survival improved over time for all degrees of lesion complexity. Amongst those 
with simple and moderately complex lesions, survival according to year of 
presentation improved in a linear manner. For complex lesions survival improved 
greatly from the earliest to the second time period (HR 0.63, 95% CI 0.42-0.96, 
p=0.03) with only a small change in point estimates from then on. 
A similar pattern of survival was conferred by comorbidity across all lesion 
complexity cohorts, although AMI did not predict mortality in those with 
complex lesions (HR 0.53, 95% CI 0.16-1.70, p=0.29) but did in simple (HR 1.87, 
95% CI 1.61-2.16, p<0.01) and moderately complex (HR 1.33, 95% CI 1.10-1.61, 
p<0.01) CHD. 
Table 8-4: Hazard of all-cause mortality according to baseline characteristics for simple, 
moderate, and complex lesions 
Figure 8-2 compares survival from all cause, cardiovascular and non-
cardiovascular mortality for simple, moderate and complex CHD. Survival 
estimates are adjusted for all measured baseline characteristics as summarised 
Column1 Simple Moderate Complex
Female 1 1 1
Male 1.41 [1.27-1.57] (<0.01) 1.12 [0.99-1.27] (0.07) 1.08 [0.82-1.42] (0.58)
Age 1.08 [1.07-1.08] (<0.01) 1.07 [1.06-1.07] (<0.01) 1.06 [1.05-1.07] (<0.01)
SIMD Quintile
1 - most deprived 1 1 1
2 0.83 [0.72-0.96] (0.01) 0.95 [0.81-1.12] (0.56) 1.10 [0.75-1.62] (0.61)
3 0.80 [0.68-0.93] (<0.01) 1.00 [0.83-1.19] (0.97) 0.74 [0.49-1.11] (0.14)
4 0.69 [0.59-0.81] (<0.01) 0.75 [0.62-0.91] (<0.01) 0.83 [0.54-1.27] (0.39)
5 - least deprived 0.69 [0.58-0.81] (<0.01) 0.58 [0.47-0.72] (<0.01) 0.52 [0.32-0.86] (0.01)
Year of Presentation
1986-1990 1 1 1
1991-1995 0.89 [0.76-1.05] (0.16) 0.85 [0.64-1.13] (0.28) 0.63 [0.42-0.96] (0.03)
1996-2000 0.67 [0.55-0.82] (<0.01) 0.65 [0.50-0.84] (<0.01) 0.62 [0.39-0.98] (0.04)
2001-2005 0.46 [0.39-0.55] (<0.01) 0.51 [0.39-0.68] (<0.01) 0.70 [0.39-1.28] (0.25)
2006-2010 0.36 [0.30-0.44] (<0.01) 0.54 [0.40-0.73] (<0.01) 0.41 [0.23-0.71] (<0.01)
2011-2015 0.28 [0.23-0.35] (<0.01) 0.34 [0.24-0.49] (<0.01) 0.53 [0.29-0.97] (0.04)
Comorbidity
Diabetes 1.61 [1.34-1.94] (<0.01) 1.60 [1.29-1.98] (<0.01) 1.91 [0.99-3.71] (0.05)
Cancer 2.06 [1.67-2.53] (<0.01) 1.31 [1.04-1.65] (0.02) 1.82 [0.88-3.78] (0.11)
AF 1.15 [1.00-1.32] (0.04) 1.26 [1.10-1.44] (<0.01) 0.92 [0.60-1.43] (0.72)
CVD 0.85 [0.69-1.04] (0.11) 1.15 [0.92-1.43] (0.21) 1.90 [0.90-4.05] (0.09)
HTN 0.94 [0.77-1.15] (0.77) 1.04 [0.87-1.23] (0.69) 0.96 [0.51-1.81] (0.89)
AMI 1.87 [1.61-2.16] (<0.01) 1.33 [1.10-1.61] (<0.01) 0.53 [0.16-1.70] (0.29)
Other IHD 0.79 [0.68-0.92] (<0.01) 1.07 [0.92-1.24] (0.38) 0.84 [0.48-1.49] (0.56)
HR [95% CI] (p value)
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in Table 8-4. Increased hazard for all cause, CV and non-CV mortality was noted 
for moderate and complex CHD when compared to simple (although this does not 
achieve statistical significance for non-CV mortality amongst those with 
moderately complex CHD). Point estimates suggest that CV mortality is most 
strongly associated with increasing lesion complexity.  
 
Figure 8-2: Adjusted hazard ratios for all cause, cardiovascular, and non-cardiovascular 
mortality comparing simple, moderate and complex lesions 
 
8.2.4 Cause of death according to lesion complexity 
Cause of death according to CHD complexity and compared to the full CHD 
cohort and the general population is shown in Figure 8-3. Compared to the 
general population more deaths are due to cardiovascular causes (CHD, IHD, 
PVD/CVD and other cardiac) and fewer are attributable to malignancy in the 
study cohort. According to lesion complexity, a similar proportion of deaths are 
by cardiovascular causes. However, for those with complex CHD this is 
predominantly accounted for by deaths attributed directly to CHD and for those 
with simple and moderately complex CHD by ischaemic heart disease. 
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Figure 8-3: Cause of death according to lesion complexity and compared to the entire study 
cohort and the general population 
 
The changing proportion of cardiovascular and non-cardiovascular deaths over 
time, according to lesion complexity are shown in Figure 8-4. Across all cohorts 
of lesion complexity, the proportion of cardiovascular deaths decreases and 
trends towards that of the general population. During the most contemporary 
time cohort a similar proportion of deaths were by CV causes for simple (43.1%), 
moderate (42.5%) and complex (42.3%) CHD. For simple and moderately complex 
lesions the proportion of cardiovascular deaths begins to decrease from the 
beginning of the data period and continues in gradual manner. For complex CHD 
the proportion of cardiovascular deaths is not seen to decrease until halfway 
through the data period but then declines rapidly from 2005 onwards. The trend 
of proportions of cardiovascular deaths are compared in Figure 8-5. 
From the earliest to current time period, the proportion of CV deaths fell 
amongst those with simple lesions by a total of 28.25% equating to 1.23% per 
year. This is compared to a 22.7% amongst the general population over the total 
time period (p<0.01) and 0.73% per year, p=0.09. For moderately complex 
lesions, CV deaths fell by 51.6% over the total data period (p<0.01), 
corresponding to a 1.66% reduction per year, p<0.01 (as compared to population 
change). For lesions of great complexity, CV deaths decreased by a total of 
30.42% over the data period (p=0.04), corresponding to 0.98% per year, p=0.74 
(as compared to population change). 
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Figure 8-4: the proportion of cardiovascular and non-cardiovascular deaths over time 
according to ACHD complexity and compared to that of the general population in 2015 
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Figure 8-5: The changing proportion of cardiovascular deaths over time, comparing simple, 
moderate and complex lesions as well as the general population. 
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8.3 Discussion 
The concept of categorising CHD lesions by degree of complexity was intended 
to aid with the planning and provision of specialised health care. Despite this, it 
has become common place for stratification by lesion complexity to be used 
when comparing outcomes, particularly mortality, within the published 
literature.  
Women predominate amongst the group with simple lesions as expected, in line 
with the abundance of shunt lesions which are established to occur more 
frequently in women (55). Similarly, the male predisposition of complex lesions 
is explained by the inclusion of conotruncal lesions which occur more commonly 
in men (62). The relatively low crude mortality rate associated with complex 
when compared to simple and moderate lesions is most readily explained by the 
younger age at inclusion amongst those with complex lesions. This follows logic 
as these individuals are more likely to have presented to the data via 
intervention in the paediatric sector and followed hence forth. Indeed, age at 
death is significantly lower for those with complex CHD when compared with 
simple and moderate. This should be considered in the context of the relative 
sparsity of complex CHD in the adult population, particularly at the inception of 
our data period. In the 1980s, childhood death remained common amongst those 
with  the most complex CHD (56) and as a result, follow up and management 
protocols and guidelines for these individuals in the adult sector were less well 
defined than today. 
Age at death was seen to increase for all categorise of lesion complexity but this 
was most marked for lesions of great complexity. From the first to the second 
half of the data period mean age at death increased by 3.9 years and 3.0 years 
for simple and moderate lesions respectively. This may well be explained simply 
by population effects as the mean life expectancy in Scotland covering the same 
time periods increased by 3.2 years (123). In comparison, the mean age at death 
for complex CHD increased by 10.8 years and although this does not truly equate 
to life expectancy it is likely to represent the more significant stepwise changes 
in the management of complex CHD such as the transition towards arterial as 
opposed to atrial switch operations in the late 1980s and early 1990s. This 
increase in age at death for complex CHD was somewhat unexpected as one may 
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presume a temporal shift towards mortality in early adulthood for some 
patients, reflecting improving survival in the paediatric sector. As a result, the 
temporal increase in age at death may be actually even greater than quoted for 
the majority of the greatly complex cohort. 
Multivariate survival analysis confirms the increased mortality burden associated 
with moderate compared to simple CHD and complex compared to moderate or 
simple CHD. Interestingly, for moderate CHD this increased hazard is governed 
by the increased risk of cardiovascular mortality whereas with complex CHD a 
significantly increased hazard persists for both cardiovascular and non-
cardiovascular mortality. This may well reflect the evolving knowledge of the 
multisystem impact of many of the complex congenital heart lesions. Fontan and 
univentricular circulations in particular are increasingly implicated in both acute 
and chronic pathology in the hepatic, renal and gastrointestinal systems (172–
175). Additionally, complex CHD confers a risk of immunosuppression and 
infection (176), and of course maternal mortality is well described (177). 
The interaction, or more accurately, lack of interaction between SIMD and CHD 
complexity on survival is worth mentioning. Table 8-4 illustrates that the 
magnitude of improved survival amongst those exposed to lowest levels of 
deprivation remains essentially constant across all lesion complexities. 
Socioeconomic deprivation has most closely been linked to mortality associated 
with acquired lifestyle risk factors such as tobacco smoking, diet and exercise 
(178). One may expect that this would disproportionately influence the survival 
of those with more simple CHD who tend to live longer and acquire more risk 
factors. Our finding that SIMD risk persists even in complex disease may reflect 
either the improved survival of complex patients, allowing for more influence of 
acquired risk; or that risk factors such as smoking, diet and exercise may be of 
additional importance among younger patients with more complex CHD, owing to 
more fragile physiological conditions. A third possibility, that those of lower 
socioeconomic grouping may have lesser availability to healthcare resources 
must also be considered. Similarly, health priorities may be different depending 
on socioeconomic status leading to lesser engagement in follow up or 
treatments. In fact Ellis et al (179) have previously demonstrated in a Scottish 
population wide cohort, albeit in primary care, that SIMD groups of higher 
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socioeconomic deprivation are more likely to repeatedly not attend 
appointments. Taking this finding into context with the cause of death data 
presented in Figure 8-3 it would seem that the acquired risk factors and resource 
availability influence rather than dictate mortality amongst those with complex 
CHD as a clear tendency towards death directly attributed to CHD is noted in 
comparison to simple and moderate CHD. This is most notably seen at the 
expense of deaths attributable to IHD which is of course classically associated 
with acquired risk factors and socioeconomic deprivation (180,181). It is also 
noteworthy that deaths by CV causes are higher amongst all degrees of lesion 
complexity when compared to the general population (Figure 8-3 and Figure 
8-5). Although perhaps surprising, particularly for those with simple lesions, this 
is a finding echoed in previous studies, although the absolute risk imposed and 
underlying causes of death remain disputed and are recognised as an area for 
further study (37,182). 
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8.4 Conclusions 
Age at death is significantly lower amongst those with complex compared to 
those with simple and moderate CHD. Age at death was seen to increase 
throughout the data period but this was most notable for complex CHD. 
Cardiovascular mortality was greater amongst those with moderate compared to 
simple CHD and both cardiovascular and non-cardiovascular mortality was 
greater for those with complex CHD. Despite the most common primary cause of 
death amongst those with complex CHD being directly attributed to the 
underlying lesion, socioeconomic deprivation remains an important risk factor 
suggesting increased vulnerability to acquired risk factors and the possibility of 
inequalities in health service availability.
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9 Final Discussion 
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9.1 Summary of findings 
The aim of these studies was to delineate survival and mortality amongst adult 
survivors with congenital heart disease in Scotland. This has been outlined in 
terms of temporal trends as well as influencing factors such as sex, 
socioeconomic deprivation and disease complexity, both as observed and when 
adjusted for a range of clinical and demographic variables. Amongst this cohort 
survival was found to improve over time, for both sexes, across all lesions and 
degrees of ACHD complexity. 
By using the SMR to identify records, we have accrued the largest patient cohort 
and cumulative follow up of Scottish ACHD amongst the available literature. 
Despite the pre-requisite of an in patient episode, crude prevalence estimations 
are similar to previously published literature, suggesting a significant capture 
rate of the total Scottish ACHD population. 
The ACHD population of Scotland are a heterogenous group. At a population 
level, there are significant sex differences in ACHD. Simple lesions are more 
common in women and complex lesions in men. Women with ACHD are exposed 
to higher socioeconomic deprivation than men. Adjusted mortality is poorer for 
men than women particularly as a result of death due to non-cardiovascular 
causes. There is significant co-morbidity in adults with CHD particularly in older 
age groups. Coupled with improved temporal survival, this suggests an 
increasingly complex and multi-morbid patient cohort.  
High level socioeconomic deprivation corresponds to reduced survival. This 
remains true when adjusted for sex, age, year of presentation, underlying lesion 
and co-morbidity. It is also true across all degrees of lesion complexity. Adults 
with CHD experience higher socioeconomic deprivation than the general 
population. 
Increasing lesion complexity corresponds to higher adjusted mortality. Age at 
death increased throughout the study period for all degrees of complexity but 
this is most marked amongst lesions of great complexity. 
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9.2 Changes over time 
In some respects, caring for individuals with congenital heart disease has 
become a victim of its own success. Perhaps the greatest challenge in the 
contemporary practice of ACHD cardiology will be adapting to cater for the 
increasing patient cohort driven by improved patient survival. At least this has 
been the rhetoric amongst literature from mainland Europe and North America in 
recent years (8,9,75). My study confirms a similarly improved survival amongst 
the Scottish ACHD population since the mid 1980s with an instantaneous risk of 
all-cause mortality estimated at 65% less for those with index presentations 
between 2011-2015 than those who presented in 1986-1990. Although this may 
appear simply to agree with the existing literature, my analyses are additive on 
several fronts. Prior studies, although sometimes large scale, tend to utilise 
single centre cohorts, recruited registries, or regional private health care 
remuneration databases. Non-selective population analyses based on point of 
care coding have not previously been used to describe temporal survival. This 
study design should reduce omission bias and is not vulnerable to interviewer 
bias. Although some attempt has been made to adjust analyses in prior published 
literature (33) this has been limited to sex, age and congenital lesion. Factors 
such as the presence of comorbidity and relative socioeconomic deprivation have 
not previously been factored. We have shown that temporal survival improves 
over time, independent of theses variables.  
A further strength of these analyses has been the ability to include, by way of 
record linkage, cause of death data. As a result, and unique to the current 
literature we have demonstrated a significant and sustained trend away from 
cardiovascular and towards non-cardiovascular death. Of course, some of the 
‘non-cardiovascular death’ may well be influenced by cardiovascular factors. For 
instance, Fontan operations have in recent years been identified as a major risk 
factor the development of hepatocellular carcinoma and so death as a result 
would be non-cardiovascular but the underlying ACHD remains a major 
determinant of this (172,183,184). The changing pattern remains important 
however as it is only now that adult survivors of Fontan operations are living 
longer, that this late complication has been discovered. Similar examples of non-
cardiovascular death governed by the underlying ACHD could be argued in cases 
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of infective endocarditis or even with malignancies following high cumulative 
medical radiation exposure (185). 
The shift from cardiovascular to non-cardiovascular death is noted for men and 
women, for those exposed to both high- and low-level socioeconomic 
deprivation, and for simple, moderate and complex ACHD. This finding adds 
significant detail to the idea of improved survival in ACHD. Without this 
knowledge, population level analysis showing significant improvements in 
survival could simply correspond to individually small changes in most or all 
individuals with CHD but impacting each individual little. Understanding that the 
mode of death has changed on a population level would challenge this argument 
and suggests more wholesale changes in the prognosis of this patient cohort. 
9.3 Using mortality data to inform clinical practice 
Despite the growing ACHD patient cohort, relative to other cardiology 
subspecialties, exposure to ACHD remains low. As a result training and 
experience in ACHD has been recognised as insufficient to meet current and 
prospective demands (186). Clearly the shortage of ACHD specialist consultants 
must be addressed. Perhaps more important than ensuring adequate staffing of 
centralised, specialist centres with advanced ACHD cardiologists, will be 
ensuring a more disseminated level of expertise via cardiologist with an interest 
in ACHD and generalists with an understanding. This is crucial as it is local 
Emergency Departments that will experience growing demand in treating ACHD 
emergencies and also managing non cardiological emergencies in patients with 
ACHD. Ensuring an adequate network of ACHD knowledge is available at all times 
to acute services in Scotland will be essential to support the needs of this 
growing patient cohort. This body of work has been presented to the National 
Services Division of the NHS and forms part of a consensus drive to the expansion 
of the SACCS remit. This includes; a growing consultant body; an expanding 
regional out-reach service; and plans for an out-of-hours on-call ACHD rota for 
the first time in Scotland. Further work is planned on a collaborative basis to 
inform service provision further. 
Of course, the ACHD cohort is not simply growing, it is changing. The shift from 
cardiovascular to non-cardiovascular mortality is perhaps the best indicator of 
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this. It is telling that in some centres the term GUCH or ‘grown-up congenital 
heart disease’ remains. Adult congenital heart disease is deliberately favoured 
by the author as it better serves our patients as adults in their own right and not 
simply grown-up children. Although seemingly pedantic this is an important 
distinction which reminds us that practice has moved on. More individuals with 
ACHD than ever will be starting families, contributing to the work force, 
choosing to smoke tobacco, drink alcohol and be exposed to myriad other 
lifestyle factors common to adult medicine. In the most contemporary cohort in 
my analyses, 60% of all deaths and 57.7% of deaths in those with complex ACHD 
were due to non-cardiovascular causes. It is clear that a holistic approach to 
patient management is required for improvements to continue. It is no longer 
appropriate to simply optimise therapy related to ventricular function, assess 
rhythm control and consider haemodynamics upon specialist review. Following 
my analyses, a significant change in the proportion of my face-to-face clinic 
time is concentrated on the ‘bigger picture’ of risk factor modification, 
counselling and patient education.  
Adults with CHD often have well established relationships with ACHD specialists 
as follow up is frequently lifelong. There is a risk that this can usurp the 
individual’s engagement with local services and general practitioners; why 
bother making a GP appointment when you are due to see the congenital team 
the following week? Being responsive to signs and symptoms other than those 
traditionally gleaned from the cardiology clinic visit is paramount. Malignancy 
was responsible for many of the non-cardiovascular deaths in this cohort. It goes 
without saying that red flags such as unexplained weight loss, change in bowel 
habit and chronic, unexplained cough should never be ignored, however 
systematic measures should be in place to ensure these findings are acted upon, 
particularly when the review is in a national centre, physically and 
systematically remote from the individuals usual health board, and therefore not 
necessarily subject to the usual mechanisms for local referral for tests and 
follow up. 
According to my analyses, differences in ACHD amongst men and women are 
subtle and some differences seemingly non-modifiable such as the distribution of 
lesions by sex. Women were noted to present later in life more frequently than 
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men. This appears to be due to the increased prevalence of simple lesions, 
predominantly shunt lesions, which may be hidden until incidentally found 
subject to comorbidity or due to symptom onset later in life. Increased 
sensitivity of foetal ultrasound in recent years may improve the pick-up of some 
of these lesions, reducing this disparity (187). Also, with the increasing 
prevalence of CHD in the adult sector one would hope that the incidental pick-
up rate during non-cardiovascular imaging such as non-cardiac CT or MRI may 
improve as experience grows in this arena. Clearly education and awareness to 
this end should be driven from within the ACHD community where possible.  
More women than men with CHD reside in postcode areas corresponding to high 
level socioeconomic deprivation. The converse is also true, with fewer women 
than men residing in affluent areas. In fact, socioeconomic deprivation was 
higher for the total ACHD population than for the general population of Scotland 
and this deprivation was associated with premature mortality. This is true for 
CHD of simple, moderate and great complexity. To the best of my knowledge, no 
study has previously analysed socioeconomic deprivation amongst an adult 
cohort with CHD. 
Clearly there will be important variation by which socioeconomic deprivation 
will influence outcomes in CHD on a global scale. One would assume that the UK 
would compare rather favourably in this regard as the NHS is frequently 
considered amongst the most, if not the most, equitable health care system in 
the world (188). Of course, equity in availability of services does not necessarily 
result in equity in uptake of services. Although free at point of contact it is 
feasible that financial and non-financial barriers may still influence service 
uptake. In Scotland, ACHD care is centralised with the Golden Jubilee National 
Hospital with additional local or regional clinics in each health board. Although 
measures are in place to reasonably remunerate patients for travel and 
accommodation to the national centre for follow up and intervention, if nothing 
else this provides an extra consideration for the patient. This then needs to be 
taken into context with the greater complexity of health priorities amongst more 
socioeconomically challenging communities. Whether or not there is equity of 
service uptake across socioeconomic groups remains conjecture pending further 
study, however acceptability to the patient has previously been outlined as a 
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key principle or ‘pillar’ of quality in health care (189). Ensuring equity of uptake 
must therefore revolve around assuring acceptability to the patient. This must 
involve a fine balance; review must be adequate but not unnecessarily frequent; 
patients must be seen by an appropriately skilled specialist but remain local 
when at all possible; and time out of work and education must be factored into 
decision making, with the patient’s input being of paramount importance. 
Even if equity in uptake of services could be guaranteed irrespective of 
socioeconomic group, this does not guarantee equity in survival. The relationship 
between cardiovascular risk and socioeconomic deprivation is complex. Although 
there is an association with higher risk factor profile (smoking, obesity, 
sedentary lifestyle) (190) and the co-morbidities conferred (hypertension, 
hypercholersterolaemia, type 2 diabetes, ischaemic heart disease) (191), 
socioeconomic deprivation has been shown to increase ischaemic heart disease 
and heart failure risk even when independent of these variables (192,193). 
Although I was unable to adjust for clinical variables such as smoking and 
obesity, my results would suggest a similar association with mortality in ACHD as 
it persists even when adjusted for HTN, previous MI, and T2DM. This should not 
undermine the importance of risk factor modification amongst this group of 
patients, particularly given the increasing age at death in contemporary cohorts, 
but it does merit further study as to the role of socioeconomic deprivation as an 
independent risk factor for mortality in ACHD.  
Background factors remain important in determining the risk of mortality 
associated with socioeconomic deprivation in the ACHD patient and in recent 
years a further driver of inequality has been well-publicised. Since the 
introduction of austerity measures following the 2008 global financial crisis, 
survival improvements have slowed in Scotland (194). This finding was replicated 
in other developed countries where austerity measures were implemented but 
not those where they were not. This slowing of survival improvements was 
established to be driven by an actual increase in mortality rates for those 
residing in SIMD quintiles of greater socioeconomic deprivation. Clearly, in 
addition to clinical measures being required to narrow the gap in outcomes 
governed by socioeconomic deprivation amongst adults with CHD, a more 
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general fiscal and political review will be required to reduce the background 
effects of widening socioeconomic disparity. 
Although survival improved for all degrees of complexity of ACHD throughout my 
analyses, observed age at death increased most substantially for those with 
complex CHD. This was accompanied by a shift from cardiovascular towards non-
cardiovascular mortality, which by the end of the data period mirrored the shift 
seen for lesions of simple and moderate complexity. Of course, adjusted survival 
remained poorer for those with complex CHD than moderate or simple and 
interestingly this was true for cardiovascular and non-cardiovascular mortality. 
Arrhythmic, heart failure related, and sudden cardiac deaths have long been the 
dominant mode of mortality for those with complex CHD, so it is the higher 
hazard of non-cardiovascular mortality which appears more unusual. In recent 
years more has been learned about the long-term implications of grossly 
abnormal cardiovascular physiology imposed by lesions of great complexity or 
the surgical interventions they mandate. This has been most robustly established 
for Fontan and univentricular physiology with hepatic, gastrointestinal and 
immunological implications discussed in the previous chapter. Moving forward it 
must be essential to ensure all latest developments in this regard are 
incorporated into clinical routine. As an example, it should now be commonplace 
for individuals without a sub-pulmonary ventricle to have close monitoring of 
liver function and interval screening for hepatocellular carcinoma.  
These non-cardiovascular manifestations of complex CHD will inevitably lead to 
complex interdisciplinary networks with non-cardiology specialists, ideally with 
an interest and additional training in ACHD. A case for joint clinics with ACHD 
cardiologists could also be made. This is all the more complex due to the 
structure of congenital services in Scotland being centred around a single, 
national centre fed by multiple health boards. 
9.4 Limitations of the studies 
These studies are not without some limitations. Whilst the population-based, 
non-selective nature of the data collection is of benefit in several ways, 
including large study numbers and limiting recruitment and observer biases, it 
has its drawbacks. The ICD and OPCS coding systems were changed and 
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significantly improved during the data period. Necessarily, patient inclusion was 
not consistent throughout the data period. This was most noticeable for certain 
complex CHD lesions which were reliant on the new OPCS procedure codes to be 
defined (TGA with arterial switch and Fontan’s for example). As a result, no 
individuals with these diagnoses were identified in the early data period and 
were instead contained within the less specific lesion categories (complex CHD), 
thus limiting their study. What Is more, as only adults older than 16 were 
included, there is a lead-in time of 16 years from the updated OPCS system until 
follow up times begin for these lesions. As this ISD database matures, provided 
that the OPCS system requires no major overhaul, this will cease to be an issue 
and its usefulness will be even greater particularly when sufficient to allow for 
longitudinal analysis of an entire ‘natural’ life span of a cohort. 
Although the accuracy of coding for inclusion in the ISD database is externally 
validated on an annual basis and maintains high standards, this has not been 
independently validated for congenital heart disease ICD or OPCS codes. It is 
feasible that this esoteric area of coding may not be truly reflected by the 
reassuring figures for the ISD database as a whole.  
As the data set was solely derived from coded data with full anonymisation it 
was not possible to be certain of the complete procedural history for an 
individual. If an ICD code pertaining to ASD was encountered but no code 
corresponding to closure was found this does not necessarily mean they have not 
had this done. They may have had a procedure predating the database or the 
appropriate coding system or they may have had the procedure out with 
Scotland. For this reason, procedural status could not be factored into survival 
analyses or lesion complexity approximation.  
Accurately representing survival of this data set graphically was challenging as 
individuals were included either at the point of their 16th birthday, having been 
identified in the paediatric sector, or later in life due to an in patient episode 
during the data period. As ACHD is by definition present from birth, survival is 
equal to age. However, this mandates survival curves to be extended leftwards 
(to age 16 in my analyses) for those entering the data set at a later stage in life. 
This imposes a survivor bias as an equivalent individual may have died prior to, 
or without generating an in patient episode over the same time period. This is 
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not necessarily an inaccuracy but limits the usefulness of observed survivor data 
such as Kaplan Meier graphs as they overestimate survival. They have thus been 
included for a visual comparator of the observed data only. There is also a 
vulnerability at the ‘right’ of the survival curves as individuals will either be 
known to die or not known to die, where they will undergo administrative 
censoring. There may be some individuals who emigrate or die out-with Scotland 
who will not be recognised and will therefore contribute to the right of the 
survival curve until the administrative censorship date. This would falsely 
improve the observed survival in question. The effect of this may be expected to 
be small overall but could have a significant effect on smaller groups (such as 
with less common lesions e.g. Fontan or Ebstein’s anomaly) where excess 
mortality free follow up may introduce a significant error.  
9.5 Recommended further work 
The benefits of this large volume, unselected study methodology cannot be 
overstated given otherwise sparsity of similar data in ACHD, but there are 
limitations as stated above. To counter the drawbacks of incomplete 
interventional history, lack of investigation outcomes when defining lesions and 
their complexity, and incomplete censoring or mortality recording due to 
emigration etc. the implementation and collaborative use of a national ACHD 
database could be extremely powerful. This may allow observational analyses 
and outcome predictors to be applied to interventions and therapies whilst also 
robustly validating diagnostic coding. 
Even separate to the implementation of a national ACHD database or registry, 
which would undoubtedly incur significant financial and personnel outlay, 
independent validation of ISD data with specific regard to ACHD coding would be 
desirable. This would be unlikely to incur a significant financial cost but would 
be at the discretion of ISD as it would require unblinding of a proportion of this 
robustly anonymised data. 
The utility of the Scottish Morbidity Record and subsequent linkage to other 
national databases has been described throughout this thesis. The records 
utilised in these studies could be further utilised to describe predictors of 
mortality. For example, co-morbidity has been included as a control variable in 
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these analyses to adjust survival models. Further work could expand on this to 
estimate survival according to co-morbidity. For example, does AF predict 
mortality for all CHD or only shunt lesions? 
Recently a further database, the Prescribing Information System (PIS), has 
become available for linkage. This would allow all community prescribed 
medications for a data set to be identified and tracked longitudinally. This 
service has been provided since 2009 (195) and it has now been represented in 
the medical literature, including an observational study by Mueller et al. (196) 
regarding the comparative safety and efficacy of different direct oral 
anticoagulant (DOAC) medications amongst the Scottish AF population. This is a 
simple example of a very useful application PIS could provide in the ACHD 
population where DOAC efficacy and safety is far from established. Although 
pharmacoepidemiology in this population has myriad uses, given the extreme 
difficulty over the years of compiling randomised trials in ACHD patients, 
observational studies of outcomes relating to pharmacotherapy at a population 
level holds much promise. 
Although efforts have been made throughout my analyses to provide a 
population comparator to the study population when possible, this has been via 
the utility of freely available population statistics. Ideally certain analyses and 
even basic graphical illustration of survival would be better served using a 
matched population cohort. Again, this would be at the discretion of ISD and the 
Public Benefit Privacy Panel upon application. 
9.6 Conclusions 
The conclusions from the results reported in this thesis can be summarised as 
follows: 
The SMR is an effective tool for identifying and linking records of adults with 
CHD in Scotland. 
Individuals with ACHD in Scotland are a heterogenous group. Deaths are 
observed in all age groups and co-morbidity is frequently encountered.  
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Adults with ACHD experience disproportionate socioeconomic deprivation when 
compared to the general population. 
Women with ACHD experience more socioeconomic deprivation than men with 
ACHD. 
Higher socioeconomic deprivation is associated with increased mortality, even 
when adjusted for underlying congenital lesion, age, and multiple co-morbidities 
including IHD, HTN and diabetes. 
Individuals presenting to the data set in more recent years experienced better 
survival irrespective of underlying lesion, disease complexity, sex or 
socioeconomic group. 
At the beginning of the study, the majority of deaths were due to cardiovascular 
causes. This is no longer the case, with non-cardiovascular mortality more 
prevalent. 
Men with CHD experience higher mortality than women, and this is 
predominantly due to non-cardiovascular causes. 
The transition from cardiovascular to non-cardiovascular mortality over time is 
noted for all degrees of ACHD complexity. 
Mortality is higher for ACHD of greater complexity.
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